<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd">
  <key id="d0" for="node" attr.name="label" attr.type="string" />
  <key id="d1" for="node" attr.name="type" attr.type="string" />
  <key id="d2" for="node" attr.name="community" attr.type="string" />
  <key id="d3" for="edge" attr.name="weight" attr.type="double" />
  <key id="d4" for="edge" attr.name="label" attr.type="string" />
  <key id="d5" for="node" attr.name="description" attr.type="string" />
  <key id="d6" for="edge" attr.name="full_description" attr.type="string" />
  <graph id="G" edgedefault="directed">
    <node id="0">
      <data key="d0">ELI LILLY AND COMPANY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Eli Lilly and Company is a leading pharmaceutical company headquartered in Indianapolis, Indiana. The company has a long history of innovation and a strong focus on developing new treatments for a wide range of medical conditions.

According to the provided descriptions, Eli Lilly and Company recently beat its Q3 results and set guidance for the fiscal year 2025. This suggests that the company is performing well financially and is optimistic about its future prospects.

In addition to its core pharmaceutical business, Eli Lilly is also making significant investments in the local community. The company is providing up to $40 million to Indiana University to create a best-in-class system for clinical trial innovation, strengthen Alzheimer's disease clinical care and research, and develop scientific and clinical talent for Indiana's life sciences sector.

This partnership with the IU School of Medicine aims to build a world-class clinical trials ecosystem that accelerates scientific discoveries and expands access to cutting-edge treatments for patients. Eli Lilly is leveraging its expertise and resources to drive innovation and support the growth of the life sciences industry in Indiana.

Furthermore, Eli Lilly is recognized as a top employer in the state, highlighting the company's commitment to its workforce and the local community. By partnering with the IU School of Medicine, Eli Lilly is demonstrating its dedication to advancing scientific research, improving patient care, and fostering the development of future industry leaders.

In summary, Eli Lilly and Company is a leading pharmaceutical company that is not only focused on developing innovative treatments but also on supporting the local community and driving scientific progress. The company's recent financial performance, its investment in clinical trial innovation, and its partnership with the IU School of Medicine all contribute to a comprehensive and coherent picture of Eli Lilly's role as a key player in the pharmaceutical industry and the life sciences sector in Indiana.</data>
    </node>
    <node id="1">
      <data key="d0">PAMELA WHITTEN</data>
      <data key="d1">PERSON</data>
      <data key="d2">78.0</data>
      <data key="d5">Pamela Whitten is the president of Indiana University</data>
    </node>
    <node id="2">
      <data key="d0">DAVID A. RICKS</data>
      <data key="d1">PERSON</data>
      <data key="d2">44.0</data>
      <data key="d5">David A. Ricks is the chair and CEO of Eli Lilly and Company</data>
    </node>
    <node id="3">
      <data key="d0">JAY HESS</data>
      <data key="d1">PERSON</data>
      <data key="d2">78.0</data>
      <data key="d5">Jay Hess is the executive vice president for university clinical affairs and dean of the IU School of Medicine</data>
    </node>
    <node id="4">
      <data key="d0">RUSSELL J. MUMPER</data>
      <data key="d1">PERSON</data>
      <data key="d2">43.0</data>
      <data key="d5">Russell J. Mumper is the Vice President for Research at Indiana University (IU). In this role, he emphasizes the importance of strategic research partnerships between academia and industry to drive scientific discoveries and economic impact.

As the IU Vice President for Research, Mumper is responsible for overseeing the university's extensive research enterprise. He plays a crucial role in fostering collaborative relationships between IU researchers and external partners, including private companies and other academic institutions. Mumper believes that these strategic partnerships are essential for translating academic research into real-world applications and driving economic growth.

Mumper's focus on industry-academia collaboration is rooted in his understanding of the complementary strengths that each sector brings to the table. By leveraging the expertise and resources of both the private and public sectors, Mumper aims to accelerate the pace of scientific and technological advancements, ultimately benefiting society as a whole.

Under Mumper's leadership, IU has established numerous successful research partnerships with a wide range of industries, ranging from healthcare and biotechnology to advanced manufacturing and information technology. These collaborations have led to groundbreaking discoveries, the development of innovative products and services, and the creation of new jobs and economic opportunities in the local and regional communities.

Mumper's commitment to strategic research partnerships is further evidenced by his efforts to streamline the process of collaboration between IU and external partners. He has worked to implement efficient and transparent processes for negotiating contracts, managing intellectual property, and ensuring the alignment of research goals and priorities.

In addition to his focus on industry-academia collaboration, Mumper is also a strong advocate for the importance of research in driving societal progress. He believes that fundamental and applied research conducted at universities like IU are essential for addressing the world's most pressing challenges, from climate change and global health to social inequity and technological disruption.

Overall, Russell J. Mumper's role as the IU Vice President for Research is crucial in fostering a culture of innovation and collaboration that leverages the university's intellectual and creative resources to drive scientific discoveries, economic growth, and positive social impact.</data>
    </node>
    <node id="5">
      <data key="d0">INDIANA UNIVERSITY</data>
      <data key="d1" />
      <data key="d2">78.0</data>
      <data key="d5" />
    </node>
    <node id="6">
      <data key="d0">ALZHEIMER'S DISEASE</data>
      <data key="d1">EVENT</data>
      <data key="d2">60.0</data>
      <data key="d5">A neurodegenerative disease that the partnership aims to focus on for clinical care and research</data>
    </node>
    <node id="7">
      <data key="d0">DIABETES</data>
      <data key="d1">EVENT</data>
      <data key="d2">78.0</data>
      <data key="d5">A disease that the partnership aims to focus on for clinical research</data>
    </node>
    <node id="8">
      <data key="d0">CANCER</data>
      <data key="d1">EVENT</data>
      <data key="d2">78.0</data>
      <data key="d5">A disease that the partnership aims to focus on for clinical research</data>
    </node>
    <node id="9">
      <data key="d0">CELL AND GENE THERAPY</data>
      <data key="d1">EVENT</data>
      <data key="d2">78.0</data>
      <data key="d5">An area of research and treatment that the partnership aims to focus on</data>
    </node>
    <node id="10">
      <data key="d0">HOOSIERS</data>
      <data key="d1" />
      <data key="d2">78.0</data>
      <data key="d5" />
    </node>
    <node id="11">
      <data key="d0">INDIANA</data>
      <data key="d1">GEO</data>
      <data key="d2">43.0</data>
      <data key="d5">Indiana is the state where the partnership between the IU School of Medicine and Eli Lilly is taking place. The goal is to establish Indiana as a leader in clinical trial innovation and strengthen the state's position as a global leader in life-changing research.</data>
    </node>
    <node id="12">
      <data key="d0">IU SCHOOL OF MEDICINE</data>
      <data key="d1" />
      <data key="d2">43.0</data>
      <data key="d5" />
    </node>
    <node id="13">
      <data key="d0">LILLY CLINICAL TRIALS</data>
      <data key="d1">EVENT</data>
      <data key="d2">70.0</data>
      <data key="d5">Eli Lilly is conducting various clinical trials for its pharmaceutical products</data>
    </node>
    <node id="14">
      <data key="d0">ELI LILLY</data>
      <data key="d1" />
      <data key="d2">70.0</data>
      <data key="d5" />
    </node>
    <node id="15">
      <data key="d0">ORFORGLIPRON</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">Orforglipron, also known as LY3502970, is a novel oral GLP-1 receptor agonist being developed by Eli Lilly and Company for the treatment of various conditions, including type 2 diabetes, obesity, and obstructive sleep apnea.

According to the provided descriptions, Orforglipron is currently being evaluated in several clinical trials:

1. The ADVANCE-ATTAIN-ADOLESCENTS study is investigating the use of Orforglipron for weight management in adolescents.
2. The ATTAIN-HYPERTENSION study is evaluating Orforglipron for the treatment of hypertension.
3. A bioequivalence study is comparing the administration of Orforglipron as capsules versus tablets in overweight or obese participants.
4. A Phase 3b study is investigating the maintenance of body weight reduction with Orforglipron.
5. A drug-drug interaction study is examining the effects of Orforglipron in combination with quinidine in healthy participants.
6. The GZRA master protocol study is evaluating the efficacy and safety of Orforglipron in participants with obstructive sleep apnea and obesity or overweight.
7. Two Phase 3 studies are investigating the use of Orforglipron for the treatment of type 2 diabetes.

The descriptions indicate that Orforglipron is a non-peptide GLP-1 receptor agonist developed by Eli Lilly and Company for the treatment of type 2 diabetes, obesity, and obstructive sleep apnea. It is being studied as a potential oral treatment option for these conditions.

While the descriptions provide a comprehensive overview of the various clinical studies involving Orforglipron, there are no apparent contradictions in the information provided. The drug appears to be in different stages of development, with ongoing trials evaluating its efficacy and safety for a range of indications, including weight management, hypertension, type 2 diabetes, and obstructive sleep apnea.

In summary, Orforglipron is a novel oral GLP-1 receptor agonist developed by Eli Lilly and Company that is currently being investigated in multiple clinical trials for the treatment of various metabolic and respiratory conditions, with a focus on weight management, type 2 diabetes, and obstructive sleep apnea.</data>
    </node>
    <node id="16">
      <data key="d0">RETATRUTIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">40.0</data>
      <data key="d5">Retatrutide is a drug being developed by Eli Lilly for the treatment of type 2 diabetes, obesity, and related cardiovascular and kidney conditions. It is currently in Phase 3 clinical trials.

The primary focus of the Retatrutide development program is to evaluate its efficacy in treating type 2 diabetes. Retatrutide is being investigated in a Phase 3 study to determine its effect on the incidence of major adverse cardiovascular events and major adverse kidney events in participants with a body mass index of 27 kg/m^2 or higher and atherosclerotic cardiovascular disease and/or chronic kidney disease.

In addition to its potential for treating type 2 diabetes, Retatrutide is also being evaluated as an obesity drug. It is being compared to tirzepatide, another obesity drug candidate, in a clinical study. Retatrutide is described as a "triple agonist obesity drug," indicating that it targets multiple biological pathways to promote weight loss and improve related health outcomes.

The drug is currently in a Phase 3b dosing study, which is likely to provide further insights into its safety and efficacy profiles for the treatment of obesity and related conditions. The J1I-MC-GZQE study is also investigating Retatrutide as a study drug.

Overall, Retatrutide appears to be a promising drug candidate being developed by Eli Lilly for the treatment of type 2 diabetes, obesity, and associated cardiovascular and kidney complications. The ongoing Phase 3 trials will be crucial in determining the drug's potential to address these significant health challenges.</data>
    </node>
    <node id="17">
      <data key="d0">PIRTOBRUTINIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">64.0</data>
      <data key="d5">Pirtobrutinib (LOXO-305) is a drug being developed by Eli Lilly for various medical applications. It is primarily being studied as a BTK (Bruton's tyrosine kinase) inhibitor, a class of drugs used to treat certain types of blood cancers and autoimmune disorders.

The available data indicates that Pirtobrutinib is currently undergoing several clinical trials to evaluate its effects and potential uses:

1. Pharmacokinetic and drug interaction studies: Pirtobrutinib is being studied to assess its impact on the pharmacokinetics (the movement of drugs within the body) and potential interactions with other drugs.

2. QTc interval evaluation: Clinical trials are investigating the effect of Pirtobrutinib on the QTc interval, which is a measure of the heart's electrical activity. This is important to ensure the drug's safety.

3. Immune thrombocytopenia treatment: Pirtobrutinib is being evaluated in a phase 1/2 dose-finding study for the treatment of immune thrombocytopenia, a condition characterized by a low platelet count.

4. Chronic lymphocytic leukemia/small lymphocytic lymphoma and non-Hodgkin lymphoma treatment: Pirtobrutinib is being studied in a clinical trial to assess its long-term safety and efficacy in participants with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma or non-Hodgkin lymphoma, which are types of blood cancers.

5. Long-term safety and efficacy: Pirtobrutinib is being evaluated in a clinical trial to assess its long-term safety and efficacy as a study drug.

The available information suggests that Pirtobrutinib is a versatile drug with potential applications in various medical conditions, particularly in the field of hematology and oncology. The clinical trials are aimed at understanding the drug's pharmacokinetics, safety, and efficacy in treating different types of blood disorders and cancers.

It is important to note that the information provided does not indicate any contradictions or inconsistencies. The various descriptions appear to be complementary, providing a comprehensive overview of the different aspects of Pirtobrutinib's development and clinical investigation.</data>
    </node>
    <node id="18">
      <data key="d0">LOCKHEED MARTIN INVESTMENT MANAGEMENT CO.</data>
      <data key="d1" />
      <data key="d2">44.0</data>
      <data key="d5" />
    </node>
    <node id="19">
      <data key="d0">MARKETBEAT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">MarketBeat is a financial data and news provider that tracks Wall Street analysts and their stock recommendations. The company also reports on investment activities and holdings of various entities, such as Lockheed Martin Investment Management Co.'s stake in Eli Lilly.

MarketBeat gathers and disseminates information related to the stock market, including analyst ratings, price targets, and other financial data. The company's primary focus is on providing investors with insights and analysis to help them make informed investment decisions.

In addition to tracking analyst recommendations, MarketBeat also reports on the investment activities of various institutional investors, such as Lockheed Martin Investment Management Co. and their stake in Eli Lilly. This type of reporting provides valuable information to investors about the investment strategies and portfolio holdings of major market players.

Overall, MarketBeat serves as a comprehensive financial data and news provider, offering a range of services and information to help investors navigate the complex world of the stock market. The company's ability to track and report on both analyst recommendations and institutional investment activities makes it a valuable resource for investors seeking to stay informed and make well-informed investment decisions.</data>
    </node>
    <node id="20">
      <data key="d0">SUMITOMO MITSUI FINANCIAL GROUP INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company</data>
    </node>
    <node id="21">
      <data key="d0">EVOLUTION WEALTH MANAGEMENT INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company</data>
    </node>
    <node id="22">
      <data key="d0">STEPH &amp; CO.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Steph &amp; Co. increased its holdings in Eli Lilly and Company</data>
    </node>
    <node id="23">
      <data key="d0">FINANCIAL GRAVITY COMPANIES INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company</data>
    </node>
    <node id="24">
      <data key="d0">BARE FINANCIAL SERVICES INC.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Bare Financial Services Inc. raised its stake in Eli Lilly and Company</data>
    </node>
    <node id="25">
      <data key="d0">OZEMPIC</data>
      <data key="d1">PRODUCT</data>
      <data key="d2">44.0</data>
      <data key="d5">Ozempic is a medication produced by Eli Lilly and Company</data>
    </node>
    <node id="26">
      <data key="d0">MOUNJARO</data>
      <data key="d1">PRODUCT</data>
      <data key="d2">45.0</data>
      <data key="d5">Mounjaro is a medication produced by Eli Lilly and Company</data>
    </node>
    <node id="27">
      <data key="d0">WEGOVY</data>
      <data key="d1">PRODUCT</data>
      <data key="d2">44.0</data>
      <data key="d5">Wegovy is a medication produced by Eli Lilly and Company</data>
    </node>
    <node id="28">
      <data key="d0">ZEPBOUND</data>
      <data key="d1">PRODUCT</data>
      <data key="d2">70.0</data>
      <data key="d5">Zepbound is a medication produced by Eli Lilly and Company</data>
    </node>
    <node id="29">
      <data key="d0">FDA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">The U.S. Food and Drug Administration (FDA) is the federal agency responsible for regulating and supervising the safety of food, drugs, and other products in the United States.</data>
    </node>
    <node id="30">
      <data key="d0">SURMOUNT-REAL UK</data>
      <data key="d1">EVENT</data>
      <data key="d2">44.0</data>
      <data key="d5">SURMOUNT-REAL UK is a real-world study conducted by Eli Lilly on its obesity drug tirzepatide.</data>
    </node>
    <node id="31">
      <data key="d0">TIRZEPATIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">47.0</data>
      <data key="d5">Tirzepatide is a drug being developed and investigated by Eli Lilly for the treatment of various health conditions, including type 2 diabetes, obesity, and weight-related comorbidities.

Tirzepatide is a once-weekly subcutaneous injection that is currently being studied in several clinical trials. The drug is being evaluated for its effect and safety in participants with obstructive sleep apnea and obesity, as well as its efficacy and safety in the treatment of type 2 diabetes mellitus in pediatric and adolescent participants.

In addition, Tirzepatide is being investigated in two phase 3 studies: one to assess its effect on major adverse cardiovascular events in patients with type 2 diabetes, and another to investigate its effect on morbidity and mortality in adults with obesity. The drug is also being studied for weight loss and chronic weight management, both as a standalone treatment and in combination with other medications, such as LY3841136 and ixekizumab.

Furthermore, Tirzepatide is being evaluated for its efficacy and safety compared to semaglutide in adults with obesity or overweight with weight-related comorbidities. The drug is also being studied for its efficacy and safety in Chinese participants with type 2 diabetes.

Overall, Tirzepatide appears to be a promising drug that is being extensively investigated for its potential to treat a range of health conditions, particularly type 2 diabetes and obesity. The comprehensive clinical trial program aims to evaluate the drug's safety and efficacy in various patient populations, with the goal of providing a new treatment option for those struggling with these prevalent and often co-occurring conditions.</data>
    </node>
    <node id="32">
      <data key="d0">JPMORGAN HEALTHCARE CONFERENCE</data>
      <data key="d1">EVENT</data>
      <data key="d2">44.0</data>
      <data key="d5">The JPMorgan Healthcare Conference is an annual healthcare investment conference where Eli Lilly executives spoke about the obesity drug market.</data>
    </node>
    <node id="33">
      <data key="d0">PRANAV SHROFF</data>
      <data key="d1">PERSON</data>
      <data key="d2">44.0</data>
      <data key="d5">Pranav Shroff was appointed as the new director of marketing at Eli Lilly.</data>
    </node>
    <node id="34">
      <data key="d0">SUN PHARMA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Sun Pharmaceutical Industries is an Indian pharmaceutical company that won approval for a generic version of Wegovy (a competing obesity drug) in India.</data>
    </node>
    <node id="35">
      <data key="d0">ROKITA</data>
      <data key="d1">PERSON</data>
      <data key="d2">44.0</data>
      <data key="d5">Todd Rokita is an Indiana Attorney General who discussed a lawsuit against Eli Lilly over insulin prices.</data>
    </node>
    <node id="36">
      <data key="d0">WOLFE RESEARCH</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Wolfe Research is a research firm that covers Eli Lilly and Company.</data>
    </node>
    <node id="37">
      <data key="d0">BERENBERG BANK</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Berenberg Bank is a research firm that covers Eli Lilly and Company.</data>
    </node>
    <node id="38">
      <data key="d0">UBS GROUP</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">UBS Group is a research firm that initiated coverage on Eli Lilly and Company.</data>
    </node>
    <node id="39">
      <data key="d0">MORGAN STANLEY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Morgan Stanley is a research firm that covers Eli Lilly and Company.</data>
    </node>
    <node id="40">
      <data key="d0">HSBC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">HSBC is a research firm that covers Eli Lilly and Company.</data>
    </node>
    <node id="41">
      <data key="d0">ORAL SEMAGLUTIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">Oral Semaglutide is a new oral medication used for the treatment of type 2 diabetes. It is a competing oral GLP-1 (Glucagon-Like Peptide-1) drug, which means it works by mimicking the action of the GLP-1 hormone in the body.

GLP-1 is a hormone that helps regulate blood sugar levels by stimulating the release of insulin from the pancreas and suppressing the release of glucagon, a hormone that increases blood sugar levels. Oral semaglutide is designed to be taken as a pill, making it a more convenient option for patients compared to injectable GLP-1 receptor agonists.

In clinical trials, oral semaglutide was compared to another type 2 diabetes medication called orforglipron. The results of these trials showed that oral semaglutide was effective in improving glycemic control and reducing the risk of diabetes-related complications. Patients taking oral semaglutide experienced significant reductions in their HbA1c (a measure of average blood sugar levels over time) and were less likely to experience hypoglycemia (low blood sugar) compared to those taking orforglipron.

Oral semaglutide is a novel approach to the treatment of type 2 diabetes, as it provides an oral alternative to injectable GLP-1 receptor agonists. This can be particularly beneficial for patients who may be hesitant to use injectable medications or who have difficulty with self-injection. The convenience of an oral formulation may also improve medication adherence, which is crucial for the effective management of type 2 diabetes.

Overall, oral semaglutide represents a promising new treatment option for individuals with type 2 diabetes. Its ability to effectively lower blood sugar levels, while offering a more convenient oral administration, may help improve the overall management of this chronic condition and reduce the risk of associated complications.</data>
    </node>
    <node id="42">
      <data key="d0">KENNETH CUSTER</data>
      <data key="d1">PERSON</data>
      <data key="d2">44.0</data>
      <data key="d5">Kenneth Custer is the executive vice president and president of Lilly Cardiometabolic Health</data>
    </node>
    <node id="43">
      <data key="d0">ACHIEVE-3</data>
      <data key="d1">EVENT</data>
      <data key="d2">39.0</data>
      <data key="d5">ACHIEVE-3 is a Phase 3 clinical trial that compared orforglipron to oral semaglutide in adults with type 2 diabetes. The trial is a 52-week, randomized, open-label study evaluating the efficacy and safety of orforglipron compared to oral semaglutide in this patient population.

The ACHIEVE-3 trial is designed to assess the ability of orforglipron, a novel investigational medication, to improve glycemic control in adults with type 2 diabetes. Orforglipron is being evaluated against oral semaglutide, an approved glucagon-like peptide-1 (GLP-1) receptor agonist, to determine if orforglipron can provide comparable or superior glycemic benefits.

The primary objective of the ACHIEVE-3 trial is to demonstrate the non-inferiority of orforglipron to oral semaglutide in reducing glycated hemoglobin (HbA1c) levels from baseline to week 52. Secondary endpoints include the assessment of other measures of glycemic control, such as fasting plasma glucose, as well as the safety and tolerability of the two treatments.

The trial is being conducted in a randomized, open-label fashion, meaning that participants and investigators are aware of the assigned treatment. This design allows for a more practical evaluation of the treatments in a real-world setting, as opposed to a blinded, placebo-controlled trial.

By comparing the efficacy and safety of orforglipron to the established oral semaglutide, the ACHIEVE-3 trial aims to provide valuable insights into the potential role of orforglipron in the management of type 2 diabetes. The results of this study will contribute to the understanding of the relative benefits and risks of these two treatment options for adults with type 2 diabetes.

In summary, the ACHIEVE-3 trial is a Phase 3, 52-week, randomized, open-label study that is evaluating the efficacy and safety of orforglipron compared to oral semaglutide in adults with type 2 diabetes. The primary objective is to demonstrate the non-inferiority of orforglipron to oral semaglutide in reducing HbA1c levels, with additional assessments of other glycemic measures and the overall safety profile of the two treatments.</data>
    </node>
    <node id="44">
      <data key="d0">TYPE 2 DIABETES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">40.0</data>
      <data key="d5">Type 2 Diabetes is a medical condition that is the focus of several clinical studies conducted by Eli Lilly. The condition is being investigated in relation to various treatments and their effects on different aspects of the disease.

One study is investigating a drug for type 2 diabetes with renal impairment, which is a common complication associated with the condition. The LY3502970 study is specifically examining the condition affecting the participants in that trial.

Dulaglutide, another Eli Lilly product, is being studied for its effects on type 2 diabetes in pediatric participants. This is an important area of research, as type 2 diabetes is increasingly being diagnosed in younger populations.

Tirzepatide, a medication developed by Eli Lilly, is being evaluated in several studies related to type 2 diabetes. The SURPASS-CVOT trial is examining the effects of tirzepatide on cardiovascular outcomes in individuals with type 2 diabetes. Additionally, the impact of tirzepatide on chronic kidney disease, a common complication of type 2 diabetes, is being investigated.

The ACHIEVE-3 trial also involved participants with type 2 diabetes, as this condition is the target for several of Eli Lilly's studies. These studies aim to explore various aspects of type 2 diabetes, including weight management, renal function, and cardiovascular health, in an effort to develop more effective treatments and improve the overall management of the condition.

Despite the different studies and treatments being investigated, the common thread is the focus on type 2 diabetes, a medical condition that is becoming increasingly prevalent worldwide. Eli Lilly's research efforts in this area demonstrate the company's commitment to addressing the challenges posed by type 2 diabetes and improving the lives of those affected by this chronic condition.</data>
    </node>
    <node id="45">
      <data key="d0">METFORMIN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">39.0</data>
      <data key="d5">Metformin is a medication that plays a significant role in the management of type 2 diabetes mellitus. Based on the provided descriptions, Metformin is a background medication used in some of the Eli Lilly studies, and it is also the medication that participants with type 2 diabetes mellitus are taking and being studied in combination with tirzepatide.

Participants in the ACHIEVE-3 trial, a study conducted by Eli Lilly, had type 2 diabetes that was inadequately controlled with Metformin. This suggests that Metformin was the primary medication these participants were taking to manage their condition, but it was not providing sufficient control of their diabetes.

The descriptions indicate that Metformin is a key component in the treatment of type 2 diabetes, both as a standalone medication and in combination with other therapies, such as tirzepatide. Metformin is widely used as a first-line treatment for type 2 diabetes, and it is often prescribed in combination with other medications to help manage the condition more effectively.

In the context of the Eli Lilly studies, Metformin is being used as a background medication, which means it is being administered alongside the primary investigational drug or treatment being studied. This suggests that Metformin is a well-established and commonly used medication in the management of type 2 diabetes, and it is being used as a reference point or comparator in these studies.

Overall, the provided descriptions paint a consistent picture of Metformin as a widely used and important medication in the treatment of type 2 diabetes. It is being used both as a standalone therapy and in combination with other medications, and it is a key component in the management of the condition, even in cases where it may not be providing adequate control on its own.</data>
    </node>
    <node id="46">
      <data key="d0">CHUGAI PHARMACEUTICAL CO., LTD.</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">Chugai Pharmaceutical Co., Ltd. discovered orforglipron and licensed it to Lilly in 2018</data>
    </node>
    <node id="47">
      <data key="d0">LILLY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">Lilly is a pharmaceutical company that is currently developing a new drug called orforglipron. The company is running Phase 3 clinical studies on this drug and expects to submit it for regulatory approval in 2026.

Lilly is a well-established pharmaceutical company that has been in the industry for many years. They are known for their research and development of innovative drugs that address various medical conditions. The company's focus on orforglipron is part of their ongoing efforts to expand their drug portfolio and provide new treatment options for patients.

The Phase 3 studies on orforglipron are a critical stage in the drug development process, as they involve large-scale clinical trials to evaluate the drug's safety and efficacy. These studies are designed to gather the necessary data to support the submission of the drug for regulatory approval, which is expected to occur in 2026.

Lilly's commitment to the development of orforglipron demonstrates their dedication to advancing medical research and improving patient outcomes. The company's expertise in drug development and their track record of successful drug approvals suggest that they are well-positioned to bring this new drug to market.

Overall, Lilly's work on orforglipron is a significant development in the pharmaceutical industry, and the successful approval and commercialization of this drug could have a positive impact on the treatment of the medical conditions it is designed to address.</data>
    </node>
    <node id="48">
      <data key="d0">UNITED STATES</data>
      <data key="d1">GEO</data>
      <data key="d2">39.0</data>
      <data key="d5">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </node>
    <node id="49">
      <data key="d0">ARGENTINA</data>
      <data key="d1">GEO</data>
      <data key="d2">39.0</data>
      <data key="d5">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </node>
    <node id="50">
      <data key="d0">CHINA</data>
      <data key="d1">GEO</data>
      <data key="d2">39.0</data>
      <data key="d5">China is a key market for the pharmaceutical company Eli Lilly. The country is a focus for Eli Lilly's efforts to expand its portfolio of GLP-1 therapies, which are used to treat various health conditions.

In addition to being a target market for Eli Lilly's products, China is also the location where a clinical study on the drug selpercatinib is being conducted. Selpercatinib is being investigated for its potential to treat RET fusion-positive solid tumors, medullary thyroid cancer, and other types of cancer with RET activation.

The ACHIEVE-3 clinical trial, which is evaluating Eli Lilly's therapies, has been conducted across multiple countries, including China, the United States, Argentina, Japan, Mexico, and Puerto Rico. This global approach to the clinical trial suggests that Eli Lilly is seeking to gather data and regulatory approvals in various markets, including China, as part of its strategy to make its products available to patients worldwide.

Overall, China appears to be a significant focus for Eli Lilly's pharmaceutical research and development efforts, as well as a key target market for the company's existing and upcoming therapies. The country's large population and growing healthcare needs make it an attractive opportunity for Eli Lilly to expand its global reach and impact.</data>
    </node>
    <node id="51">
      <data key="d0">JAPAN</data>
      <data key="d1">GEO</data>
      <data key="d2">39.0</data>
      <data key="d5">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </node>
    <node id="52">
      <data key="d0">MEXICO</data>
      <data key="d1">GEO</data>
      <data key="d2">39.0</data>
      <data key="d5">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </node>
    <node id="53">
      <data key="d0">PUERTO RICO</data>
      <data key="d1">GEO</data>
      <data key="d2">39.0</data>
      <data key="d5">Puerto Rico is a U.S. territory located in the Caribbean Sea, not an independent country. The ACHIEVE-3 trial, a clinical study, was conducted across several countries including the United States, Argentina, China, Japan, Mexico, and Puerto Rico.

Puerto Rico is an unincorporated territory of the United States, with a population of over 3.2 million people. It is an archipelago made up of the main island of Puerto Rico and several smaller islands. The capital and largest city is San Juan. Puerto Rico has a rich cultural heritage, with influences from Spanish, African, and indigenous Ta√≠no traditions.

The ACHIEVE-3 trial was a multi-national, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of a new investigational drug. The trial was conducted across several countries, including the United States, Argentina, China, Japan, Mexico, and Puerto Rico. The inclusion of Puerto Rico in this multinational study suggests that the researchers were able to enroll participants from the territory to contribute to the overall data and findings of the trial.

In summary, Puerto Rico is a U.S. territory, not an independent country, and was one of the locations where the ACHIEVE-3 clinical trial was conducted, along with several other countries around the world.</data>
    </node>
    <node id="54">
      <data key="d0">AMERICAN DIABETES ASSOCIATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">The American Diabetes Association publishes standards of care for diabetes management</data>
    </node>
    <node id="55">
      <data key="d0">ACHIEVE PHASE 3</data>
      <data key="d1" />
      <data key="d2">35.0</data>
      <data key="d5" />
    </node>
    <node id="56">
      <data key="d0">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">The United States Securities and Exchange Commission is the regulatory body that Eli Lilly and Company files reports with</data>
    </node>
    <node id="57">
      <data key="d0">FORM 10-K</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Form 10-K is a comprehensive annual report filed by public companies with the United States Securities and Exchange Commission</data>
    </node>
    <node id="58">
      <data key="d0">FORM 10-Q</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">44.0</data>
      <data key="d5">Form 10-Q is a quarterly financial report filed by public companies with the United States Securities and Exchange Commission</data>
    </node>
    <node id="59">
      <data key="d0">CLINICAL TRIALS</data>
      <data key="d1" />
      <data key="d2">35.0</data>
      <data key="d5" />
    </node>
    <node id="60">
      <data key="d0">WEILY SOONG</data>
      <data key="d1">PERSON</data>
      <data key="d2">53.0</data>
      <data key="d5">Weily Soong is an individual associated with Eli Lilly, a pharmaceutical company. Based on the provided descriptions, Weily Soong serves as a contact for one of Eli Lilly's clinical trials and is also an author related to the studies conducted by the company.

Weily Soong's role as a contact for an Eli Lilly clinical trial suggests that they are involved in the research and development of new pharmaceutical products or treatments. Clinical trials are a crucial part of the drug development process, as they help evaluate the safety and efficacy of potential new medications before they can be approved for widespread use.

The description that Weily Soong is an author related to the studies conducted by Eli Lilly further indicates their involvement in the company's research activities. Authors are often researchers or scientists who have contributed to the publication of scientific papers or reports detailing the findings of their studies.

By serving as both a contact for a clinical trial and an author related to Eli Lilly's research, Weily Soong appears to play a significant role in the company's efforts to develop new pharmaceutical products. Their expertise and knowledge in the field of clinical research and study design likely contribute to Eli Lilly's overall research and development efforts.

It is important to note that the provided descriptions do not contain any contradictory information about Weily Soong's role or involvement with Eli Lilly. The two descriptions are complementary and provide a consistent picture of Weily Soong's association with the company.

In summary, Weily Soong is an individual who is closely involved with Eli Lilly, a leading pharmaceutical company. Weily Soong serves as a contact for one of Eli Lilly's clinical trials and is also an author related to the studies conducted by the company, indicating their significant contribution to the research and development of new pharmaceutical products.</data>
    </node>
    <node id="61">
      <data key="d0">ALMENA FREE</data>
      <data key="d1">PERSON</data>
      <data key="d2">70.0</data>
      <data key="d5">Almena Free is an individual who is involved in a clinical trial or study conducted by the pharmaceutical company Eli Lilly. Based on the provided descriptions, Almena Free serves as a contact for one of Eli Lilly's clinical trials, and is also a participant in a clinical study.

The descriptions indicate that Almena Free has a connection to Eli Lilly's research and development efforts, likely as either a study coordinator or a patient enrolled in a clinical trial. Clinical trials are an essential part of the drug development process, as they allow pharmaceutical companies to test the safety and efficacy of new medications before seeking regulatory approval for their use.

While the provided descriptions do not offer detailed information about the specific nature of Almena Free's involvement, it is clear that they play a role in Eli Lilly's clinical research activities. This could involve tasks such as serving as a point of contact for study participants, assisting with the coordination of trial logistics, or providing feedback and data as a participant in the study.

The descriptions do not contain any contradictory information, suggesting that Almena Free's involvement with Eli Lilly's clinical trials is consistent across the available data. However, without additional details, it is difficult to provide a more comprehensive summary of Almena Free's exact role or the specific study they are associated with.

In conclusion, Almena Free is an individual who is connected to Eli Lilly's clinical research efforts, either as a contact or a participant in one of the company's clinical trials. This involvement likely contributes to Eli Lilly's ongoing efforts to develop new and improved pharmaceutical products, though the exact nature of Almena Free's role remains somewhat limited based on the information provided.</data>
    </node>
    <node id="62">
      <data key="d0">LY3209590</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">26.0</data>
      <data key="d5">LY3209590 is a drug being developed by the pharmaceutical company Eli Lilly. It is currently undergoing clinical trials to evaluate its pharmacokinetics and potential as a treatment for type 2 diabetes in pediatric patients.

The available information indicates that LY3209590 is an insulin product, meaning it is a form of insulin that is being investigated as a potential therapeutic option. Insulin is a hormone that plays a crucial role in regulating blood sugar levels, and insulin products are commonly used to manage diabetes.

The primary focus of the ongoing research is to assess the pharmacokinetics of LY3209590, which refers to the study of how the drug is absorbed, distributed, metabolized, and eliminated by the body. This type of study is essential in understanding the drug's behavior and optimizing its dosing and administration for safe and effective use in patients.

The clinical trials involving LY3209590 are specifically targeting pediatric participants with type 2 diabetes. Type 2 diabetes is a chronic condition characterized by the body's inability to effectively use insulin, leading to high blood sugar levels. While type 2 diabetes was traditionally more common in adults, the prevalence of the disease has been increasing in children and adolescents as well.

By conducting these studies in the pediatric population, the researchers aim to gather valuable data on the safety, efficacy, and appropriate use of LY3209590 in this specific patient group. This information will be crucial in developing effective treatment strategies and improving the management of type 2 diabetes in children and adolescents.

In summary, LY3209590 is an insulin product being developed by Eli Lilly for the treatment of type 2 diabetes in pediatric patients. The current focus of the research is on evaluating the pharmacokinetics of the drug, which will help guide its further development and potential clinical application in the management of diabetes in the younger population.</data>
    </node>
    <node id="63">
      <data key="d0">LY3537031</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY3537031 is a product being studied by Eli Lilly</data>
    </node>
    <node id="64">
      <data key="d0">LEBRIKIZUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">53.0</data>
      <data key="d5">Lebrikizumab is a drug that is being extensively studied and evaluated for the treatment of various medical conditions. The primary focus of the research on lebrikizumab appears to be in the area of dermatological and respiratory disorders.

Lebrikizumab is being evaluated for the treatment of moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition. The drug is currently in Phase 3 clinical trials conducted by Eli Lilly to assess its safety and efficacy in treating this condition. Additionally, an open-label study is being conducted by Eli Lilly to evaluate the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis who have previously been treated with dupilumab.

Beyond atopic dermatitis, lebrikizumab is also being studied for the treatment of moderate-to-severe atopic hand and foot dermatitis, another type of inflammatory skin condition. Furthermore, the drug is being evaluated in a clinical trial by Chao Ci, though the specific details of this study are not provided.

In the respiratory domain, lebrikizumab is being investigated for the treatment of perennial allergic rhinitis, a chronic condition characterized by nasal inflammation and symptoms such as sneezing, itching, and congestion. The drug is currently in a Phase 3 clinical study to assess its efficacy in treating this condition.

Additionally, lebrikizumab is being evaluated for the treatment of chronic rhinosinusitis with nasal polyps, a condition characterized by inflammation of the sinuses and the presence of polyps in the nasal passages. This potential application of lebrikizumab is being explored, though the specific details of the research are not provided.

In summary, lebrikizumab is a drug that is being extensively studied and evaluated for the treatment of a variety of medical conditions, with a particular focus on dermatological and respiratory disorders. The drug is currently in various stages of clinical trials, including Phase 3 studies, to assess its safety and efficacy in treating these conditions. The research on lebrikizumab is being conducted by Eli Lilly and other research organizations, with the goal of developing new treatment options for patients suffering from these challenging medical conditions.</data>
    </node>
    <node id="65">
      <data key="d0">BIMAGRUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">74.0</data>
      <data key="d5">Bimagrumab is a drug being developed by the pharmaceutical company Eli Lilly. It is currently in the research and development stage, with several ongoing studies investigating its potential uses.

According to the available information, Bimagrumab is being studied alone or in addition to another drug called semaglutide. The purpose of these studies is to explore the potential of Bimagrumab for the treatment of overweight or obese men and women. The specific mechanism of action and intended therapeutic application of Bimagrumab are not clearly defined in the provided descriptions.

The descriptions indicate that Bimagrumab is being studied for an unspecified purpose, suggesting that its exact clinical indication is still under investigation. However, the information provided also suggests that Bimagrumab is being evaluated, either alone or in combination with semaglutide, for the management of overweight and obesity in adults.

It is important to note that the descriptions do not contain any contradictory information. The various statements about Bimagrumab being studied for an unspecified purpose, alone or in combination with semaglutide, and for the treatment of overweight or obese individuals, can be reconciled into a coherent summary.

In conclusion, Bimagrumab is a drug being developed by Eli Lilly that is currently undergoing research and clinical studies. The available information suggests that Bimagrumab is being investigated, either alone or in combination with semaglutide, for the potential treatment of overweight and obesity in adults. However, the exact therapeutic purpose and mechanism of action of Bimagrumab are still under investigation and not clearly defined in the provided descriptions.</data>
    </node>
    <node id="66">
      <data key="d0">TYPE 1 DIABETES</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">47.0</data>
      <data key="d5">Type 1 diabetes is a condition being studied in Eli Lilly's clinical trials</data>
    </node>
    <node id="67">
      <data key="d0">OBESITY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">74.0</data>
      <data key="d5">Obesity is a medical condition that is being extensively studied in various clinical trials conducted by Eli Lilly, a pharmaceutical company. The descriptions provided indicate that obesity is the target condition for several of Eli Lilly's studies, including those involving the investigational drugs tirzepatide and LY3437943.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being evaluated for its potential to treat obesity. The clinical trials of tirzepatide are examining its efficacy and safety in managing obesity and overweight conditions.

Similarly, LY3437943 is another Eli Lilly investigational drug that is being studied for its ability to address obesity. The descriptions suggest that obesity is the specific condition that LY3305677, another Eli Lilly compound, is being investigated for.

In addition to these specific drug candidates, the provided information indicates that obesity, as a medical condition, is being broadly studied in Eli Lilly's clinical trials. The descriptions mention that obesity is a condition being studied in the clinical trials of various Eli Lilly products, including tirzepatide and ixekizumab.

The consistent references to obesity as the target condition across multiple Eli Lilly studies suggest that the company is actively engaged in researching and developing potential treatments for this prevalent health issue. The comprehensive nature of the descriptions indicates that Eli Lilly is committed to understanding the complexities of obesity and exploring various therapeutic approaches to address this growing public health concern.

In summary, obesity is a medical condition that is the focus of extensive clinical research efforts by Eli Lilly. The company is investigating the use of various investigational drugs, including tirzepatide, LY3437943, and ixekizumab, for their potential to manage and treat obesity. The consistent references to obesity across the provided descriptions suggest a concerted effort by Eli Lilly to address this significant health challenge.</data>
    </node>
    <node id="68">
      <data key="d0">OVERWEIGHT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">76.0</data>
      <data key="d5">Overweight is a medical condition that is being extensively studied in the clinical trials conducted by Eli Lilly, a leading pharmaceutical company. The descriptions provided indicate that overweight is the target condition for several of Eli Lilly's studies, including those involving the investigational drugs tirzepatide, LY3437943, and LY3305677.

Overweight is a complex medical condition characterized by an excessive accumulation of body fat, often resulting in a body mass index (BMI) greater than 25. This condition is associated with a range of health risks, including an increased risk of developing type 2 diabetes, cardiovascular disease, certain types of cancer, and other chronic health problems.

Eli Lilly's clinical trials are focused on exploring new treatment options and strategies to address the growing prevalence of overweight and obesity worldwide. The company's research efforts aim to develop safe and effective interventions that can help individuals manage their weight and improve their overall health and well-being.

The descriptions suggest that Eli Lilly is taking a comprehensive approach to studying overweight, with multiple clinical trials investigating different investigational drugs and treatment approaches. This indicates the company's commitment to finding innovative solutions to this significant public health challenge.

It is important to note that while the descriptions provided do not appear to be contradictory, the specific details of the clinical trials, such as the study designs, patient populations, and outcome measures, are not fully disclosed. As with any clinical research, the results and conclusions drawn from these studies will need to be carefully evaluated and validated through the rigorous scientific process before any new treatments can be approved and made available to patients.

In summary, Overweight is a medical condition that is the focus of extensive clinical research efforts by Eli Lilly, a leading pharmaceutical company. The company's studies are exploring various investigational drugs and treatment approaches to address this complex and prevalent health issue, with the ultimate goal of developing safe and effective interventions to improve the lives of individuals affected by overweight and related health conditions.</data>
    </node>
    <node id="69">
      <data key="d0">ATOPIC DERMATITIS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">53.0</data>
      <data key="d5">Atopic Dermatitis: A Comprehensive Summary

Atopic dermatitis is a chronic inflammatory skin condition that is the focus of several clinical trials conducted by Eli Lilly. The condition is characterized by dry, itchy, and inflamed skin, and can significantly impact an individual's quality of life.

The primary focus of the clinical trials is the investigation of the use of lebrikizumab, a monoclonal antibody, in the treatment of atopic dermatitis. Lebrikizumab is being studied in an open-label study, as well as in other clinical trials, to evaluate its efficacy and safety in participants with moderate-to-severe atopic dermatitis.

The clinical trials aim to assess the potential of lebrikizumab as a treatment option for individuals suffering from this debilitating skin condition. Atopic dermatitis can be a challenging condition to manage, and the development of new therapies is crucial to improving the quality of life for those affected.

The studies are designed to gather comprehensive data on the use of lebrikizumab in the treatment of atopic dermatitis, including its impact on the severity of symptoms, the duration of remission, and the overall safety profile of the medication. The results of these trials will be closely monitored and analyzed to determine the potential of lebrikizumab as a viable treatment option for individuals with moderate-to-severe atopic dermatitis.

In summary, Eli Lilly is conducting clinical trials focused on the use of lebrikizumab in the treatment of atopic dermatitis, a chronic and often debilitating skin condition. The trials are designed to evaluate the efficacy and safety of this monoclonal antibody in participants with moderate-to-severe atopic dermatitis, with the goal of providing a new and effective treatment option for those affected by this condition.</data>
    </node>
    <node id="70">
      <data key="d0">MARSHALL SCHREEDER</data>
      <data key="d1">PERSON</data>
      <data key="d2">70.0</data>
      <data key="d5">Marshall Schreeder is a participant in a clinical study</data>
    </node>
    <node id="71">
      <data key="d0">OLIVER KLEIN</data>
      <data key="d1">PERSON</data>
      <data key="d2">70.0</data>
      <data key="d5">Oliver Klein is a participant in two clinical studies</data>
    </node>
    <node id="72">
      <data key="d0">LY3537982</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">34.0</data>
      <data key="d5">LY3537982 is a drug being investigated in clinical studies for the treatment of KRAS G12C-mutant advanced solid tumors. The drug is currently in a Phase 1 study, which is being conducted in Chinese patients with KRAS G12C-mutant advanced solid tumors.

The descriptions provided indicate that LY3537982 is a study drug, meaning it is an investigational medication that is being evaluated for its safety and efficacy in treating a specific medical condition. In this case, the drug is being studied for its potential to treat KRAS G12C-mutant advanced solid tumors, which are a type of cancer characterized by the presence of a specific genetic mutation in the KRAS gene.

The Phase 1 study is the first stage of clinical trials, which are designed to assess the safety and tolerability of the drug in a small group of patients. This study is being conducted in Chinese patients, which suggests that the drug may have particular relevance or potential for treating this population.

While the descriptions do not provide detailed information about the mechanism of action or the specific formulation of LY3537982, they do indicate that the drug is being developed and investigated by Eli Lilly, a major pharmaceutical company. This suggests that the drug has shown promise in preclinical studies and has been selected for further clinical evaluation.

In summary, LY3537982 is an investigational drug that is currently being studied in a Phase 1 clinical trial for the treatment of KRAS G12C-mutant advanced solid tumors in Chinese patients. The drug is being developed by Eli Lilly and has the potential to provide a new treatment option for this specific type of cancer.</data>
    </node>
    <node id="73">
      <data key="d0">PEMBROLIZUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">Pembrolizumab is a drug that is being evaluated for the treatment of various types of cancer. It is a standard of care anti-cancer drug that is currently being used in a clinical study.

Pembrolizumab is being evaluated in combination with another drug called abemaciclib for the treatment of non-small cell lung cancer and breast cancer. The combination of these two drugs is being studied to determine its effectiveness in treating these types of cancer.

Pembrolizumab is a type of immunotherapy drug that works by helping the body's immune system recognize and attack cancer cells. It is designed to target a specific protein called PD-1, which is found on the surface of certain immune cells. By blocking the PD-1 protein, pembrolizumab can help the immune system recognize and attack cancer cells more effectively.

The clinical study involving pembrolizumab is aimed at evaluating the safety and efficacy of the drug, both as a standalone treatment and in combination with other therapies. The study is likely to provide valuable insights into the potential of pembrolizumab as a treatment option for non-small cell lung cancer and breast cancer.

Overall, pembrolizumab is a promising anti-cancer drug that is being actively studied for its potential to improve outcomes for patients with certain types of cancer. The combination of pembrolizumab with abemaciclib is a particularly interesting area of research, as it may offer a more effective treatment approach for non-small cell lung cancer and breast cancer.</data>
    </node>
    <node id="74">
      <data key="d0">PEMETREXED</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">34.0</data>
      <data key="d5">Pemetrexed is a standard of care anti-cancer drug being used in a clinical study</data>
    </node>
    <node id="75">
      <data key="d0">PLATINUM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">34.0</data>
      <data key="d5">Platinum is a standard of care anti-cancer drug being used in a clinical study</data>
    </node>
    <node id="76">
      <data key="d0">LY4057996</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">40.0</data>
      <data key="d5">LY4057996 is a study drug being investigated in a clinical study</data>
    </node>
    <node id="77">
      <data key="d0">CHRONIC KIDNEY DISEASE</data>
      <data key="d1" />
      <data key="d2">40.0</data>
      <data key="d5" />
    </node>
    <node id="78">
      <data key="d0">HYPERTENSION</data>
      <data key="d1" />
      <data key="d2">35.0</data>
      <data key="d5" />
    </node>
    <node id="79">
      <data key="d0">GZL2</data>
      <data key="d1">EVENT</data>
      <data key="d2">38.0</data>
      <data key="d5">An independent study conducted under the GZPL master protocol to evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight</data>
    </node>
    <node id="80">
      <data key="d0">GPI1</data>
      <data key="d1">EVENT</data>
      <data key="d2">47.0</data>
      <data key="d5">A study evaluating tirzepatide in participants with obstructive sleep apnea and obesity who are unwilling or unable to use Positive Airway Pressure (PAP) therapy</data>
    </node>
    <node id="81">
      <data key="d0">GPI2</data>
      <data key="d1">EVENT</data>
      <data key="d2">47.0</data>
      <data key="d5">A study evaluating tirzepatide in participants with obstructive sleep apnea and obesity who are and plan to stay on PAP therapy</data>
    </node>
    <node id="82">
      <data key="d0">LY3372993</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">62.0</data>
      <data key="d5">LY3372993 is a drug being developed and assessed by Eli Lilly for the treatment of early symptomatic Alzheimer's disease. The drug is currently undergoing clinical trials to evaluate its safety, tolerability, and efficacy in patients with early-stage Alzheimer's.

Alzheimer's disease is a progressive neurodegenerative disorder that affects cognitive function, memory, and behavior. The early stages of the disease are characterized by subtle changes in cognitive abilities, such as difficulty with memory, problem-solving, and language. As the disease progresses, these symptoms worsen, and individuals may experience more severe cognitive impairment, as well as changes in mood and behavior.

The development of LY3372993 is part of Eli Lilly's efforts to find new treatments for Alzheimer's disease. The drug is currently being evaluated in clinical trials to assess its potential to slow the progression of the disease or improve cognitive function in individuals with early-stage Alzheimer's.

The clinical trials are designed to gather data on the safety and tolerability of LY3372993, as well as its efficacy in improving or stabilizing cognitive function in patients. The trials may involve a range of assessments, such as cognitive tests, neuroimaging, and measures of daily functioning, to evaluate the drug's impact on the various symptoms and manifestations of Alzheimer's disease.

By focusing on the early stages of Alzheimer's, the development of LY3372993 aims to intervene at a critical point in the disease process, potentially slowing or even preventing the more severe cognitive and functional decline that occurs in later stages. This approach is based on the understanding that early intervention may be more effective in managing Alzheimer's disease and improving the quality of life for those affected.

The results of the ongoing clinical trials will be closely monitored and analyzed to determine the potential of LY3372993 as a new treatment option for individuals with early-stage Alzheimer's disease. If the drug demonstrates promising results in terms of safety, tolerability, and efficacy, it may pave the way for further development and potential regulatory approval, offering new hope for those living with this debilitating condition.</data>
    </node>
    <node id="83">
      <data key="d0">REMTERNETUG</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">62.0</data>
      <data key="d5">Remternetug is a drug that is currently being investigated in a clinical study for the treatment of early Alzheimer's disease. The study is focused on evaluating the efficacy and safety of Remternetug in individuals with early symptomatic Alzheimer's disease.

Alzheimer's disease is a progressive neurodegenerative disorder that affects cognitive function, memory, and daily living activities. The early stages of the disease are characterized by subtle changes in cognitive abilities, which can be challenging to detect and diagnose. The development of effective treatments for the early stages of Alzheimer's disease is a critical area of research, as early intervention may have the potential to slow the progression of the disease and improve patient outcomes.

The study on Remternetug is designed to assess the drug's ability to address the underlying pathological processes associated with Alzheimer's disease, with the goal of improving cognitive function and delaying the onset of more severe symptoms. The study is being conducted in a population of individuals with early symptomatic Alzheimer's disease, which means that they are experiencing the initial signs and symptoms of the condition but have not yet progressed to the more advanced stages.

The details of the study, including the specific dosage regimen, duration, and outcome measures, are not provided in the information given. However, the study is likely designed to evaluate the safety and efficacy of Remternetug in this patient population, with the ultimate goal of determining whether the drug can be a viable treatment option for individuals with early Alzheimer's disease.

It is important to note that the information provided does not indicate any contradictions or inconsistencies in the descriptions of Remternetug and the study. The descriptions are aligned and provide a coherent understanding of the drug and the research being conducted.

In summary, Remternetug is a drug that is currently being investigated in a clinical study for the treatment of early Alzheimer's disease. The study is focused on evaluating the safety and efficacy of the drug in individuals with early symptomatic Alzheimer's disease, with the goal of potentially slowing the progression of the disease and improving patient outcomes.</data>
    </node>
    <node id="84">
      <data key="d0">CWMM</data>
      <data key="d1">EVENT</data>
      <data key="d2">70.0</data>
      <data key="d5">A master protocol for a randomized, controlled, clinical trial of multiple interventions for chronic weight management in adult participants with obesity or overweight</data>
    </node>
    <node id="85">
      <data key="d0">LY4086940</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">A drug being evaluated for safety, tolerability, and pharmacokinetics in healthy participants and participants with overweight or obesity, with or without type 2 diabetes</data>
    </node>
    <node id="86">
      <data key="d0">LIBRETTO-432</data>
      <data key="d1">EVENT</data>
      <data key="d2">65.0</data>
      <data key="d5">A placebo-controlled, double-blinded, randomized phase 3 study of adjuvant selpercatinib following definitive locoregional treatment in participants with stage IB-IIIA RET fusion-positive NSCLC</data>
    </node>
    <node id="87">
      <data key="d0">SELPERCATINIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">65.0</data>
      <data key="d5">Selpercatinib (also known as LOXO-292) is a drug that is currently being studied in clinical trials for the treatment of various types of advanced solid tumors. The primary focus of these studies is on the use of selpercatinib for the treatment of RET fusion-positive solid tumors, medullary thyroid cancer, and other tumors with RET activation.

One of the key studies involving selpercatinib is the LIBRETTO-432 study, which is comparing the drug to standard treatment for RET fusion-positive non-small cell lung cancer. This study is evaluating the safety and efficacy of selpercatinib in this specific patient population.

Selpercatinib is a targeted therapy that has been designed to inhibit the activity of the RET (rearranged during transfection) protein, which is a receptor tyrosine kinase that plays a crucial role in the development and progression of certain types of cancer. By targeting the RET protein, selpercatinib aims to disrupt the signaling pathways that drive tumor growth and spread.

The clinical trials involving selpercatinib are investigating its potential to provide a more effective and targeted treatment option for patients with advanced solid tumors, particularly those with RET fusion-positive or RET-activated tumors. These studies are designed to assess the safety, tolerability, and efficacy of selpercatinib in these patient populations, with the goal of potentially expanding the treatment options available for individuals with these challenging cancer types.

Overall, the data provided indicates that selpercatinib is a promising investigational drug that is being evaluated for its ability to improve outcomes for patients with advanced solid tumors, including RET fusion-positive non-small cell lung cancer. The ongoing clinical trials will provide valuable insights into the potential clinical benefits and safety profile of this targeted therapy.</data>
    </node>
    <node id="88">
      <data key="d0">NSCLC</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">71.0</data>
      <data key="d5">Non-small cell lung cancer (NSCLC) is a type of lung cancer that is being studied in the clinical trial of abemaciclib. NSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases.

NSCLC is a broad term that includes several subtypes of lung cancer, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes are classified based on the appearance of the cancer cells under a microscope.

NSCLC is typically treated with a combination of therapies, including surgery, chemotherapy, radiation therapy, and targeted therapies. The specific treatment plan will depend on the stage of the cancer, the patient's overall health, and other factors.

In the clinical trial of abemaciclib, NSCLC is being studied as a potential target for this investigational drug. Abemaciclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, which means it works by blocking the activity of certain proteins that are involved in cell division. This can help slow the growth and spread of cancer cells.

The clinical trial is evaluating the safety and efficacy of abemaciclib in patients with NSCLC. The study is designed to assess whether the addition of abemaciclib to standard treatment can improve outcomes for patients with this type of lung cancer.

Overall, NSCLC is a complex and challenging disease, but ongoing research and clinical trials, such as the one involving abemaciclib, are helping to advance our understanding and treatment of this condition.</data>
    </node>
    <node id="89">
      <data key="d0">J1I-MC-GZQE</data>
      <data key="d1">EVENT</data>
      <data key="d2">41.0</data>
      <data key="d5">A phase 1 study to investigate the effect of retatrutide on metoprolol pharmacokinetics in healthy participants</data>
    </node>
    <node id="90">
      <data key="d0">METOPROLOL</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">41.0</data>
      <data key="d5">The drug whose pharmacokinetics are being evaluated in the presence of retatrutide</data>
    </node>
    <node id="91">
      <data key="d0">LY3502970</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY3502970 is a drug that is currently being evaluated in several phase 3 clinical studies for the treatment of type 2 diabetes, obesity, and overweight in adult participants.

The primary focus of the clinical development of LY3502970 is in the treatment of type 2 diabetes. One phase 3 study is specifically evaluating the efficacy and safety of LY3502970 in adult participants with type 2 diabetes who have inadequate glycemic control despite diet and exercise alone. This study aims to assess the ability of LY3502970 to improve glycemic control in this patient population.

In addition to the type 2 diabetes studies, LY3502970 is also being investigated in phase 3 trials for the treatment of obesity and overweight. These studies are exploring the potential of LY3502970 to facilitate weight loss and improve associated metabolic parameters in individuals struggling with excess weight.

To further characterize the long-term safety profile of LY3502970, a dedicated long-term safety study is also being conducted in adult participants with type 2 diabetes. This study is designed to provide additional data on the safety and tolerability of LY3502970 when used for extended durations in the management of type 2 diabetes.

Overall, the available data suggests that LY3502970 is a promising investigational drug that is being evaluated for its potential to address the significant unmet medical needs in the management of type 2 diabetes, obesity, and overweight. The comprehensive clinical development program aims to establish the efficacy, safety, and long-term tolerability of LY3502970 in these important therapeutic areas.</data>
    </node>
    <node id="92">
      <data key="d0">ATTAIN-HYPERTENSION</data>
      <data key="d1" />
      <data key="d2">38.0</data>
      <data key="d5" />
    </node>
    <node id="93">
      <data key="d0">GZPL</data>
      <data key="d1" />
      <data key="d2">38.0</data>
      <data key="d5" />
    </node>
    <node id="94">
      <data key="d0">OLOMORASIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">
Olomorasib is a drug being studied by Eli Lilly in combination with immunotherapy for treating KRAS G12C-mutant non-small cell lung cancer</data>
    </node>
    <node id="95">
      <data key="d0">MAZDUTIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">
Mazdutide is a drug being studied by Eli Lilly in a proof-of-concept trial for treating alcohol use disorder</data>
    </node>
    <node id="96">
      <data key="d0">LOXO-292</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">
LOXO-292 is an oral RET inhibitor being studied by Eli Lilly in a Phase 1/2 trial for treating advanced RET-altered solid or primary central nervous system tumors in pediatric patients</data>
    </node>
    <node id="97">
      <data key="d0">LOXO-435</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">
LOXO-435 is a drug being studied by Eli Lilly in a Phase 1 trial for treating locally advanced or metastatic solid tumors including urothelial cancer with FGFR3 alterations</data>
    </node>
    <node id="98">
      <data key="d0">KRISTIN CASTORINO</data>
      <data key="d1">PERSON</data>
      <data key="d2">47.0</data>
      <data key="d5">Kristin Castorino is involved in the clinical trial of tirzepatide</data>
    </node>
    <node id="99">
      <data key="d0">LY4066434</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">LY4066434 is a pan-KRAS inhibitor drug being studied in a clinical trial for the treatment of KRAS mutant solid tumors</data>
    </node>
    <node id="100">
      <data key="d0">LY3962673</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">28.0</data>
      <data key="d5">LY3962673 is a drug being studied in a clinical trial for the treatment of KRAS G12D-mutant solid tumors</data>
    </node>
    <node id="101">
      <data key="d0">LY3437943</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">75.0</data>
      <data key="d5">LY3437943 (also known as retatrutide) is a drug that is currently being studied in clinical trials. The drug is being evaluated for its safety and efficacy in two different populations:

1. Participants who have obesity or are overweight and have osteoarthritis of the knee: In this clinical trial, the safety and efficacy of LY3437943 are being evaluated in this specific group of participants.

2. Participants without type 2 diabetes: LY3437943 is also being investigated in a master protocol study to evaluate its efficacy and safety in this broader population.

The descriptions provided do not appear to be contradictory, but rather, they highlight the different clinical trials and populations being studied with LY3437943. The drug is being investigated for its potential benefits in both individuals with obesity or overweight and osteoarthritis of the knee, as well as in those without type 2 diabetes.

The clinical trials are designed to assess the safety and efficacy of LY3437943 in these various populations. Safety is a critical aspect of any drug development process, and the trials will closely monitor the participants for any adverse events or side effects associated with the use of the drug.

Efficacy, on the other hand, refers to the drug's ability to achieve the desired therapeutic effect. In the case of LY3437943, the trials are likely evaluating the drug's potential to improve outcomes related to weight management, osteoarthritis symptoms, or other relevant measures, depending on the specific population being studied.

It is important to note that the results of these clinical trials are not yet available, and the ultimate safety and efficacy of LY3437943 will be determined based on the data collected during the studies. The findings from these trials will provide valuable insights into the potential use of LY3437943 as a treatment option for the conditions being investigated.

In summary, LY3437943 is a drug that is currently being studied in clinical trials to evaluate its safety and efficacy in two different populations: individuals with obesity or overweight and osteoarthritis of the knee, as well as those without type 2 diabetes. The ongoing research aims to provide a better understanding of the potential benefits and risks associated with the use of this investigational drug.</data>
    </node>
    <node id="102">
      <data key="d0">ABEMACICLIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">Abemaciclib is a drug that is being extensively evaluated in various clinical trials for the treatment of different types of cancer. 

Abemaciclib is a CDK4/6 inhibitor drug that is being studied in the MONARCH 2 trial for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. It is being evaluated alone or in combination with tamoxifen for the treatment of previously treated hormone receptor-positive, HER2-negative metastatic breast cancer.

In addition to breast cancer, Abemaciclib is also being studied for the treatment of metastatic castration-resistant prostate cancer. It is being evaluated in combination with abiraterone acetate and prednisone for this indication. Eli Lilly is also studying Abemaciclib in combination with abiraterone acetate for the treatment of metastatic prostate cancer.

Abemaciclib is also being evaluated for the treatment of stage IV non-small cell lung cancer with a detectable KRAS mutation who have progressed after platinum-based chemotherapy. It is being studied to evaluate its safety and efficacy in this patient population.

Furthermore, Abemaciclib is being investigated in combination with chemotherapy for the treatment of Ewing's sarcoma. It is also being studied in combination with imlunestrant in a clinical trial by Eli Lilly.

Lastly, Abemaciclib will be evaluated in combination with pembrolizumab for the treatment of non-small cell lung cancer and breast cancer.

In summary, Abemaciclib is a versatile drug that is being extensively studied in various clinical trials for the treatment of different types of cancer, including breast cancer, prostate cancer, non-small cell lung cancer, and Ewing's sarcoma. The drug is being evaluated both as a monotherapy and in combination with other therapies to assess its safety and efficacy in these patient populations.</data>
    </node>
    <node id="103">
      <data key="d0">LOXO-260</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">66.0</data>
      <data key="d5">LOXO-260 is a drug that is currently being studied in a clinical trial for the treatment of various types of cancer. According to the provided descriptions, LOXO-260 is being evaluated for the treatment of RET fusion-positive solid tumors, medullary thyroid cancer, and other tumors with RET activation that are refractory (resistant) to selective RET inhibitors.

The descriptions indicate that LOXO-260 is a study drug, meaning it is still in the research and development phase and has not yet been approved for widespread use. The clinical trial is likely aimed at assessing the safety and efficacy of LOXO-260 in treating the targeted cancer types.

RET fusion-positive solid tumors and tumors with RET activation are the primary focus of the LOXO-260 clinical trial. RET (Rearranged during Transfection) is a gene that can become abnormally activated in certain types of cancer, leading to uncontrolled cell growth and tumor formation. LOXO-260 is being investigated as a potential treatment option for these RET-driven cancers, particularly those that have become resistant to other selective RET inhibitors.

Medullary thyroid cancer is also specifically mentioned as a target for LOXO-260 in the provided descriptions. Medullary thyroid cancer is a rare type of thyroid cancer that originates from the C cells of the thyroid gland and is often associated with RET gene mutations.

The descriptions do not provide any contradictory information about LOXO-260 or its intended uses. The summary indicates that LOXO-260 is a promising investigational drug that is being evaluated for its potential to treat various types of RET-driven cancers, including RET fusion-positive solid tumors, medullary thyroid cancer, and other tumors with RET activation that have become resistant to other selective RET inhibitors.

Overall, the comprehensive summary of the data provided suggests that LOXO-260 is a drug with a specific focus on targeting RET-driven cancers, and that its clinical development is ongoing to assess its safety and efficacy in treating these challenging cancer types.</data>
    </node>
    <node id="104">
      <data key="d0">KRAS MUTATION</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">22.0</data>
      <data key="d5">KRAS mutation is a genetic condition being studied in the clinical trials of LY4066434, LY3962673, and abemaciclib</data>
    </node>
    <node id="105">
      <data key="d0">SOLID TUMORS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">67.0</data>
      <data key="d5">Solid tumors are a type of cancer being studied in the clinical trials of LY4066434, LY3962673, selpercatinib, and LOXO-260</data>
    </node>
    <node id="106">
      <data key="d0">MEDULLARY THYROID CANCER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">66.0</data>
      <data key="d5">Medullary thyroid cancer is a type of cancer being studied in the clinical trials of selpercatinib and LOXO-260</data>
    </node>
    <node id="107">
      <data key="d0">RET FUSION-POSITIVE SOLID TUMORS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">65.0</data>
      <data key="d5">RET fusion-positive solid tumors are a type of cancer being studied in the clinical trials of selpercatinib and LOXO-260</data>
    </node>
    <node id="108">
      <data key="d0">CHRONIC LYMPHOCYTIC LEUKEMIA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">64.0</data>
      <data key="d5">Chronic lymphocytic leukemia is a type of cancer being studied in the clinical trial of pirtobrutinib</data>
    </node>
    <node id="109">
      <data key="d0">SMALL LYMPHOCYTIC LYMPHOMA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">64.0</data>
      <data key="d5">Small lymphocytic lymphoma is a type of cancer being studied in the clinical trial of pirtobrutinib</data>
    </node>
    <node id="110">
      <data key="d0">NON-HODGKIN LYMPHOMA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">63.0</data>
      <data key="d5">Non-Hodgkin Lymphoma is a type of cancer that is being studied in several clinical trials. It is a group of blood cancers that develop from lymphocytes, a type of white blood cell.

In one clinical trial, the investigational drug pirtobrutinib is being evaluated for the treatment of non-Hodgkin lymphoma. Pirtobrutinib is a type of targeted therapy that works by inhibiting a protein called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of lymphoma cells.

Another investigational drug, LOXO-305, is also being studied for the treatment of non-Hodgkin lymphoma. LOXO-305 is a selective inhibitor of the BTK protein, similar to pirtobrutinib, and is being evaluated for its potential to treat various types of non-Hodgkin lymphoma.

Non-Hodgkin lymphoma is a heterogeneous disease, with several different subtypes that can vary in their aggressiveness and response to treatment. The specific subtype of non-Hodgkin lymphoma being studied in these clinical trials is not explicitly stated in the provided information.

The goal of these clinical trials is to evaluate the safety and efficacy of pirtobrutinib and LOXO-305 in patients with non-Hodgkin lymphoma, with the hope of developing new treatment options for this group of blood cancers. The results of these trials will provide valuable insights into the potential of these investigational drugs as novel therapies for non-Hodgkin lymphoma.

In summary, non-Hodgkin lymphoma is a type of cancer that is being studied in clinical trials of the investigational drugs pirtobrutinib and LOXO-305. These targeted therapies aim to inhibit the BTK protein, which is involved in the growth and survival of lymphoma cells, with the goal of improving treatment outcomes for patients with this group of blood cancers.</data>
    </node>
    <node id="111">
      <data key="d0">OSTEOARTHRITIS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">75.0</data>
      <data key="d5">Osteoarthritis is a medical condition being studied in the clinical trial of LY3437943</data>
    </node>
    <node id="112">
      <data key="d0">KRAS G12D MUTATION</data>
      <data key="d1" />
      <data key="d2">28.0</data>
      <data key="d5" />
    </node>
    <node id="113">
      <data key="d0">LY3372689</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">60.0</data>
      <data key="d5">LY3372689 is a study drug being evaluated for the treatment of early symptomatic Alzheimer's Disease</data>
    </node>
    <node id="114">
      <data key="d0">LY3549492</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">76.0</data>
      <data key="d5">LY3549492 is a study drug being evaluated for weight management in adults with obesity or overweight</data>
    </node>
    <node id="115">
      <data key="d0">LY3457263</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">50.0</data>
      <data key="d5">LY3457263 is a study drug being evaluated for the treatment of type 2 diabetes mellitus</data>
    </node>
    <node id="116">
      <data key="d0">LY4101174</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">67.0</data>
      <data key="d5">LY4101174 is an antibody-drug conjugate being evaluated for the treatment of recurrent, advanced or metastatic solid tumors</data>
    </node>
    <node id="117">
      <data key="d0">CRAIG GEDYE</data>
      <data key="d1">PERSON</data>
      <data key="d2">67.0</data>
      <data key="d5">Craig Gedye is an expert involved in the study of LY4101174</data>
    </node>
    <node id="118">
      <data key="d0">JOHN TESSER</data>
      <data key="d1">PERSON</data>
      <data key="d2">64.0</data>
      <data key="d5">John Tesser is an expert involved in the study of LY3541860</data>
    </node>
    <node id="119">
      <data key="d0">LY3541860</data>
      <data key="d1" />
      <data key="d2">70.0</data>
      <data key="d5" />
    </node>
    <node id="120">
      <data key="d0">TYPE 2 DIABETES MELLITUS</data>
      <data key="d1">GEO</data>
      <data key="d2">50.0</data>
      <data key="d5">LY3457263 is being evaluated for the treatment of type 2 diabetes mellitus</data>
    </node>
    <node id="121">
      <data key="d0">LUNG CANCER</data>
      <data key="d1" />
      <data key="d2">31.0</data>
      <data key="d5" />
    </node>
    <node id="122">
      <data key="d0">DC-853</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">DC-853 is a drug being evaluated in a phase 1 study for safety, tolerability, and pharmacokinetics in healthy participants</data>
    </node>
    <node id="123">
      <data key="d0">DULAGLUTIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">50.0</data>
      <data key="d5">Dulaglutide is a pharmaceutical drug that has been the subject of various clinical studies and research. Based on the provided descriptions, the key information about Dulaglutide can be summarized as follows:

Dulaglutide is a comparator drug used in the SURPASS-CVOT study, which is evaluating the efficacy of another drug, tirzepatide, in patients with type 2 diabetes and increased cardiovascular risk. This suggests that Dulaglutide is being used as a reference point or comparison to assess the performance of tirzepatide in this specific patient population.

Additionally, Dulaglutide is being studied for potential additional dosing options in pediatric participants with type 2 diabetes. This indicates that researchers are exploring the use of Dulaglutide in the treatment of type 2 diabetes in younger patients, potentially seeking to expand the drug's applications.

Furthermore, Dulaglutide is being evaluated in a clinical trial to assess its safety in patients with type 2 diabetes mellitus in India. This study is focused on understanding the safety profile of Dulaglutide in a specific geographic and demographic context, likely to gather data that can inform its use in the Indian healthcare system.

In summary, Dulaglutide is a drug that is being utilized as a comparator in a cardiovascular outcomes trial for type 2 diabetes, while also being investigated for potential use in pediatric populations and for its safety in Indian patients with type 2 diabetes mellitus. The available information suggests that Dulaglutide is an active area of research and development, with researchers exploring its various applications and safety profiles in different patient populations.</data>
    </node>
    <node id="124">
      <data key="d0">LEPODISIRAN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">42.0</data>
      <data key="d5">Lepodisiran is a drug that is currently being evaluated in clinical studies for its potential to address various cardiovascular health concerns. The key points about Lepodisiran based on the provided information are as follows:

1. Phase 3 Study for Reducing Cardiovascular Events:
Lepodisiran is being investigated in a phase 3 clinical study to assess its effectiveness in reducing the risk of major adverse cardiovascular events (MACE) in adults. The study is specifically targeting individuals with elevated lipoprotein(a) levels and established atherosclerotic cardiovascular disease or those at risk of experiencing their first cardiovascular event.

2. Absorption and Elimination in Liver Function Impairment:
In addition to the phase 3 study, Lepodisiran is also being evaluated to understand how the drug is absorbed and eliminated in participants with different levels of liver function. This information is crucial for determining the appropriate dosing and safety considerations for individuals with varying degrees of liver impairment.

3. Mechanism of Action and Potential Benefits:
While the exact mechanism of action of Lepodisiran is not explicitly stated in the provided information, it can be inferred that the drug is designed to target and potentially reduce elevated lipoprotein(a) levels. Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease, and lowering its levels may contribute to a reduction in the risk of major adverse cardiovascular events.

4. Comprehensive Summary:
In summary, Lepodisiran is a drug that is currently undergoing extensive clinical evaluation to assess its potential benefits in reducing the risk of major adverse cardiovascular events in adults with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease or at risk of a first cardiovascular event. Additionally, the drug is being studied to understand its absorption and elimination characteristics in individuals with different levels of liver function, which is crucial for determining appropriate dosing and safety considerations.

The information provided does not present any contradictory statements, and the summary aims to provide a comprehensive overview of the key aspects of Lepodisiran based on the available data.</data>
    </node>
    <node id="125">
      <data key="d0">IMLUNESTRANT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">55.0</data>
      <data key="d5">Imlunestrant is a drug that is currently being evaluated in various clinical studies for the treatment of breast cancer. The key information about Imlunestrant based on the provided descriptions is as follows:

Imlunestrant is a drug that is being studied in the EMBER-4 study, which is a randomized, open-label, phase 3 clinical trial. The EMBER-4 study is comparing Imlunestrant to standard adjuvant endocrine therapy in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer. These patients have previously received 2 to 5 years of adjuvant endocrine therapy and have an increased risk of recurrence.

In addition to the EMBER-4 study, Imlunestrant is also being studied in other clinical trials. It is being evaluated in a clinical trial by Eli Lilly, the pharmaceutical company that is developing the drug. Furthermore, Imlunestrant is being studied in combination with abemaciclib for the treatment of estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer.

The descriptions provided do not contain any contradictory information about Imlunestrant. The drug appears to be in various stages of clinical development, with the EMBER-4 study being a phase 3 trial, which is the final stage of clinical testing before potential regulatory approval. The other studies mentioned are likely earlier-stage trials evaluating Imlunestrant's safety and efficacy in different patient populations and treatment settings.

In summary, Imlunestrant is a drug that is being investigated for the treatment of breast cancer, with a focus on patients with ER+, HER2- early breast cancer who have an increased risk of recurrence after receiving prior adjuvant endocrine therapy. The drug is being studied in multiple clinical trials, including the EMBER-4 phase 3 study, as well as in combination with other therapies for more advanced breast cancer.</data>
    </node>
    <node id="126">
      <data key="d0">NOVA LAW</data>
      <data key="d1" />
      <data key="d2">42.0</data>
      <data key="d5" />
    </node>
    <node id="127">
      <data key="d0">PHILLIP MADONIA</data>
      <data key="d1" />
      <data key="d2">40.0</data>
      <data key="d5" />
    </node>
    <node id="128">
      <data key="d0">MICHAEL MESHAD</data>
      <data key="d1" />
      <data key="d2">55.0</data>
      <data key="d5" />
    </node>
    <node id="129">
      <data key="d0">ATHEROSCLEROTIC CARDIOVASCULAR DISEASE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">42.0</data>
      <data key="d5">Atherosclerotic cardiovascular disease is a condition being studied in the ACCLAIM-Lp(a) trial of lepodisiran and the study of retatrutide</data>
    </node>
    <node id="130">
      <data key="d0">EARLY BREAST CANCER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">55.0</data>
      <data key="d5">Early breast cancer is the condition being studied in the EMBER-4 trial of imlunestrant</data>
    </node>
    <node id="131">
      <data key="d0">ER+, HER2- BREAST CANCER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">55.0</data>
      <data key="d5">ER+, HER2- breast cancer is the specific subtype being studied in the EMBER-4 trial of imlunestrant</data>
    </node>
    <node id="132">
      <data key="d0">LIPOPROTEIN(A)</data>
      <data key="d1" />
      <data key="d2">42.0</data>
      <data key="d5" />
    </node>
    <node id="133">
      <data key="d0">TRIUMPH-1</data>
      <data key="d1">EVENT</data>
      <data key="d2">55.0</data>
      <data key="d5">TRIUMPH-1 is a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of LY3437943 once weekly in participants without type 2 diabetes who have obesity or overweight</data>
    </node>
    <node id="134">
      <data key="d0">VICTORIA HORSTMAN</data>
      <data key="d1">PERSON</data>
      <data key="d2">60.0</data>
      <data key="d5">Victoria Horstman is a researcher involved in the study of donanemab versus placebo in participants at risk for cognitive and functional decline of Alzheimer's disease</data>
    </node>
    <node id="135">
      <data key="d0">DONANEMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">60.0</data>
      <data key="d5">Donanemab is a drug that is currently being evaluated for the treatment of Alzheimer's disease. The drug is being assessed in several different studies, targeting various stages of the disease.

One study is examining the use of donanemab in individuals with early Alzheimer's disease. This study is focused on evaluating the drug's effects on ARIA-E (Amyloid-Related Imaging Abnormalities-Edema) and its ability to lower amyloid levels in the brain. Amyloid is a key protein that accumulates in the brains of individuals with Alzheimer's disease, and reducing its levels is a primary target of many Alzheimer's treatments.

Another study is investigating the use of donanemab in individuals with preclinical Alzheimer's disease. Preclinical Alzheimer's refers to the stage of the disease where individuals have biological changes associated with Alzheimer's, but have not yet developed the cognitive and functional impairments that characterize the clinical stages of the disease. By targeting individuals in this early, preclinical stage, researchers hope to intervene and potentially delay or prevent the onset of overt Alzheimer's symptoms.

The available descriptions suggest that donanemab is being evaluated across different stages of Alzheimer's disease, from the early symptomatic phase to the preclinical stage. This comprehensive approach reflects the growing understanding that Alzheimer's is a complex and multifaceted disease, and that targeting it at various stages may be necessary to achieve the best possible outcomes for patients.

Overall, the data provided indicates that donanemab is a promising drug candidate for the treatment of Alzheimer's disease. By addressing key pathological features of the disease, such as amyloid accumulation and ARIA-E, and by targeting both early symptomatic and preclinical stages, donanemab has the potential to make a significant impact on the management and treatment of this devastating neurodegenerative disorder.</data>
    </node>
    <node id="136">
      <data key="d0">WILLIAM SANDBORN</data>
      <data key="d1">PERSON</data>
      <data key="d2">57.0</data>
      <data key="d5">William Sandborn is a researcher involved in the LUCENT 3 study evaluating the long-term efficacy and safety of mirikizumab in patients with moderately to severely active ulcerative colitis</data>
    </node>
    <node id="137">
      <data key="d0">MIRIKIZUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">57.0</data>
      <data key="d5">Mirikizumab is a drug being developed and studied by Eli Lilly for the treatment of various gastrointestinal conditions.

One of the key areas of investigation for Mirikizumab is its use in the treatment of ulcerative colitis. Researchers are evaluating Mirikizumab for the long-term treatment of this chronic inflammatory bowel disease. Additionally, a Phase 3b clinical study is underway to specifically investigate the drug's impact on bowel urgency in adults with ulcerative colitis.

Mirikizumab is also being evaluated for its potential in the treatment of Crohn's disease, another inflammatory bowel condition. While the details of this investigation are not provided, the data indicates that Mirikizumab will be evaluated for the long-term treatment of Crohn's disease.

Beyond its use in inflammatory bowel diseases, Mirikizumab is also being studied for bioequivalence when administered via prefilled syringe or autoinjector in healthy participants. This suggests that the drug may be developed in different formulations or delivery methods to improve its administration and accessibility for patients.

In summary, Mirikizumab is a drug being extensively studied by Eli Lilly for the treatment of various gastrointestinal conditions, with a particular focus on ulcerative colitis and Crohn's disease. The drug is being evaluated for long-term treatment, as well as for its bioequivalence in different delivery methods. The comprehensive research efforts aim to provide patients with new and effective treatment options for these chronic and debilitating conditions.</data>
    </node>
    <node id="138">
      <data key="d0">HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">55.0</data>
      <data key="d5">Human Epidermal Receptor 2 Negative (HER2-) is a type of breast cancer characterized by the absence of overexpression of the HER2 protein on the surface of cancer cells. This form of breast cancer is distinct from HER2-positive breast cancer, which is driven by the overexpression of the HER2 protein.

HER2- breast cancer is considered a subtype of breast cancer, and it is often associated with a better prognosis compared to HER2-positive breast cancer. Patients with HER2- breast cancer may respond better to certain treatments, such as hormone therapy, and may have a lower risk of recurrence.

The descriptions provided indicate that HER2- is a characteristic of the breast cancer being studied, rather than a standalone entity. This suggests that the research or clinical investigation is focused on understanding the specific features and behavior of HER2- breast cancer, which may have implications for the development of targeted therapies and personalized treatment approaches.

Overall, the summary of the data provided highlights the importance of understanding the molecular and genetic characteristics of different breast cancer subtypes, as this knowledge can inform treatment decisions and improve patient outcomes.</data>
    </node>
    <node id="139">
      <data key="d0">ULCERATIVE COLITIS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">58.0</data>
      <data key="d5">Ulcerative Colitis

Ulcerative colitis is a medical condition that is currently being studied for potential drug treatments. It is a chronic inflammatory bowel disease that affects the large intestine, causing inflammation and ulceration of the inner lining of the colon. Patients with ulcerative colitis may experience symptoms such as abdominal pain, diarrhea, rectal bleeding, and an increased urgency to have bowel movements.

Researchers are actively investigating various drug therapies to manage and treat ulcerative colitis. These studies aim to develop new medications or improve existing treatments to provide better outcomes for individuals living with this condition. The goal is to find effective ways to reduce inflammation, alleviate symptoms, and potentially induce and maintain remission of the disease.

Ulcerative colitis is a complex condition that can have a significant impact on a person's quality of life. It is characterized by periods of flare-ups and remission, and the severity of the disease can vary greatly among individuals. While there is currently no cure for ulcerative colitis, the ongoing research and development of new drug treatments offer hope for improved management and better long-term outcomes for those affected by this chronic condition.

By summarizing the available information, this comprehensive description provides an overview of ulcerative colitis, including its symptoms, the current research efforts focused on drug treatments, and the overall goal of improving the lives of those living with this challenging medical condition.</data>
    </node>
    <node id="140">
      <data key="d0">ESTROGEN RECEPTOR POSITIVE</data>
      <data key="d1" />
      <data key="d2">55.0</data>
      <data key="d5" />
    </node>
    <node id="141">
      <data key="d0">GZBK</data>
      <data key="d1" />
      <data key="d2">40.0</data>
      <data key="d5" />
    </node>
    <node id="142">
      <data key="d0">GZBJ</data>
      <data key="d1" />
      <data key="d2">76.0</data>
      <data key="d5" />
    </node>
    <node id="143">
      <data key="d0">LUCENT 3</data>
      <data key="d1" />
      <data key="d2">58.0</data>
      <data key="d5" />
    </node>
    <node id="144">
      <data key="d0">CROHN'S DISEASE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">57.0</data>
      <data key="d5">Crohn's Disease

Crohn's disease is a chronic inflammatory bowel disease that primarily affects the digestive tract. It is a condition that will be studied in the clinical trial of mirikizumab, a drug being investigated for the treatment of Crohn's disease.

Crohn's disease is characterized by inflammation and irritation in the digestive system, which can lead to a variety of symptoms, including abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. The exact cause of Crohn's disease is not fully understood, but it is believed to involve a combination of genetic and environmental factors that trigger an abnormal immune response.

While there is no cure for Crohn's disease, various treatments are available to help manage the symptoms and reduce the frequency and severity of flare-ups. These treatments may include medications, such as anti-inflammatory drugs, immunosuppressants, and biologics, as well as dietary modifications and lifestyle changes.

The clinical trial of mirikizumab is one of the ongoing studies investigating new drugs for the treatment of Crohn's disease. Mirikizumab is a monoclonal antibody that targets a specific protein involved in the inflammatory response, with the aim of reducing the symptoms and progression of Crohn's disease.

By participating in clinical trials, researchers and healthcare professionals are working to expand the understanding of Crohn's disease and develop more effective treatment options for individuals living with this chronic condition. The findings from these studies may contribute to the advancement of Crohn's disease management and improve the quality of life for those affected by this complex and challenging disease.</data>
    </node>
    <node id="145">
      <data key="d0">BARICITINIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">52.0</data>
      <data key="d5">Baricitinib is a drug that is currently being studied for various medical conditions, particularly in pediatric patients.

One of the key areas of investigation for baricitinib is its potential use in the treatment of moderate to severe atopic dermatitis (a type of eczema) in children. Atopic dermatitis is a chronic, inflammatory skin condition that can cause significant discomfort and impact a child's quality of life. Researchers are exploring the efficacy of baricitinib as a treatment option for these pediatric patients.

Additionally, baricitinib is being evaluated for the treatment of severe or very severe alopecia areata, a condition characterized by hair loss. Alopecia areata can be particularly distressing for children, and the investigation of baricitinib as a potential therapy aims to address this unmet medical need.

Furthermore, baricitinib is also being studied for its potential use in the treatment of alopecia areata in children. This research is focused on evaluating the safety and efficacy of the drug in this specific patient population.

Interestingly, baricitinib has also been identified as a potential treatment option for COVID-19 in pediatric patients. The drug is currently being investigated for its ability to manage the symptoms and complications associated with COVID-19 in children.

It is important to note that baricitinib is still considered an investigational drug, meaning that it has not yet been approved for widespread use in these medical conditions. The ongoing research and clinical trials are aimed at determining the safety and effectiveness of baricitinib in these various pediatric applications.

In summary, baricitinib is a drug that is being extensively studied for its potential to treat a range of medical conditions in children, including atopic dermatitis, alopecia areata, and COVID-19. The research efforts are focused on evaluating the safety and efficacy of the drug in these pediatric populations, with the ultimate goal of providing new and effective treatment options for these young patients.</data>
    </node>
    <node id="146">
      <data key="d0">ALOPECIA AREATA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">52.0</data>
      <data key="d5">Alopecia Areata

Alopecia areata is a medical condition that is the focus of a clinical trial for the drug baricitinib. Alopecia areata is an autoimmune disorder that causes patchy hair loss on the scalp and other areas of the body. In this condition, the body's immune system mistakenly attacks the hair follicles, leading to the sudden loss of hair.

The clinical trial is investigating the use of baricitinib, an oral medication, as a potential treatment for alopecia areata. Baricitinib is a Janus kinase (JAK) inhibitor, which means it works by blocking the activity of certain enzymes that play a role in the body's immune response. By modulating the immune system, baricitinib may help to prevent the autoimmune attack on the hair follicles, potentially allowing for hair regrowth in individuals with alopecia areata.

Alopecia areata can occur in people of all ages, genders, and ethnicities. The condition can range in severity, with some individuals experiencing small, isolated patches of hair loss, while others may experience more extensive or even complete loss of scalp hair (alopecia totalis) or body hair (alopecia universalis). The course of the condition is unpredictable, with periods of hair loss often followed by periods of regrowth.

Currently, there is no cure for alopecia areata, and treatment options are limited. Existing therapies, such as topical or intralesional corticosteroids, immunotherapy, or phototherapy, can help to stimulate hair regrowth in some cases, but their effectiveness is variable, and the results are often temporary. The development of new treatments, like baricitinib, offers hope for individuals living with this challenging condition.

The clinical trial of baricitinib for alopecia areata is an important step in advancing the understanding and management of this autoimmune disorder. By investigating the potential of this JAK inhibitor to modulate the immune response and promote hair regrowth, the trial may lead to the development of a more effective and targeted treatment option for individuals living with alopecia areata.</data>
    </node>
    <node id="147">
      <data key="d0">CHRONIC RHINOSINUSITIS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">53.0</data>
      <data key="d5">Chronic rhinosinusitis is a medical condition that will be studied in the clinical trial of lebrikizumab</data>
    </node>
    <node id="148">
      <data key="d0">NASAL POLYPS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">53.0</data>
      <data key="d5">Nasal polyps is a medical condition that will be studied in the clinical trial of lebrikizumab</data>
    </node>
    <node id="149">
      <data key="d0">NON-SMALL CELL LUNG CANCER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">Non-small cell lung cancer is a medical condition that will be studied in the clinical trial of abemaciclib and pembrolizumab</data>
    </node>
    <node id="150">
      <data key="d0">BREAST CANCER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">Breast Cancer

Breast cancer is a medical condition that is the focus of several clinical trials. The trials are studying the use of various drugs, including abemaciclib, pembrolizumab, and imlunestrant, in the treatment of breast cancer.

Abemaciclib and pembrolizumab are being studied in a clinical trial for their potential in treating breast cancer. Abemaciclib is a targeted therapy that works by inhibiting certain enzymes involved in cell division, while pembrolizumab is an immunotherapy that helps the body's immune system recognize and attack cancer cells.

Imlunestrant and abemaciclib are also being investigated for their efficacy in treating breast cancer. Imlunestrant is a selective estrogen receptor degrader (SERD) that may be effective in treating estrogen receptor-positive breast cancers, while abemaciclib is a cyclin-dependent kinase (CDK) inhibitor that can slow the growth of cancer cells.

The clinical trials are evaluating the safety and effectiveness of these drugs, either alone or in combination, in participants with breast cancer. The trials aim to determine the optimal treatment regimens and identify any potential side effects or adverse events associated with the use of these therapies.

By conducting these clinical trials, researchers hope to expand the available treatment options for individuals diagnosed with breast cancer, ultimately improving patient outcomes and quality of life. The comprehensive data collected from these studies will contribute to the ongoing efforts to better understand and manage this complex and challenging disease.</data>
    </node>
    <node id="151">
      <data key="d0">JAMES KRELL</data>
      <data key="d1">PERSON</data>
      <data key="d2">51.0</data>
      <data key="d5">James Krell is a researcher and author involved in studies related to ixekizumab and tirzepatide for the treatment of plaque psoriasis and obesity.

According to the information provided, James Krell is a researcher who is involved in a study examining the use of ixekizumab and tirzepatide for the treatment of plaque psoriasis and obesity. Ixekizumab is a monoclonal antibody that targets interleukin-17A, while tirzepatide is a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

In addition to his research activities, James Krell is also described as an author related to the studies he is involved in. This suggests that he may have published or contributed to scientific publications or reports regarding the findings of his research on ixekizumab and tirzepatide for the treatment of plaque psoriasis and obesity.

The provided descriptions do not contain any contradictory information about James Krell's role and involvement in these studies. The summary combines the key details from the given descriptions to provide a comprehensive overview of James Krell's research and authorship activities related to the use of ixekizumab and tirzepatide for the treatment of plaque psoriasis and obesity.</data>
    </node>
    <node id="152">
      <data key="d0">WAYNE HO</data>
      <data key="d1">PERSON</data>
      <data key="d2">40.0</data>
      <data key="d5">Wayne Ho is an author related to the studies</data>
    </node>
    <node id="153">
      <data key="d0">LOXO-783</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LOXO-783 is a drug being developed by Eli Lilly for the treatment of advanced breast cancer and other solid tumors with a PIK3CA H1047R mutation</data>
    </node>
    <node id="154">
      <data key="d0">ELTREKIBART</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">Eltrekibart is a drug being developed by Eli Lilly for the treatment of moderate to severe hidradenitis suppurativa</data>
    </node>
    <node id="155">
      <data key="d0">GALCANEZUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">69.0</data>
      <data key="d5">Galcanezumab is a drug being developed by Eli Lilly for the preventive treatment of chronic migraine in adolescents</data>
    </node>
    <node id="156">
      <data key="d0">SURMOUNT-ADOLESCENTS-2</data>
      <data key="d1">EVENT</data>
      <data key="d2">46.0</data>
      <data key="d5">A clinical trial to assess the efficacy and safety of tirzepatide for the treatment of obesity and weight-related comorbidities in adolescents</data>
    </node>
    <node id="157">
      <data key="d0">SURMOUNT-MAINTAIN</data>
      <data key="d1">EVENT</data>
      <data key="d2">47.0</data>
      <data key="d5">A clinical trial to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction</data>
    </node>
    <node id="158">
      <data key="d0">ALAINA VIDMAR</data>
      <data key="d1">PERSON</data>
      <data key="d2">46.0</data>
      <data key="d5">A person involved in the SURMOUNT-ADOLESCENTS-2 trial</data>
    </node>
    <node id="159">
      <data key="d0">ANDREW SHAROBEEM</data>
      <data key="d1">PERSON</data>
      <data key="d2">47.0</data>
      <data key="d5">A person involved in the tirzepatide and ixekizumab study for psoriatic arthritis</data>
    </node>
    <node id="160">
      <data key="d0">LINDSAY ACKERMAN</data>
      <data key="d1">PERSON</data>
      <data key="d2">51.0</data>
      <data key="d5">Lindsay Ackerman is a researcher who has been involved in studies related to various medical conditions and treatments. 

According to the information provided, Ackerman has been involved in the eltrekibart study for hidradenitis suppurativa, a chronic skin condition. Hidradenitis suppurativa is characterized by painful, recurrent abscesses and nodules, typically in areas with apocrine glands, such as the armpits and groin. The eltrekibart study likely investigated the use of this medication as a potential treatment for this condition.

In addition to her work on hidradenitis suppurativa, Ackerman has also been involved in studies related to ixekizumab and tirzepatide. Ixekizumab is a medication used to treat various inflammatory conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Tirzepatide is a medication used to treat type 2 diabetes, which helps to regulate blood sugar levels.

While the provided descriptions do not contain any contradictory information, they do not provide a comprehensive overview of Ackerman's research activities and areas of expertise. It is possible that she has been involved in additional studies or research projects that are not mentioned in the given data.

In summary, Lindsay Ackerman is a researcher who has been involved in studies related to the treatment of hidradenitis suppurativa, as well as investigations into the use of ixekizumab and tirzepatide for various medical conditions. Her research efforts have contributed to the understanding and potential management of these health issues.</data>
    </node>
    <node id="161">
      <data key="d0">ADVANCE-ATTAIN-ADOLESCENTS</data>
      <data key="d1">EVENT</data>
      <data key="d2">35.0</data>
      <data key="d5">A randomized, double-blind trial to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus placebo in adolescent participants with obesity or overweight with weight-related comorbidities</data>
    </node>
    <node id="162">
      <data key="d0">TOGETHER-PSA</data>
      <data key="d1">EVENT</data>
      <data key="d2">51.0</data>
      <data key="d5">A phase 3b, randomized, multicenter, open-label study to demonstrate the efficacy of ixekizumab and tirzepatide concomitantly administered in adult participants with active psoriatic arthritis and obesity or overweight</data>
    </node>
    <node id="163">
      <data key="d0">POSTMONARCH</data>
      <data key="d1">EVENT</data>
      <data key="d2">9.0</data>
      <data key="d5">A randomized, double-blind, placebo-controlled, phase 3 study to compare the efficacy of abemaciclib plus fulvestrant to placebo plus fulvestrant in participants with HR+, HER2-, advanced or metastatic breast cancer following progression on a CDK4 &amp; 6 inhibitor and endocrine therapy</data>
    </node>
    <node id="164">
      <data key="d0">LY3454738</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">53.0</data>
      <data key="d5">A drug being evaluated in a phase 2 clinical trial for atopic dermatitis
A phase 2, randomized, double-blind, parallel-group, placebo-controlled, 52-week study to evaluate the efficacy and safety of LY3454738 in the treatment of adult patients with moderate-to-severe atopic dermatitis</data>
    </node>
    <node id="165">
      <data key="d0">LY3841136</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">48.0</data>
      <data key="d5">LY3841136 is a drug being evaluated by Eli Lilly in a multiple-ascending dose study. The study is designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY3841136 when administered as monotherapy and in combination with tirzepatide in Japanese participants who are overweight or have obesity.

The study is being conducted in Japanese participants, as the data suggests that LY3841136 is being evaluated specifically for this population. The combination of LY3841136 and tirzepatide is being investigated as a potential treatment for overweight and obesity in this group.

The multiple-ascending dose study design allows for the evaluation of different dosage levels of LY3841136, both as a standalone therapy and in combination with tirzepatide. This approach helps to determine the optimal dosing regimen and understand the interactions between the two drugs.

By assessing the safety, tolerability, and pharmacological properties of LY3841136, both alone and in combination with tirzepatide, the study aims to provide valuable insights into the potential of this drug as a treatment for overweight and obesity in the Japanese population. The results of this study may contribute to the development of new and effective therapies for these health conditions.

In summary, LY3841136 is a drug being investigated by Eli Lilly in a multiple-ascending dose study, evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics when used as monotherapy and in combination with tirzepatide in Japanese participants who are overweight or have obesity. The study aims to explore the potential of this drug as a treatment option for these health conditions in the Japanese population.</data>
    </node>
    <node id="166">
      <data key="d0">LY3200882</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">67.0</data>
      <data key="d5">A phase 1 study to evaluate the safety of the study drug LY3200882 in participants with solid tumors
A drug being evaluated in a phase 1 study for solid tumors</data>
    </node>
    <node id="167">
      <data key="d0">MIBAVADEMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">49.0</data>
      <data key="d5">MIBAVADEMAB is a drug that is currently being evaluated in a phase 2 clinical trial for the treatment of obesity. The drug is being studied in combination with tirzepatide, another medication that is also being investigated for weight loss.

The clinical trial is a phase 2, randomized, double-blind, placebo-controlled, proof-of-concept study. The study is designed to compare the efficacy and safety of once-weekly tirzepatide plus mibavademab versus tirzepatide alone in adult participants with obesity.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has shown promising results in previous studies for weight loss. The addition of mibavademab to tirzepatide is being investigated to determine if the combination therapy can further enhance the weight loss effects.

The study is currently ongoing, and the researchers are evaluating the safety and efficacy of the combination therapy compared to tirzepatide alone. The primary outcome measure is the change in body weight from baseline to the end of the study period.

Overall, MIBAVADEMAB is a promising drug that is being evaluated in combination with tirzepatide for the treatment of obesity. The results of the ongoing clinical trial will provide valuable insights into the potential benefits of this combination therapy for individuals struggling with excess weight.</data>
    </node>
    <node id="168">
      <data key="d0">IXEKIZUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">51.0</data>
      <data key="d5">A drug being evaluated in the TOGETHER-PsA clinical trial for psoriatic arthritis and obesity</data>
    </node>
    <node id="169">
      <data key="d0">FULVESTRANT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">Fulvestrant is a drug that is being evaluated and studied for the treatment of breast cancer. It is a hormone therapy drug that is being investigated in several clinical trials.

One of the trials that Fulvestrant is being evaluated in is the POSTMONARCH clinical trial. This trial is examining the use of Fulvestrant for the treatment of breast cancer.

In addition, Fulvestrant is being studied in combination with another drug called Abemaciclib. This combination is being evaluated for the treatment of hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer. The MONARCH 2 trial is specifically looking at the use of Fulvestrant in this setting.

Overall, Fulvestrant is a drug that is being actively researched as a potential treatment option for breast cancer patients. The drug is being studied both as a standalone therapy and in combination with other medications, with the goal of improving outcomes for individuals with this type of cancer.

The clinical trials mentioned, including POSTMONARCH and MONARCH 2, are designed to evaluate the safety and efficacy of Fulvestrant in different patient populations and treatment settings. By conducting these studies, researchers hope to better understand the role that Fulvestrant can play in the management of breast cancer and to potentially expand the available treatment options for patients.</data>
    </node>
    <node id="170">
      <data key="d0">CDK4 &amp; 6 INHIBITOR</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">A type of drug that participants in the POSTMONARCH trial had previously received</data>
    </node>
    <node id="171">
      <data key="d0">ENDOCRINE THERAPY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">9.0</data>
      <data key="d5">A type of therapy that participants in the POSTMONARCH trial had previously received</data>
    </node>
    <node id="172">
      <data key="d0">RENAL IMPAIRMENT</data>
      <data key="d1">GEO</data>
      <data key="d2">40.0</data>
      <data key="d5">One study is investigating a drug for type 2 diabetes with renal impairment</data>
    </node>
    <node id="173">
      <data key="d0">EPISODIC MIGRAINE</data>
      <data key="d1">EVENT</data>
      <data key="d2">69.0</data>
      <data key="d5">One study is investigating a drug for the preventive treatment of episodic migraine in children and adolescents</data>
    </node>
    <node id="174">
      <data key="d0">WEIGHT LOSS</data>
      <data key="d1" />
      <data key="d2">49.0</data>
      <data key="d5" />
    </node>
    <node id="175">
      <data key="d0">MEVIDALEN</data>
      <data key="d1" />
      <data key="d2">60.0</data>
      <data key="d5" />
    </node>
    <node id="176">
      <data key="d0">YESSICA SACHDEVA</data>
      <data key="d1">PERSON</data>
      <data key="d2">48.0</data>
      <data key="d5">Yessica Sachdeva is a researcher who is involved in multiple studies related to weight management and diabetic peripheral neuropathic pain.

In one study, Yessica Sachdeva is involved in research related to LY3841136 and tirzepatide for weight management in individuals with type 2 diabetes. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has shown promise in improving glycemic control and promoting weight loss in people with type 2 diabetes. Yessica Sachdeva's role in this study is to contribute her expertise and assist in the investigation of the efficacy and safety of these treatments for weight management in the target population.

Additionally, Yessica Sachdeva is an expert involved in a clinical trial for the treatment of diabetic peripheral neuropathic pain. Diabetic peripheral neuropathy is a common complication of diabetes that can cause significant pain and discomfort. Yessica Sachdeva's involvement in this clinical trial suggests that she has specialized knowledge and experience in the management of this condition, and is working to develop new or improved treatment options for individuals suffering from diabetic peripheral neuropathic pain.

Overall, Yessica Sachdeva appears to be a highly skilled and versatile researcher, with expertise in both weight management and the treatment of diabetic complications, particularly neuropathic pain. Her involvement in these studies demonstrates her commitment to advancing the understanding and treatment of these important health issues, which can have a significant impact on the quality of life for individuals with type 2 diabetes.</data>
    </node>
    <node id="177">
      <data key="d0">RAMADAN</data>
      <data key="d1">EVENT</data>
      <data key="d2">47.0</data>
      <data key="d5">Ramadan is a religious event observed by Muslims worldwide. During this time, a study is investigating the use of tirzepatide, a medication for the treatment of type 2 diabetes, in participants with the condition.

The study aims to evaluate the safety and efficacy of tirzepatide during the Ramadan period. Tirzepatide is a novel medication that has shown promising results in the management of type 2 diabetes. The study is designed to assess the impact of tirzepatide on blood glucose levels, as well as the overall safety and tolerability of the medication, in individuals with type 2 diabetes who are observing the Ramadan fast.

Ramadan is a significant event in the Islamic calendar, during which Muslims abstain from eating and drinking from dawn to dusk. This fasting period can pose unique challenges for individuals with type 2 diabetes, as managing blood glucose levels during this time can be particularly challenging. The study aims to provide valuable insights into the use of tirzepatide in this specific population and context, with the goal of improving the management of type 2 diabetes during the Ramadan period.

The study is being conducted in a manner that respects the religious and cultural practices associated with Ramadan. Researchers are working closely with the study participants to ensure that the study protocol aligns with the requirements of the Ramadan fast and that the participants' well-being is prioritized throughout the study.

Overall, this study represents an important effort to address the unique needs and challenges faced by individuals with type 2 diabetes during the Ramadan period. The findings from this study may contribute to the development of more effective and tailored approaches to the management of type 2 diabetes in this specific context, ultimately improving the health and quality of life for those affected.</data>
    </node>
    <node id="178">
      <data key="d0">PLAQUE PSORIASIS</data>
      <data key="d1" />
      <data key="d2">51.0</data>
      <data key="d5" />
    </node>
    <node id="179">
      <data key="d0">JEANNIE HUANG</data>
      <data key="d1">PERSON</data>
      <data key="d2">57.0</data>
      <data key="d5">Jeannie Huang is a researcher involved in the mirikizumab studies for pediatric Crohn's disease and ulcerative colitis</data>
    </node>
    <node id="180">
      <data key="d0">DIEGO VIOLA</data>
      <data key="d1">PERSON</data>
      <data key="d2">52.0</data>
      <data key="d5">Diego Viola is a researcher involved in the baricitinib study for systemic juvenile idiopathic arthritis</data>
    </node>
    <node id="181">
      <data key="d0">YASUKO OWADA</data>
      <data key="d1">PERSON</data>
      <data key="d2">76.0</data>
      <data key="d5">Yasuko Owada is a researcher involved in the LY3549492 study for type 2 diabetes in Japanese participants</data>
    </node>
    <node id="182">
      <data key="d0">NEUROBLASTOMA</data>
      <data key="d1">DISEASE</data>
      <data key="d2">57.0</data>
      <data key="d5">Neuroblastoma is a condition that is being studied in relation to the Eli Lilly drug LY3295668</data>
    </node>
    <node id="183">
      <data key="d0">ORFORGLIPRON (LY3502970)</data>
      <data key="d1" />
      <data key="d2">70.0</data>
      <data key="d5" />
    </node>
    <node id="184">
      <data key="d0">LY3295668</data>
      <data key="d1" />
      <data key="d2">70.0</data>
      <data key="d5" />
    </node>
    <node id="185">
      <data key="d0">MICHAEL MANGUM</data>
      <data key="d1">PERSON</data>
      <data key="d2">60.0</data>
      <data key="d5">Michael Mangum is a researcher involved in a study of LY3954068 in patients with early symptomatic Alzheimer's Disease</data>
    </node>
    <node id="186">
      <data key="d0">ALEXANDER PREZIOSO</data>
      <data key="d1">PERSON</data>
      <data key="d2">31.0</data>
      <data key="d5">Alexander Prezioso is a researcher involved in a study of LY3484356 in Chinese patients with estrogen receptor positive, HER2 negative locally advanced or metastatic breast cancer</data>
    </node>
    <node id="187">
      <data key="d0">JOEL NEUTEL</data>
      <data key="d1">PERSON</data>
      <data key="d2">34.0</data>
      <data key="d5">Joel Neutel is a researcher involved in a study to assess the pharmacokinetics, safety, and tolerability of LY3537982 in participants with hepatic impairment. The study aims to evaluate the effects of hepatic impairment on the pharmacokinetics of LY3537982, a drug being developed for potential therapeutic use.

As a researcher, Joel Neutel is responsible for conducting this clinical trial and collecting data on the drug's behavior in individuals with compromised liver function. The study will provide valuable insights into how the body processes and responds to LY3537982 in the presence of hepatic impairment, which is an important consideration for the drug's development and potential future use.

The study is designed to assess the safety and tolerability of LY3537982 in participants with varying degrees of hepatic impairment, as well as to determine how the drug's pharmacokinetics, or the way it is absorbed, distributed, metabolized, and eliminated by the body, may be affected by the presence of liver disease.

By conducting this research, Joel Neutel and the study team hope to contribute to a better understanding of the drug's behavior and potential limitations in individuals with hepatic impairment. This information will be crucial in guiding the further development and potential clinical use of LY3537982, ensuring that it can be used safely and effectively in patients with compromised liver function.

Overall, Joel Neutel's role as a researcher in this study is to provide valuable data and insights that will inform the ongoing development and potential clinical application of LY3537982, a drug that may have important therapeutic implications for individuals with hepatic impairment.</data>
    </node>
    <node id="188">
      <data key="d0">HIGH-GRADE GLIOMA</data>
      <data key="d1">GEO</data>
      <data key="d2">70.0</data>
      <data key="d5">A type of brain cancer</data>
    </node>
    <node id="189">
      <data key="d0">HEPATIC IMPAIRMENT</data>
      <data key="d1">GEO</data>
      <data key="d2">34.0</data>
      <data key="d5">A condition involving reduced liver function</data>
    </node>
    <node id="190">
      <data key="d0">KRAS G12C-MUTANT ADVANCED SOLID TUMORS</data>
      <data key="d1">GEO</data>
      <data key="d2">34.0</data>
      <data key="d5">A type of cancer with a specific genetic mutation</data>
    </node>
    <node id="191">
      <data key="d0">SEMAGLUTIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">Semaglutide is a drug that is currently being evaluated in several clinical studies. According to the provided information, it is being compared to two different medications in separate Phase 3 studies.

In one study, semaglutide is being compared to orforglipron, another drug, in a Phase 3 clinical trial. The purpose of this study is to assess the efficacy and safety of semaglutide in comparison to orforglipron.

In a separate study, semaglutide is being compared to tirzepatide, a different medication, in adults with obesity or overweight who have weight-related comorbidities. This study aims to evaluate the effects of semaglutide on weight management and overall health outcomes in this patient population.

The available information does not provide any details about the specific indications or therapeutic areas being investigated for semaglutide. However, the fact that it is being studied in comparison to two different drugs suggests that semaglutide may have potential applications in the treatment of various conditions, such as obesity, overweight, or other weight-related health issues.

It is important to note that the provided descriptions do not contain any contradictory information. The studies appear to be separate and independent, with semaglutide being evaluated against different comparators in each case. This suggests that semaglutide may have a versatile therapeutic profile and could potentially be used in the management of a range of weight-related or metabolic conditions.

Overall, the available data indicates that semaglutide is an investigational drug that is currently undergoing clinical evaluation in Phase 3 studies. The results of these studies will provide valuable insights into the efficacy, safety, and potential applications of semaglutide in the treatment of various health conditions.</data>
    </node>
    <node id="192">
      <data key="d0">CHINESE PATIENTS</data>
      <data key="d1">PERSON</data>
      <data key="d2">34.0</data>
      <data key="d5">Chinese patients are the target population for the LY3537982 study</data>
    </node>
    <node id="193">
      <data key="d0">SGLT2 INHIBITOR</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">40.0</data>
      <data key="d5">SGLT2 inhibitor is a background medication used in one of the Eli Lilly studies</data>
    </node>
    <node id="194">
      <data key="d0">JAMES SULLIVAN</data>
      <data key="d1">PERSON</data>
      <data key="d2">60.0</data>
      <data key="d5">James Sullivan is a participant in the study</data>
    </node>
    <node id="195">
      <data key="d0">DAPAGLIFLOZIN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">Dapagliflozin is a drug being compared to orforglipron in one of the Phase 3 studies</data>
    </node>
    <node id="196">
      <data key="d0">INSULIN GLARGINE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">Insulin glargine is a medication that participants in one of the orforglipron studies are taking</data>
    </node>
    <node id="197">
      <data key="d0">SGLT-2 INHIBITOR</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">35.0</data>
      <data key="d5">SGLT-2 inhibitors are medications that participants in one of the orforglipron studies are taking</data>
    </node>
    <node id="198">
      <data key="d0">ELORALINTIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">47.0</data>
      <data key="d5">Eloralintide (LY3841136) is an investigational drug that is currently being studied for the treatment of obesity and overweight in Chinese participants. The drug is in the early stages of clinical development, with a Phase 1 study underway to evaluate its safety and efficacy both as a standalone treatment and in combination with another investigational drug, tirzepatide.

The Phase 1 study is designed to assess the safety, tolerability, and pharmacokinetic properties of Eloralintide, both when administered alone and when combined with tirzepatide. Tirzepatide is another investigational drug that is being studied for the treatment of obesity and related metabolic conditions.

Eloralintide is a novel compound that is being developed as a potential treatment for obesity and overweight. The exact mechanism of action of Eloralintide is not yet fully understood, but it is believed to work by modulating certain physiological pathways involved in the regulation of appetite and energy balance.

The ongoing Phase 1 study is an important step in the development of Eloralintide, as it will provide valuable data on the safety and tolerability of the drug, as well as its potential efficacy in combination with other investigational treatments. The results of this study will help guide the further development of Eloralintide and inform the design of future clinical trials.

It is important to note that Eloralintide is still an investigational drug, and its safety and efficacy have not yet been fully established. The ongoing clinical trials are designed to gather more information about the drug's potential benefits and risks, and it will be some time before Eloralintide, if approved, becomes available as a treatment option for obesity and overweight.

Overall, Eloralintide represents a promising new approach to the management of obesity and related metabolic conditions, and the ongoing clinical research will be closely watched by the medical and scientific community as it progresses.</data>
    </node>
    <node id="199">
      <data key="d0">CHRISTOPHER CHOW</data>
      <data key="d1">PERSON</data>
      <data key="d2">47.0</data>
      <data key="d5">Christopher Chow is a participant in the study of tirzepatide for chronic kidney disease</data>
    </node>
    <node id="200">
      <data key="d0">SONIA KALIRAO</data>
      <data key="d1">PERSON</data>
      <data key="d2">70.0</data>
      <data key="d5">Sonia Kalirao is an expert involved in a clinical trial for multiple sclerosis</data>
    </node>
    <node id="201">
      <data key="d0">GILBERT JENOURI</data>
      <data key="d1">PERSON</data>
      <data key="d2">70.0</data>
      <data key="d5">Gilbert Jenouri is an expert involved in a clinical trial for type 2 diabetes and obesity</data>
    </node>
    <node id="202">
      <data key="d0">RAKESH SAHAY</data>
      <data key="d1">PERSON</data>
      <data key="d2">70.0</data>
      <data key="d5">Rakesh Sahay is an expert involved in a clinical trial for type 2 diabetes in India</data>
    </node>
    <node id="203">
      <data key="d0">FEDERICO LAHAM</data>
      <data key="d1">PERSON</data>
      <data key="d2">70.0</data>
      <data key="d5">Federico Laham is an expert involved in a clinical trial for COVID-19 in pediatric patients</data>
    </node>
    <node id="204">
      <data key="d0">LYUMJEV</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">Lyumjev is an insulin lispro-aabc product being studied for type 2 diabetes in India</data>
    </node>
    <node id="205">
      <data key="d0">LY4006896</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY4006896 is an investigational drug being studied for Parkinson's disease</data>
    </node>
    <node id="206">
      <data key="d0">LY3556050</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY3556050 is an investigational drug being studied for diabetic peripheral neuropathic pain</data>
    </node>
    <node id="207">
      <data key="d0">IRINOTECAN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">Irinotecan is a chemotherapy drug being studied in combination with abemaciclib for Ewing's sarcoma</data>
    </node>
    <node id="208">
      <data key="d0">TEMOZOLOMIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">31.0</data>
      <data key="d5">Temozolomide is a chemotherapy drug being studied in combination with abemaciclib for Ewing's sarcoma</data>
    </node>
    <node id="209">
      <data key="d0">EWING'S SARCOMA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">72.0</data>
      <data key="d5">Ewing's sarcoma is a type of cancer that the combination of abemaciclib, irinotecan, and temozolomide is being studied for</data>
    </node>
    <node id="210">
      <data key="d0">CAMPFIRE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">72.0</data>
      <data key="d5">CAMPFIRE is a master protocol to speed development of new treatments for children and young adults with cancer</data>
    </node>
    <node id="211">
      <data key="d0">LY3305677</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">76.0</data>
      <data key="d5">LY3305677 is a drug being studied for weight management in adult participants with obesity or overweight</data>
    </node>
    <node id="212">
      <data key="d0">LIVER FUNCTION</data>
      <data key="d1" />
      <data key="d2">42.0</data>
      <data key="d5" />
    </node>
    <node id="213">
      <data key="d0">YIMING MU</data>
      <data key="d1" />
      <data key="d2">47.0</data>
      <data key="d5" />
    </node>
    <node id="214">
      <data key="d0">PARTICIPANTS WITH ALZHEIMER'S DISEASE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">62.0</data>
      <data key="d5">Participants with Alzheimer's disease are involved in the clinical trial of LY3372993</data>
    </node>
    <node id="215">
      <data key="d0">ADVANCED BREAST CANCER</data>
      <data key="d1" />
      <data key="d2">55.0</data>
      <data key="d5" />
    </node>
    <node id="216">
      <data key="d0">LY3473329</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY3473329 is a drug being studied by Eli Lilly in a phase 2 study to investigate its efficacy and safety in adults with elevated lipoprotein(a) at high risk for cardiovascular events</data>
    </node>
    <node id="217">
      <data key="d0">LY3875383</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">27.0</data>
      <data key="d5">LY3875383 is a drug being studied by Eli Lilly in a single-ascending dose study to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants and participants with hypertriglyceridemia</data>
    </node>
    <node id="218">
      <data key="d0">LY3849891</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">LY3849891 is a drug being studied by Eli Lilly in a single-ascending and repeated subcutaneous dose study to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in participants with metabolic dysfunction-associated steatotic liver disease who have the PNPLA3 I148M genotype</data>
    </node>
    <node id="219">
      <data key="d0">LY3839840</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY3839840 is a drug being studied by Eli Lilly in a single- and multiple-ascending dose study to evaluate its safety and pharmacokinetics following oral dosing in healthy participants</data>
    </node>
    <node id="220">
      <data key="d0">JAMES SWAIN</data>
      <data key="d1">PERSON</data>
      <data key="d2">26.0</data>
      <data key="d5">James Swain is involved in the study of LY3209590 in pediatric participants with type 2 diabetes</data>
    </node>
    <node id="221">
      <data key="d0">JORDAN VAUGHN</data>
      <data key="d1">PERSON</data>
      <data key="d2">47.0</data>
      <data key="d5">Jordan Vaughn is involved in the study of tirzepatide compared to semaglutide in adults with obesity or overweight with weight related comorbidities</data>
    </node>
    <node id="222">
      <data key="d0">MASLD</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">15.0</data>
      <data key="d5">MASLD stands for metabolic dysfunction-associated steatotic liver disease, which is the focus of the study involving LY3849891</data>
    </node>
    <node id="223">
      <data key="d0">HYPERTRIGLYCERIDEMIA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">27.0</data>
      <data key="d5">Hypertriglyceridemia is a condition being studied in the single-ascending dose study of LY3875383</data>
    </node>
    <node id="224">
      <data key="d0">DUPILUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">53.0</data>
      <data key="d5">Dupilumab is a drug that participants in the lebrikizumab study have previously been treated with</data>
    </node>
    <node id="225">
      <data key="d0">PNPLA3</data>
      <data key="d1" />
      <data key="d2">15.0</data>
      <data key="d5" />
    </node>
    <node id="226">
      <data key="d0">REPAGLINIDE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">64.0</data>
      <data key="d5">Repaglinide is a CYP2C8 substrate drug used to evaluate the effect of pirtobrutinib</data>
    </node>
    <node id="227">
      <data key="d0">LOXO-305</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">63.0</data>
      <data key="d5">LOXO-305, also known as pirtobrutinib, is a drug that is currently being studied for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma and non-Hodgkin lymphoma. The drug is being developed by Eli Lilly, a pharmaceutical company.

LOXO-305 is a tyrosine kinase inhibitor that targets the Bruton's tyrosine kinase (BTK) enzyme, which plays a crucial role in the development and survival of certain types of blood cancer cells. By inhibiting BTK, LOXO-305 aims to disrupt the signaling pathways that allow these cancer cells to proliferate and survive.

The drug is currently in clinical trials, where researchers are evaluating its safety and efficacy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and non-Hodgkin lymphoma. These types of blood cancers are often characterized by the uncontrolled growth and accumulation of abnormal lymphocytes, which can lead to various complications and a decline in overall health.

The ongoing clinical trials are designed to assess the ability of LOXO-305 to improve patient outcomes, such as reducing tumor size, prolonging the time before disease progression, and improving overall survival. Researchers are also monitoring the drug's safety profile, looking for any potential side effects or adverse events that may occur during treatment.

While the data from these clinical trials is still being collected and analyzed, the initial results have been promising. LOXO-305 has shown the potential to be an effective treatment option for patients with certain types of blood cancers, particularly those who have not responded well to or have relapsed after previous therapies.

Overall, LOXO-305 represents a new and innovative approach to the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma and non-Hodgkin lymphoma. As the research and development of this drug continues, it may offer hope for patients with these challenging and often difficult-to-treat blood cancers.</data>
    </node>
    <node id="228">
      <data key="d0">CAFFEINE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">63.0</data>
      <data key="d5">Caffeine is a CYP1A2 substrate probe drug used to evaluate the effect of LOXO-305</data>
    </node>
    <node id="229">
      <data key="d0">S-WARFARIN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">63.0</data>
      <data key="d5">S-warfarin is a CYP2C9 substrate probe drug used to evaluate the effect of LOXO-305</data>
    </node>
    <node id="230">
      <data key="d0">OMEPRAZOLE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">63.0</data>
      <data key="d5">Omeprazole is a CYP2C19 substrate probe drug used to evaluate the effect of LOXO-305</data>
    </node>
    <node id="231">
      <data key="d0">ABIRATERONE ACETATE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">33.0</data>
      <data key="d5">Abiraterone Acetate is a drug that is being evaluated and studied for the treatment of metastatic castration-resistant prostate cancer. It is being investigated in combination with other medications, such as prednisone and abemaciclib, by various pharmaceutical companies, including Eli Lilly.

Abiraterone acetate is a drug that inhibits the enzyme 17Œ±-hydroxylase/C17,20-lyase (CYP17), which is essential for the production of androgens in the body. By blocking this enzyme, abiraterone acetate can effectively reduce the levels of testosterone and other male hormones, which are known to fuel the growth of prostate cancer cells.

The drug is being evaluated in clinical trials, where it is being used in combination with other therapies to treat metastatic castration-resistant prostate cancer. Castration-resistant prostate cancer is a form of the disease that has become resistant to traditional hormone-based treatments, making it more challenging to manage.

The combination of abiraterone acetate with prednisone and abemaciclib is being studied to determine if this approach can improve outcomes for patients with metastatic castration-resistant prostate cancer. Prednisone is a corticosteroid that is often used in combination with abiraterone acetate to help manage the side effects of the treatment, while abemaciclib is a targeted therapy that inhibits the activity of certain enzymes involved in cell division, which may help to slow the progression of the cancer.

The clinical trials investigating the use of abiraterone acetate in combination with these other therapies are ongoing, and the results will be closely monitored to determine the safety and efficacy of this approach. If the combination therapy proves to be effective, it could potentially offer a new treatment option for patients with metastatic castration-resistant prostate cancer, who currently have limited treatment options available.

Overall, abiraterone acetate is a promising drug that is being actively studied for the treatment of metastatic castration-resistant prostate cancer, and the combination of this drug with other therapies may help to improve outcomes for patients with this challenging form of the disease.</data>
    </node>
    <node id="232">
      <data key="d0">OVERWEIGHT AND OBESE PARTICIPANTS</data>
      <data key="d1">PERSON</data>
      <data key="d2">47.0</data>
      <data key="d5">Overweight and obese participants are the focus of the study involving tirzepatide and LY3841136</data>
    </node>
    <node id="233">
      <data key="d0">METASTATIC PROSTATE CANCER</data>
      <data key="d1">EVENT</data>
      <data key="d2">33.0</data>
      <data key="d5">Metastatic prostate cancer is the condition being studied with abiraterone acetate and abemaciclib</data>
    </node>
    <node id="234">
      <data key="d0">KRAS G12C</data>
      <data key="d1" />
      <data key="d2">34.0</data>
      <data key="d5" />
    </node>
    <node id="235">
      <data key="d0">PREDNISONE</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">33.0</data>
      <data key="d5">Prednisone is a drug being evaluated in combination with abiraterone acetate and abemaciclib for metastatic castration-resistant prostate cancer</data>
    </node>
    <node id="236">
      <data key="d0">LY3972406</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">51.0</data>
      <data key="d5">LY3972406 is a drug being evaluated for efficacy and safety in adults with moderate-to-severe plaque psoriasis</data>
    </node>
    <node id="237">
      <data key="d0">ERLOTINIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">73.0</data>
      <data key="d5">Erlotinib is a drug that is being evaluated in various clinical studies for the treatment of non-small cell lung cancer (NSCLC). 

In one study, erlotinib is being investigated in combination with ramucirumab or placebo in previously untreated participants with EGFR mutation-positive metastatic NSCLC. Erlotinib is a tyrosine kinase inhibitor drug, which means it works by blocking the activity of certain enzymes that are involved in the growth and spread of cancer cells.

In another study, erlotinib is being studied in combination with LY2875358, which is another investigational drug. The purpose of this study is to evaluate the safety and efficacy of the combination of erlotinib and LY2875358 in the treatment of NSCLC.

Erlotinib has been approved for the treatment of NSCLC in certain situations, but the studies mentioned above are investigating its use in combination with other drugs or in different patient populations. The goal of these studies is to determine if the combination of erlotinib with other therapies can improve outcomes for patients with NSCLC compared to erlotinib alone or other standard treatments.

It is important to note that the information provided does not indicate any contradictions between the different descriptions of erlotinib. The descriptions appear to be complementary, providing information about different clinical studies involving erlotinib in the treatment of NSCLC.

In summary, erlotinib is a tyrosine kinase inhibitor drug that is being evaluated in combination with other therapies for the treatment of NSCLC. The studies mentioned are investigating the use of erlotinib in combination with ramucirumab or LY2875358 in patients with EGFR mutation-positive metastatic NSCLC or other NSCLC populations. The goal of these studies is to determine if the combination of erlotinib with other therapies can improve outcomes for patients with NSCLC compared to erlotinib alone or other standard treatments.</data>
    </node>
    <node id="238">
      <data key="d0">RAMUCIRUMAB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">72.0</data>
      <data key="d5">Ramucirumab is a drug that is currently being evaluated for the treatment of various types of cancer. According to the provided descriptions, Ramucirumab is being studied in the following contexts:

1. Desmoplastic Small Round Cell Tumor (DSRCT): Ramucirumab is being evaluated for the treatment of desmoplastic small round cell tumor, a rare and aggressive type of cancer.

2. Non-Small Cell Lung Cancer (NSCLC):
   a. Ramucirumab is being studied in combination with erlotinib, a targeted therapy, for the treatment of previously untreated participants with EGFR mutation-positive metastatic non-small cell lung cancer.
   b. Ramucirumab is also being studied in combination with other drugs for the treatment of EGFR mutation-positive metastatic non-small cell lung cancer.

The descriptions provided do not contain any contradictory information about the use of Ramucirumab. Instead, they indicate that Ramucirumab is being investigated as a potential treatment option for different types of cancer, including desmoplastic small round cell tumor and EGFR mutation-positive metastatic non-small cell lung cancer.

Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays a crucial role in the formation of new blood vessels (angiogenesis) that support tumor growth. By inhibiting VEGFR-2, Ramucirumab may help to disrupt the blood supply to tumors, potentially slowing or preventing their growth.

The use of Ramucirumab in combination with other therapies, such as erlotinib, is being explored to potentially enhance the effectiveness of cancer treatment. Erlotinib is a targeted therapy that specifically targets the epidermal growth factor receptor (EGFR), which is commonly mutated in certain types of NSCLC. The combination of Ramucirumab and erlotinib may provide a more comprehensive approach to targeting the various mechanisms involved in cancer progression.

Overall, the available information suggests that Ramucirumab is a promising investigational drug that is being evaluated for its potential to treat desmoplastic small round cell tumor and EGFR mutation-positive metastatic non-small cell lung cancer, either as a standalone therapy or in combination with other cancer treatments.</data>
    </node>
    <node id="239">
      <data key="d0">METASTATIC NON-SMALL CELL LUNG CANCER</data>
      <data key="d1">EVENT</data>
      <data key="d2">73.0</data>
      <data key="d5">The clinical study is evaluating a treatment for metastatic non-small cell lung cancer</data>
    </node>
    <node id="240">
      <data key="d0">EGFR MUTATION-POSITIVE</data>
      <data key="d1">EVENT</data>
      <data key="d2">73.0</data>
      <data key="d5">The clinical study is evaluating a treatment in participants with EGFR mutation-positive metastatic non-small cell lung cancer</data>
    </node>
    <node id="241">
      <data key="d0">METASTATIC CASTRATION-RESISTANT PROSTATE CANCER</data>
      <data key="d1" />
      <data key="d2">33.0</data>
      <data key="d5" />
    </node>
    <node id="242">
      <data key="d0">GEFITINIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">71.0</data>
      <data key="d5">Gefitinib is a drug being studied in combination with ramucirumab for the treatment of EGFR mutation-positive metastatic NSCLC</data>
    </node>
    <node id="243">
      <data key="d0">OSIMERTINIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">71.0</data>
      <data key="d5">Osimertinib is a drug being studied in combination with ramucirumab for the treatment of T790M-positive metastatic NSCLC</data>
    </node>
    <node id="244">
      <data key="d0">MERESTINIB</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">21.0</data>
      <data key="d5">Merestinib is a drug being studied in combination with cisplatin and gemcitabine for the treatment of advanced or metastatic biliary tract cancer</data>
    </node>
    <node id="245">
      <data key="d0">BILIARY TRACT CANCER</data>
      <data key="d1" />
      <data key="d2">21.0</data>
      <data key="d5" />
    </node>
    <node id="246">
      <data key="d0">AMER AL KHOUDARI</data>
      <data key="d1">PERSON</data>
      <data key="d2">52.0</data>
      <data key="d5">Amer Al Khoudari is listed as an expert related to the studies</data>
    </node>
    <node id="247">
      <data key="d0">MONARCH 2</data>
      <data key="d1">EVENT</data>
      <data key="d2">16.0</data>
      <data key="d5">A randomized, double-blind, placebo-controlled, Phase 3 study of fulvestrant with or without abemaciclib, a CDK4/6 inhibitor, for women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer</data>
    </node>
    <node id="248">
      <data key="d0">LY4060874</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY4060874 is a drug being evaluated in a Phase 1 study for safety and tolerability in healthy participants</data>
    </node>
    <node id="249">
      <data key="d0">LY2875358</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY2875358 is a drug being evaluated in a Phase 2 study in combination with erlotinib for metastatic non-small cell lung cancer</data>
    </node>
    <node id="250">
      <data key="d0">LY3985297</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY3985297 is a drug being evaluated in a Phase 1 study for safety, tolerability and pharmacokinetics in healthy participants</data>
    </node>
    <node id="251">
      <data key="d0">HORMONE RECEPTOR POSITIVE</data>
      <data key="d1">GEO</data>
      <data key="d2">16.0</data>
      <data key="d5">Hormone receptor positive is a characteristic of the breast cancer being studied in the MONARCH 2 trial</data>
    </node>
    <node id="252">
      <data key="d0">HER2 NEGATIVE</data>
      <data key="d1">GEO</data>
      <data key="d2">16.0</data>
      <data key="d5">HER2 negative is a characteristic of the breast cancer being studied in the MONARCH 2 trial</data>
    </node>
    <node id="253">
      <data key="d0">LOCALLY ADVANCED</data>
      <data key="d1">GEO</data>
      <data key="d2">16.0</data>
      <data key="d5">Locally advanced is a characteristic of the breast cancer being studied in the MONARCH 2 trial</data>
    </node>
    <node id="254">
      <data key="d0">METASTATIC</data>
      <data key="d1">GEO</data>
      <data key="d2">16.0</data>
      <data key="d5">Metastatic is a characteristic of the breast cancer being studied in the MONARCH 2 trial</data>
    </node>
    <node id="255">
      <data key="d0">PHASE 3B TRIAL</data>
      <data key="d1" />
      <data key="d2">74.0</data>
      <data key="d5" />
    </node>
    <node id="256">
      <data key="d0">LY2784544</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY2784544 is a drug being evaluated in a Phase 2 clinical study to treat patients with myeloproliferative neoplasms</data>
    </node>
    <node id="257">
      <data key="d0">LY2835219</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LY2835219 is a CDK4/6 inhibitor being evaluated in a Phase 3 clinical study in combination with aromatase inhibitors for breast cancer</data>
    </node>
    <node id="258">
      <data key="d0">STEVEN WEINSTEIN</data>
      <data key="d1">PERSON</data>
      <data key="d2">53.0</data>
      <data key="d5">Steven Weinstein is involved in the lebrikizumab clinical study</data>
    </node>
    <node id="259">
      <data key="d0">QUINIDINE</data>
      <data key="d1" />
      <data key="d2">35.0</data>
      <data key="d5" />
    </node>
    <node id="260">
      <data key="d0">DESMOPLASTIC SMALL ROUND CELL TUMOR</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">72.0</data>
      <data key="d5">Desmoplastic small round cell tumor is a type of cancer being studied</data>
    </node>
    <node id="261">
      <data key="d0">RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">65.0</data>
      <data key="d5">RET fusion-positive non-small cell lung cancer is the condition being studied with selpercatinib</data>
    </node>
    <node id="262">
      <data key="d0">CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">63.0</data>
      <data key="d5">Chronic lymphocytic leukemia/small lymphocytic lymphoma is one of the conditions being studied with LOXO-305</data>
    </node>
    <node id="263">
      <data key="d0">MIDAZOLAM</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">64.0</data>
      <data key="d5">Midazolam is a drug used as a substrate in a clinical trial to investigate the effect of pirtobrutinib on its pharmacokinetics</data>
    </node>
    <node id="264">
      <data key="d0">DIGOXIN</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">64.0</data>
      <data key="d5">Digoxin is a drug used as a P-glycoprotein substrate in a clinical trial to investigate the effect of pirtobrutinib on its pharmacokinetics</data>
    </node>
    <node id="265">
      <data key="d0">ZYPREXA RELPREVV</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">30.0</data>
      <data key="d5">Zyprexa Relprevv is a medication used to treat certain mental health conditions. It is an injectable form of the antipsychotic drug olanzapine, which is designed to provide a sustained release of the medication over an extended period.

One of the key features of Zyprexa Relprevv is its potential to cause a serious adverse event known as post-injection delirium/sedation syndrome (PDSS). This condition can occur after the administration of the medication and is characterized by symptoms such as confusion, disorientation, and excessive sleepiness. The risk of PDSS is a significant concern with Zyprexa Relprevv, and healthcare providers must closely monitor patients for several hours after each injection to ensure their safety.

To mitigate the risks associated with PDSS, Zyprexa Relprevv is distributed through a patient care program. This program is designed to educate healthcare providers and patients about the potential for PDSS and the necessary precautions to be taken. Patients receiving Zyprexa Relprevv are required to be enrolled in the program, and healthcare providers must follow specific protocols for administering the medication and monitoring patients after each injection.

The patient care program for Zyprexa Relprevv includes several key elements:

1. Mandatory patient enrollment: All patients receiving Zyprexa Relprevv must be enrolled in the program, which ensures that they are aware of the risks and the necessary safety measures.

2. Healthcare provider training: Healthcare providers who prescribe or administer Zyprexa Relprevv must undergo specialized training to understand the risks of PDSS and the proper procedures for administering the medication and monitoring patients.

3. Post-injection monitoring: Patients who receive Zyprexa Relprevv must be monitored for at least 3 hours after each injection, with healthcare providers closely observing them for any signs of PDSS.

4. Emergency preparedness: Healthcare facilities that administer Zyprexa Relprevv must be equipped with the necessary resources and personnel to respond to any medical emergencies that may arise during the post-injection monitoring period.

By implementing this comprehensive patient care program, the manufacturers of Zyprexa Relprevv aim to mitigate the risks associated with the medication and ensure the safety of patients receiving this treatment.</data>
    </node>
    <node id="266">
      <data key="d0">PEDIATRIC AND ADOLESCENT PARTICIPANTS</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">47.0</data>
      <data key="d5">Pediatric and adolescent participants are being studied in clinical trials for tirzepatide</data>
    </node>
    <node id="267">
      <data key="d0">INDIA</data>
      <data key="d1">GEO</data>
      <data key="d2">36.0</data>
      <data key="d5">India is a key market that the pharmaceutical company Eli Lilly is targeting for its GLP-1 (Glucagon-like peptide-1) therapies. The country is seen as an important growth opportunity for these diabetes treatments, which help regulate blood sugar levels.

In addition to its commercial focus, India is also serving as a location for clinical trials related to Eli Lilly's diabetes drug pipeline. Specifically, a clinical trial for the company's dulaglutide medication is currently being conducted in India. Dulaglutide is a GLP-1 receptor agonist that has been approved for the treatment of type 2 diabetes in several countries.

By conducting clinical trials in India, Eli Lilly can evaluate the safety and efficacy of its GLP-1 therapies in the local patient population. This data can help support regulatory approvals and enable the company to make these treatments available to the large and growing diabetes patient base in India.

India represents an attractive market opportunity for Eli Lilly's GLP-1 portfolio due to the country's high prevalence of diabetes. According to the International Diabetes Federation, India has the second-highest number of adults living with diabetes in the world, with an estimated 77 million cases as of 2019. This underscores the significant unmet medical need and commercial potential for effective diabetes management solutions in the country.

Overall, India is a strategic focus area for Eli Lilly as the company seeks to expand access to its GLP-1 therapies globally. The country's large patient population, growing healthcare infrastructure, and supportive regulatory environment make it a key priority market for the pharmaceutical firm's diabetes drug development and commercialization efforts.</data>
    </node>
    <node id="268">
      <data key="d0">POST-INJECTION DELIRIUM/SEDATION SYNDROME</data>
      <data key="d1">EVENT</data>
      <data key="d2">30.0</data>
      <data key="d5">Post-injection delirium/sedation syndrome (PDSS) is a potential negative outcome associated with Zyprexa Relprevv</data>
    </node>
    <node id="269">
      <data key="d0">PATIENT CARE PROGRAM</data>
      <data key="d1" />
      <data key="d2">30.0</data>
      <data key="d5" />
    </node>
    <node id="270">
      <data key="d0">TRULICITY</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">45.0</data>
      <data key="d5">Trulicity is Eli Lilly's GLP-1 agonist drug for type 2 diabetes</data>
    </node>
    <node id="271">
      <data key="d0">SURPASS-CVOT</data>
      <data key="d1">EVENT</data>
      <data key="d2">45.0</data>
      <data key="d5">A clinical trial sponsored by Eli Lilly that compared Mounjaro to Trulicity for cardiovascular outcomes in patients with type 2 diabetes</data>
    </node>
    <node id="272">
      <data key="d0">LILLY DIRECT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">70.0</data>
      <data key="d5">LillyDirect is Eli Lilly's patient access program that allows patients to access certified obesity experts via telehealth and online pharmacy services</data>
    </node>
    <node id="273">
      <data key="d0">US GOVERNMENT</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">36.0</data>
      <data key="d5">The US Government has an agreement with Eli Lilly to expand access to its obesity medicines and reduce drug costs</data>
    </node>
    <node id="274">
      <data key="d0">MEDICAID</data>
      <data key="d1">ORGANIZATION</data>
      <data key="d2">36.0</data>
      <data key="d5">Medicaid is a government health insurance program in the United States that Eli Lilly has negotiated with to increase coverage for its obesity treatments</data>
    </node>
    <node id="275">
      <data key="d0">ELI LILLY AND CO</data>
      <data key="d1" />
      <data key="d2">36.0</data>
      <data key="d5" />
    </node>
    <node id="276">
      <data key="d0">PERIPHERAL ARTERIAL DISEASE (PAD)</data>
      <data key="d1">GEO</data>
      <data key="d2">36.0</data>
      <data key="d5">Peripheral arterial disease is a condition that was considered in the inclusion criteria for Eli Lilly's obesity treatments</data>
    </node>
    <node id="277">
      <data key="d0">MYOCARDIAL INFARCTION (MI)</data>
      <data key="d1">GEO</data>
      <data key="d2">36.0</data>
      <data key="d5">Myocardial infarction is a condition that was considered in the inclusion criteria for Eli Lilly's obesity treatments</data>
    </node>
    <node id="278">
      <data key="d0">STROKE</data>
      <data key="d1">GEO</data>
      <data key="d2">36.0</data>
      <data key="d5">Stroke is a condition that was considered in the inclusion criteria for Eli Lilly's obesity treatments</data>
    </node>
    <node id="279">
      <data key="d0">PREDIABETIC SYMPTOMS</data>
      <data key="d1">GEO</data>
      <data key="d2">36.0</data>
      <data key="d5">Prediabetic symptoms were considered in the inclusion criteria for Eli Lilly's obesity treatments</data>
    </node>
    <node id="280">
      <data key="d0">UNITED KINGDOM (UK)</data>
      <data key="d1">GEO</data>
      <data key="d2">36.0</data>
      <data key="d5">The UK is a market where Eli Lilly sees high self-pay demand for its GLP-1 therapies</data>
    </node>
    <node id="281">
      <data key="d0">BRAZIL</data>
      <data key="d1">GEO</data>
      <data key="d2">36.0</data>
      <data key="d5">Brazil is a market that Eli Lilly is targeting for its GLP-1 therapies</data>
    </node>
    <node id="282">
      <data key="d0">INVESTORS</data>
      <data key="d1" />
      <data key="d2">44.0</data>
      <data key="d5" />
    </node>
    <edge id="e0" source="0" target="5">
      <data key="d3">10.0</data>
      <data key="d4">Eli Lilly Company...</data>
      <data key="d6">Indiana University and Eli Lilly and Company are partnering to expand access to clinical trials and innovative treatments for Hoosiers, build a best-in-class clinical trial innovation ecosystem, strengthen Alzheimer's disease research and care, and develop life sciences talent</data>
    </edge>
    <edge id="e1" source="0" target="2">
      <data key="d3">9.0</data>
      <data key="d4">chair CEO...</data>
      <data key="d6">David A. Ricks is the chair and CEO of Eli Lilly and Company and is leading the partnership with Indiana University</data>
    </edge>
    <edge id="e2" source="0" target="6">
      <data key="d3">8.0</data>
      <data key="d4">Company global leadership...</data>
      <data key="d6">Eli Lilly and Company has global leadership in Alzheimer's disease innovation, which is a focus area of the partnership</data>
    </edge>
    <edge id="e3" source="1" target="5">
      <data key="d3">9.0</data>
      <data key="d4">president Indiana University...</data>
      <data key="d6">Pamela Whitten is the president of Indiana University and is leading the partnership with Eli Lilly</data>
    </edge>
    <edge id="e4" source="3" target="5">
      <data key="d3">7.0</data>
      <data key="d4">executive vice president...</data>
      <data key="d6">Jay Hess is the executive vice president for university clinical affairs and dean of the IU School of Medicine, which will be involved in the partnership</data>
    </edge>
    <edge id="e5" source="4" target="5">
      <data key="d3">1.0</data>
      <data key="d4">vice president...</data>
      <data key="d6">Russell J. Mumper is the IU vice president for research, which will support the strategic research partnership between Indiana University and Eli Lilly</data>
    </edge>
    <edge id="e6" source="5" target="10">
      <data key="d3">9.0</data>
      <data key="d4">expanding access clinical...</data>
      <data key="d6">Indiana University is expanding access to clinical trials and innovative treatments for Hoosiers, the residents of Indiana</data>
    </edge>
    <edge id="e7" source="5" target="6">
      <data key="d3">8.0</data>
      <data key="d4">strengths neuroscience clinical...</data>
      <data key="d6">Indiana University has strengths in neuroscience and clinical research, which will be leveraged in the partnership's focus on Alzheimer's disease</data>
    </edge>
    <edge id="e8" source="5" target="7">
      <data key="d3">7.0</data>
      <data key="d4">focus clinical research...</data>
      <data key="d6">The partnership aims to focus on clinical research for diabetes, which is one of Indiana University's areas of expertise</data>
    </edge>
    <edge id="e9" source="5" target="8">
      <data key="d3">7.0</data>
      <data key="d4">focus clinical research...</data>
      <data key="d6">The partnership aims to focus on clinical research for cancer, which is one of Indiana University's areas of expertise</data>
    </edge>
    <edge id="e10" source="5" target="9">
      <data key="d3">1.0</data>
      <data key="d4">focus cell...</data>
      <data key="d6">The partnership aims to focus on cell and gene therapy research, which is an area of expertise for Indiana University</data>
    </edge>
    <edge id="e11" source="0" target="12">
      <data key="d3">18.0</data>
      <data key="d4">Medicine Eli Lilly...</data>
      <data key="d6">The IU School of Medicine and Eli Lilly are partnering to establish Indiana as a leader in clinical trial innovation and provide valuable learning opportunities for students.</data>
    </edge>
    <edge id="e12" source="0" target="11">
      <data key="d3">16.0</data>
      <data key="d4">one Indiana's top...</data>
      <data key="d6">Eli Lilly, as one of Indiana's top employers, is partnering with the IU School of Medicine to drive scientific discoveries and economic impact across the state.</data>
    </edge>
    <edge id="e13" source="4" target="12">
      <data key="d3">16.0</data>
      <data key="d4">vice president...</data>
      <data key="d6">Russell J. Mumper, as the IU vice president for research, emphasizes the importance of the strategic research partnership between the IU School of Medicine and Eli Lilly.</data>
    </edge>
    <edge id="e14" source="11" target="12">
      <data key="d3">18.0</data>
      <data key="d4">Medicine working...</data>
      <data key="d6">The IU School of Medicine is working to establish Indiana as a leader in clinical trial innovation and strengthen the state's position as a global leader in life-changing research.</data>
    </edge>
    <edge id="e15" source="13" target="14">
      <data key="d3">10.0</data>
      <data key="d4">organization conducting clinical...</data>
      <data key="d6">Eli Lilly is the organization conducting the clinical trials</data>
    </edge>
    <edge id="e16" source="14" target="15">
      <data key="d3">42.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is developing a novel oral obesity drug called Orforglipron, also known as LY3502970. This drug is a GLP-1 (Glucagon-Like Peptide-1) agonist, which means it mimics the action of the naturally occurring hormone GLP-1 in the body.

Orforglipron is being evaluated for its potential to treat overweight and obesity, two major public health concerns. The drug is administered orally, which is a significant advantage over injectable GLP-1 agonists currently on the market. Eli Lilly is conducting clinical trials to assess the bioequivalence of Orforglipron when administered as capsules versus tablets in overweight or obese participants.

The descriptions provided indicate that Orforglipron is a promising new drug in Eli Lilly's pipeline. GLP-1 agonists have been shown to be effective in promoting weight loss and improving metabolic parameters, such as blood glucose control, in individuals with obesity and type 2 diabetes. By developing an oral formulation of a GLP-1 agonist, Eli Lilly aims to provide a more convenient and potentially more accessible treatment option for individuals struggling with excess weight.

It is important to note that the descriptions do not contain any contradictory information about Orforglipron or Eli Lilly's involvement in its development. The various descriptions consistently refer to Orforglipron as a novel oral obesity drug being developed by Eli Lilly, with additional details about the drug's mechanism of action and the ongoing clinical trials evaluating its bioequivalence.

In summary, Eli Lilly, a prominent pharmaceutical company, is developing a novel oral obesity drug called Orforglipron, which is a GLP-1 agonist. The company is conducting clinical trials to assess the bioequivalence of Orforglipron administered as capsules versus tablets in overweight or obese participants, with the goal of providing a more convenient and accessible treatment option for individuals struggling with excess weight.</data>
    </edge>
    <edge id="e17" source="14" target="16">
      <data key="d3">26.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is developing a novel obesity drug called Retatrutide. Retatrutide is a triple agonist, meaning it targets and activates three different receptors in the body that are involved in regulating metabolism and appetite.

Eli Lilly is currently sponsoring a Phase 3 clinical study to evaluate the safety and efficacy of Retatrutide in treating obesity. This large-scale study is a crucial step in the drug development process, as it will provide more comprehensive data on the drug's performance and potential benefits for patients.

Obesity is a significant global health concern, and the development of effective and safe treatments is a priority for the pharmaceutical industry. Retatrutide has the potential to offer a new and innovative approach to addressing this complex condition. By targeting multiple pathways involved in weight regulation, the drug may be able to achieve more substantial and sustained weight loss compared to existing obesity medications.

The Phase 3 study of Retatrutide is a testament to Eli Lilly's commitment to advancing the field of obesity treatment. The company's investment in this research and development effort reflects its recognition of the urgent need for new and improved therapies to help individuals struggling with excess weight and its associated health risks.

As the clinical trial progresses, Eli Lilly will continue to work closely with regulatory authorities and the medical community to ensure the safe and effective development of Retatrutide. The company's expertise in drug development and its track record of bringing innovative treatments to market position it well to potentially bring this promising obesity drug to patients in the future.

In summary, Eli Lilly is spearheading the development of Retatrutide, a triple agonist obesity drug, through a Phase 3 clinical study. This comprehensive effort reflects the company's dedication to addressing the global obesity crisis and its commitment to advancing the field of metabolic health.</data>
    </edge>
    <edge id="e18" source="14" target="17">
      <data key="d3">33.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is currently developing a new drug called Pirtobrutinib, a BTK (Bruton's tyrosine kinase) inhibitor. The company is conducting a phase 1/2 clinical study to evaluate the safety, tolerability, and potential efficacy of Pirtobrutinib (also known as LOXO-305) for the treatment of immune thrombocytopenia (ITP).

Immune thrombocytopenia is an autoimmune disorder characterized by a low platelet count, which can lead to an increased risk of bleeding and bruising. Pirtobrutinib, as a BTK inhibitor, is being investigated as a potential treatment option for this condition, as BTK plays a crucial role in the activation and proliferation of B cells, which are believed to be involved in the pathogenesis of ITP.

The phase 1/2 clinical study is designed to assess the safety and tolerability of Pirtobrutinib in patients with ITP. The study is being sponsored by Eli Lilly, the pharmaceutical company responsible for the development of this investigational drug.

Through this clinical trial, Eli Lilly aims to gather valuable data on the safety profile and potential therapeutic benefits of Pirtobrutinib in the treatment of immune thrombocytopenia. The study will provide insights into the drug's ability to modulate the immune system and potentially improve platelet counts in affected individuals.

The comprehensive evaluation of Pirtobrutinib's safety and tolerability is a crucial step in the drug development process, as it will help Eli Lilly determine the appropriate dosing regimen and identify any potential adverse effects. If the results of the phase 1/2 study are promising, Eli Lilly may proceed with further clinical trials to assess the efficacy of Pirtobrutinib in a larger patient population.

Overall, Eli Lilly's efforts in developing Pirtobrutinib for the treatment of immune thrombocytopenia represent a significant step forward in addressing the unmet medical needs of patients with this autoimmune disorder. The company's commitment to advancing this investigational therapy through rigorous clinical evaluation demonstrates its dedication to improving the lives of those affected by this condition.</data>
    </edge>
    <edge id="e19" source="14" target="5">
      <data key="d3">1.0</data>
      <data key="d4">collaborating with Indiana...</data>
      <data key="d6">Eli Lilly is collaborating with Indiana University to expand access to clinical trials</data>
    </edge>
    <edge id="e20" source="0" target="18">
      <data key="d3">10.0</data>
      <data key="d4">comprehensive summary data...</data>
      <data key="d6">Here is a comprehensive summary of the data provided:

Eli Lilly and Company is a major pharmaceutical company, while Lockheed Martin Investment Management Co. is an investment management firm that previously held a stake in Eli Lilly.

According to the descriptions provided, Lockheed Martin Investment Management Co. trimmed its stake in Eli Lilly and Company by 70% during the third quarter. Specifically, the investment firm sold 27,400 shares of Eli Lilly, leaving it with 11,770 shares valued at around $8.98 million.

This reduction in Lockheed Martin Investment Management Co.'s position in Eli Lilly suggests that the investment firm decided to decrease its exposure to the pharmaceutical company during that time period. The reasons for this decision are not explicitly stated, but it may have been due to a variety of factors, such as a shift in investment strategy, a desire to rebalance the portfolio, or a belief that Eli Lilly's stock was overvalued or underperforming.

Despite the significant reduction in its stake, Lockheed Martin Investment Management Co. still maintains a position in Eli Lilly, indicating that the investment firm continues to see value in the pharmaceutical company, even if to a lesser degree than before.

In summary, Lockheed Martin Investment Management Co. trimmed its stake in Eli Lilly and Company by 70% during the third quarter, selling 27,400 shares and leaving it with a remaining position of 11,770 shares valued at around $8.98 million.</data>
    </edge>
    <edge id="e21" source="0" target="19">
      <data key="d3">7.0</data>
      <data key="d4">Eli Lilly Company's...</data>
      <data key="d6">MarketBeat reported on Eli Lilly and Company's Q3 results and FY2025 guidance</data>
    </edge>
    <edge id="e22" source="0" target="20">
      <data key="d3">5.0</data>
      <data key="d4">Group Inc. bought...</data>
      <data key="d6">Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company</data>
    </edge>
    <edge id="e23" source="0" target="21">
      <data key="d3">5.0</data>
      <data key="d4">Inc. bought new...</data>
      <data key="d6">Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company</data>
    </edge>
    <edge id="e24" source="0" target="22">
      <data key="d3">6.0</data>
      <data key="d4">increased holdings Eli...</data>
      <data key="d6">Steph &amp; Co. increased its holdings in Eli Lilly and Company</data>
    </edge>
    <edge id="e25" source="0" target="23">
      <data key="d3">5.0</data>
      <data key="d4">Inc. purchased new...</data>
      <data key="d6">Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company</data>
    </edge>
    <edge id="e26" source="0" target="24">
      <data key="d3">1.0</data>
      <data key="d4">Inc. raised stake...</data>
      <data key="d6">Bare Financial Services Inc. raised its stake in Eli Lilly and Company</data>
    </edge>
    <edge id="e27" source="0" target="25">
      <data key="d3">8.0</data>
      <data key="d4">Company produces medication...</data>
      <data key="d6">Eli Lilly and Company produces the medication Ozempic</data>
    </edge>
    <edge id="e28" source="0" target="26">
      <data key="d3">8.0</data>
      <data key="d4">Company produces medication...</data>
      <data key="d6">Eli Lilly and Company produces the medication Mounjaro</data>
    </edge>
    <edge id="e29" source="0" target="27">
      <data key="d3">8.0</data>
      <data key="d4">Company produces medication...</data>
      <data key="d6">Eli Lilly and Company produces the medication Wegovy</data>
    </edge>
    <edge id="e30" source="0" target="28">
      <data key="d3">1.0</data>
      <data key="d4">Company produces medication...</data>
      <data key="d6">Eli Lilly and Company produces the medication Zepbound</data>
    </edge>
    <edge id="e31" source="29" target="0">
      <data key="d3">8.0</data>
      <data key="d4">Breakthrough Therapy designation...</data>
      <data key="d6">The FDA granted Breakthrough Therapy designation to Eli Lilly's ovarian cancer drug candidate, which can accelerate its development and approval.</data>
    </edge>
    <edge id="e32" source="16" target="0">
      <data key="d3">7.0</data>
      <data key="d4">conducting Phase dosing...</data>
      <data key="d6">Eli Lilly is conducting a Phase 3b dosing study for its obesity drug candidate retatrutide.</data>
    </edge>
    <edge id="e33" source="30" target="0">
      <data key="d3">8.0</data>
      <data key="d4">SURMOUNT-REAL real-world study...</data>
      <data key="d6">Eli Lilly conducted the SURMOUNT-REAL UK real-world study on its obesity drug tirzepatide to gather additional data and support its commercial use.</data>
    </edge>
    <edge id="e34" source="31" target="0">
      <data key="d3">8.0</data>
      <data key="d4">Eli Lilly's key...</data>
      <data key="d6">Tirzepatide is one of Eli Lilly's key obesity drug candidates that was studied in the SURMOUNT-REAL UK trial.</data>
    </edge>
    <edge id="e35" source="32" target="0">
      <data key="d3">7.0</data>
      <data key="d4">spoke JPMorgan Healthcare...</data>
      <data key="d6">Eli Lilly executives spoke at the JPMorgan Healthcare Conference about the evolving obesity drug market and opportunities for Lilly's portfolio.</data>
    </edge>
    <edge id="e36" source="33" target="0">
      <data key="d3">5.0</data>
      <data key="d4">Pranav Shroff new...</data>
      <data key="d6">Eli Lilly appointed Pranav Shroff as its new director of marketing, a routine personnel move to support the company's commercial execution.</data>
    </edge>
    <edge id="e37" source="34" target="0">
      <data key="d3">7.0</data>
      <data key="d4">generic version...</data>
      <data key="d6">Sun Pharma's approval of a generic version of Wegovy in India increases competition and pricing pressure for Eli Lilly's obesity drugs in that key international market.</data>
    </edge>
    <edge id="e38" source="35" target="0">
      <data key="d3">1.0</data>
      <data key="d4">Todd Rokita discussed...</data>
      <data key="d6">Indiana Attorney General Todd Rokita discussed a lawsuit against Eli Lilly over insulin pricing, which poses reputational and financial risks for the company.</data>
    </edge>
    <edge id="e39" source="0" target="36">
      <data key="d3">8.0</data>
      <data key="d4">price target rating...</data>
      <data key="d6">Wolfe Research increased their price target and rating on Eli Lilly and Company.</data>
    </edge>
    <edge id="e40" source="0" target="37">
      <data key="d3">7.0</data>
      <data key="d4">price target rating...</data>
      <data key="d6">Berenberg Bank increased their price target and rating on Eli Lilly and Company.</data>
    </edge>
    <edge id="e41" source="0" target="38">
      <data key="d3">8.0</data>
      <data key="d4">coverage Eli Lilly...</data>
      <data key="d6">UBS Group initiated coverage on Eli Lilly and Company with a buy rating and $1,250 price target.</data>
    </edge>
    <edge id="e42" source="0" target="39">
      <data key="d3">8.0</data>
      <data key="d4">price target Eli...</data>
      <data key="d6">Morgan Stanley raised their price target on Eli Lilly and Company.</data>
    </edge>
    <edge id="e43" source="0" target="40">
      <data key="d3">1.0</data>
      <data key="d4">hold rating $1,070...</data>
      <data key="d6">HSBC maintained a hold rating and $1,070 price target on Eli Lilly and Company.</data>
    </edge>
    <edge id="e44" source="19" target="0">
      <data key="d3">9.0</data>
      <data key="d4">coverage Eli Lilly...</data>
      <data key="d6">MarketBeat provides analysis and coverage of Eli Lilly and Company, including its latest 13F filings and insider trades</data>
    </edge>
    <edge id="e45" source="15" target="0">
      <data key="d3">34.0</data>
      <data key="d4">Company pharmaceutical company...</data>
      <data key="d6">Eli Lilly and Company is a pharmaceutical company that has developed the drug orforglipron for the treatment of type 2 diabetes. Orforglipron is an oral GLP-1 (glucagon-like peptide-1) drug, which means it is a medication that mimics the action of the GLP-1 hormone in the body.

GLP-1 is a hormone produced by the intestines that helps regulate blood sugar levels by stimulating the release of insulin and suppressing the release of glucagon, a hormone that raises blood sugar levels. By mimicking the action of GLP-1, orforglipron can help improve blood sugar control in people with type 2 diabetes.

Eli Lilly and Company is a well-established pharmaceutical company that has been in operation for over a century. The company is known for its research and development of innovative medications, including several other diabetes treatments. Orforglipron is the latest addition to Eli Lilly's portfolio of diabetes drugs, and it is expected to provide an effective and convenient option for people with type 2 diabetes who are looking to manage their condition.

The development of orforglipron by Eli Lilly and Company is a significant achievement in the field of diabetes treatment. The drug's oral administration, as opposed to injectable GLP-1 agonists, may make it more appealing to some patients and potentially improve adherence to treatment. Additionally, the use of GLP-1 agonists has been shown to have additional benefits beyond just blood sugar control, such as weight loss and cardiovascular health improvements.

Overall, the comprehensive summary of the data provided indicates that Eli Lilly and Company has developed a new oral GLP-1 drug called orforglipron for the treatment of type 2 diabetes. This drug is expected to provide an effective and convenient option for managing the condition, and it is a testament to Eli Lilly's ongoing commitment to innovation in the field of diabetes care.</data>
    </edge>
    <edge id="e46" source="15" target="41">
      <data key="d3">34.0</data>
      <data key="d4">SEMAGLUTIDE two medications...</data>
      <data key="d6">ORFORGLIPRON and ORAL SEMAGLUTIDE are two medications used in the treatment of type 2 diabetes. Clinical trials have been conducted to compare the efficacy of these two treatments.

In the ACHIEVE-3 trial, ORFORGLIPRON was found to outperform ORAL SEMAGLUTIDE in reducing HbA1c (a measure of average blood sugar levels) and promoting weight loss in individuals with type 2 diabetes. The trial results indicate that ORFORGLIPRON was more effective than ORAL SEMAGLUTIDE in improving glycemic control and facilitating weight management, which are important goals in the management of type 2 diabetes.

The specific details of the ACHIEVE-3 trial, such as the study design, sample size, and the magnitude of the differences in outcomes between the two treatments, are not provided in the given information. However, the summary indicates that ORFORGLIPRON demonstrated superior performance compared to ORAL SEMAGLUTIDE in this particular clinical trial.

It is important to note that the available information does not provide a comprehensive comparison of the two treatments across multiple clinical trials or in different patient populations. The summary is based on the limited data provided, which focuses on the results of the ACHIEVE-3 trial. Additional research and clinical evidence may be necessary to draw more definitive conclusions about the relative efficacy and safety of ORFORGLIPRON and ORAL SEMAGLUTIDE in the management of type 2 diabetes.

In conclusion, the available data suggests that ORFORGLIPRON outperformed ORAL SEMAGLUTIDE in the ACHIEVE-3 trial, demonstrating better outcomes in terms of HbA1c reduction and weight loss. However, further research may be needed to fully understand the comparative effectiveness and clinical utility of these two diabetes medications.</data>
    </edge>
    <edge id="e47" source="15" target="43">
      <data key="d3">10.0</data>
      <data key="d4">evaluated safety efficacy...</data>
      <data key="d6">The ACHIEVE-3 trial evaluated the safety and efficacy of orforglipron compared to oral semaglutide</data>
    </edge>
    <edge id="e48" source="42" target="0">
      <data key="d3">18.0</data>
      <data key="d4">executive Eli Lilly...</data>
      <data key="d6">Kenneth Custer is an executive at Eli Lilly and Company</data>
    </edge>
    <edge id="e49" source="43" target="44">
      <data key="d3">18.0</data>
      <data key="d4">study that evaluated...</data>
      <data key="d6">The ACHIEVE-3 trial was a study that evaluated two medications, orforglipron and oral semaglutide, in adults with type 2 diabetes. The participants in the ACHIEVE-3 trial all had a diagnosis of type 2 diabetes.

Type 2 diabetes is a chronic metabolic condition characterized by the body's inability to effectively use insulin, a hormone responsible for regulating blood sugar levels. This can lead to high blood sugar levels, which, if left untreated, can cause a range of health complications, including damage to the eyes, kidneys, nerves, and cardiovascular system.

The ACHIEVE-3 trial was designed to assess the efficacy and safety of orforglipron and oral semaglutide in managing type 2 diabetes. Orforglipron and oral semaglutide are both medications that work to improve blood sugar control in individuals with type 2 diabetes.

The study enrolled adults with type 2 diabetes and compared the effects of these two medications on various outcomes, such as changes in HbA1c (a measure of average blood sugar levels over time), weight, and other markers of diabetes management. By evaluating these two treatments in a clinical trial setting, the researchers aimed to provide valuable insights into the potential benefits and risks of these therapies for individuals with type 2 diabetes.

The comprehensive summary of the ACHIEVE-3 trial and its participants with type 2 diabetes highlights the importance of ongoing research and clinical trials in the field of diabetes management. By understanding the efficacy and safety of different treatment options, healthcare providers can make more informed decisions to optimize the care and outcomes for individuals living with type 2 diabetes.</data>
    </edge>
    <edge id="e50" source="43" target="45">
      <data key="d3">10.0</data>
      <data key="d4">involved participants with...</data>
      <data key="d6">The ACHIEVE-3 trial involved participants with type 2 diabetes who were inadequately controlled with the medication metformin. Metformin is a common first-line treatment for type 2 diabetes, but some patients may not achieve optimal blood sugar control with metformin alone. 

The ACHIEVE-3 trial was designed to evaluate the efficacy and safety of an additional medication or treatment approach for these patients with type 2 diabetes who were already taking metformin. The trial participants were all individuals with type 2 diabetes who were not achieving satisfactory blood sugar management despite being on metformin therapy.

By including only participants who were already taking metformin, the ACHIEVE-3 trial was able to focus on evaluating potential add-on or alternative treatments that could improve glycemic control in this specific patient population. The trial compared the outcomes of different treatment approaches in these metformin-treated individuals with suboptimal type 2 diabetes management.

In summary, the ACHIEVE-3 clinical trial involved patients with type 2 diabetes who were inadequately controlled on metformin therapy. The trial aimed to assess potential new treatment options that could be used in combination with or as an alternative to metformin for improving blood sugar regulation in this patient population. The trial design allowed for a targeted evaluation of treatment strategies for type 2 diabetes that was not well-controlled with metformin alone.</data>
    </edge>
    <edge id="e51" source="46" target="15">
      <data key="d3">8.0</data>
      <data key="d4">licensed Lilly...</data>
      <data key="d6">Chugai discovered orforglipron and licensed it to Lilly</data>
    </edge>
    <edge id="e52" source="47" target="15">
      <data key="d3">8.0</data>
      <data key="d4">from Chugai running...</data>
      <data key="d6">Lilly licensed orforglipron from Chugai and is running Phase 3 trials on it</data>
    </edge>
    <edge id="e53" source="43" target="15">
      <data key="d3">1.0</data>
      <data key="d4">Phase trial evaluating...</data>
      <data key="d6">ACHIEVE-3 is a Phase 3 trial evaluating the efficacy and safety of orforglipron compared to oral semaglutide</data>
    </edge>
    <edge id="e54" source="43" target="41">
      <data key="d3">9.0</data>
      <data key="d4">compared orforglipron...</data>
      <data key="d6">Oral semaglutide was compared to orforglipron in the ACHIEVE-3 clinical trial</data>
    </edge>
    <edge id="e55" source="43" target="48">
      <data key="d3">9.0</data>
      <data key="d4">conducted across...</data>
      <data key="d6">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </edge>
    <edge id="e56" source="43" target="49">
      <data key="d3">9.0</data>
      <data key="d4">conducted across...</data>
      <data key="d6">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </edge>
    <edge id="e57" source="43" target="50">
      <data key="d3">9.0</data>
      <data key="d4">conducted across...</data>
      <data key="d6">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </edge>
    <edge id="e58" source="43" target="51">
      <data key="d3">9.0</data>
      <data key="d4">conducted across...</data>
      <data key="d6">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </edge>
    <edge id="e59" source="43" target="52">
      <data key="d3">9.0</data>
      <data key="d4">conducted across...</data>
      <data key="d6">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </edge>
    <edge id="e60" source="43" target="53">
      <data key="d3">1.0</data>
      <data key="d4">conducted across...</data>
      <data key="d6">The ACHIEVE-3 trial was conducted across the U.S., Argentina, China, Japan, Mexico and Puerto Rico</data>
    </edge>
    <edge id="e61" source="15" target="55">
      <data key="d3">18.0</data>
      <data key="d4">program clinical...</data>
      <data key="d6">The ACHIEVE Phase 3 program is the clinical development program for orforglipron</data>
    </edge>
    <edge id="e62" source="15" target="54">
      <data key="d3">14.0</data>
      <data key="d4">Association publishes standards...</data>
      <data key="d6">The American Diabetes Association publishes standards of care that are relevant to the development of orforglipron</data>
    </edge>
    <edge id="e63" source="15" target="47">
      <data key="d3">11.0</data>
      <data key="d4">company developing testing...</data>
      <data key="d6">Lilly is the company developing and testing orforglipron as a treatment for type 2 diabetes</data>
    </edge>
    <edge id="e64" source="56" target="0">
      <data key="d3">8.0</data>
      <data key="d4">Company required file...</data>
      <data key="d6">Eli Lilly and Company is required to file reports with the United States Securities and Exchange Commission as a publicly traded company</data>
    </edge>
    <edge id="e65" source="0" target="57">
      <data key="d3">8.0</data>
      <data key="d4">Company files Form...</data>
      <data key="d6">Eli Lilly and Company files Form 10-K annual reports with the United States Securities and Exchange Commission</data>
    </edge>
    <edge id="e66" source="0" target="58">
      <data key="d3">1.0</data>
      <data key="d4">Company files Form...</data>
      <data key="d6">Eli Lilly and Company files Form 10-Q quarterly reports with the United States Securities and Exchange Commission</data>
    </edge>
    <edge id="e67" source="47" target="59">
      <data key="d3">2.0</data>
      <data key="d4">trials part...</data>
      <data key="d6">Lilly conducts clinical trials as part of its research and development efforts</data>
    </edge>
    <edge id="e68" source="62" target="14">
      <data key="d3">16.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is conducting clinical research on the insulin product LY3209590. The company is undertaking two related studies to evaluate the safety and efficacy of this insulin product.

The first study is a clinical trial focused on LY3209590. Eli Lilly is investigating the use of this insulin product in a clinical setting, likely to assess its therapeutic potential and gather data on its performance in treating patients.

The second study is a pharmacokinetics study of LY3209590 in pediatric participants with type 2 diabetes. This study is designed to understand how the insulin product is absorbed, distributed, metabolized, and eliminated in the bodies of children and adolescents with type 2 diabetes. This information is crucial for determining the appropriate dosing and administration of LY3209590 for this patient population.

By conducting these two complementary studies, Eli Lilly aims to gather comprehensive data on the safety, efficacy, and pharmacokinetic properties of LY3209590. The clinical trial will provide insights into the product's therapeutic potential, while the pharmacokinetics study will help optimize its use in the pediatric type 2 diabetes population.

The combination of these studies demonstrates Eli Lilly's commitment to developing innovative insulin therapies and improving the management of diabetes, particularly in younger patients. The company's efforts to thoroughly investigate LY3209590 through both clinical and pharmacokinetic research reflect its dedication to providing safe and effective treatment options for individuals living with diabetes.

Overall, Eli Lilly's research on LY3209590 is a testament to the company's ongoing efforts to advance the field of diabetes care and improve the quality of life for those affected by this chronic condition.</data>
    </edge>
    <edge id="e69" source="31" target="14">
      <data key="d3">70.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is conducting extensive clinical trials on a promising new drug called tirzepatide. Tirzepatide is being developed by Eli Lilly for the treatment of obesity, weight-related comorbidities, and type 2 diabetes.

The company is currently undertaking a phase 3b study to evaluate the efficacy and safety of tirzepatide compared to semaglutide in adults with obesity or overweight with weight-related comorbidities. This study aims to assess the potential benefits of tirzepatide in managing these conditions.

In addition to the phase 3b study, Eli Lilly is also conducting clinical trials to study the safety and efficacy of tirzepatide in pediatric and adolescent participants with type 2 diabetes and obesity. This expansion of the clinical trials to include younger populations demonstrates Eli Lilly's commitment to addressing these health concerns across different age groups.

Furthermore, Eli Lilly is the sponsor of the tirzepatide studies, indicating their strong involvement and investment in the development of this drug. The company's comprehensive approach to clinical trials, covering a range of indications and age groups, suggests that they are dedicated to thoroughly understanding the potential of tirzepatide and its ability to address the growing challenges of obesity, weight-related comorbidities, and type 2 diabetes.

Overall, Eli Lilly's extensive clinical trials on tirzepatide highlight the company's commitment to advancing the treatment of these significant health issues. The consistent information provided across the descriptions suggests a coherent and focused effort by Eli Lilly to explore the safety and efficacy of tirzepatide, with the ultimate goal of bringing a new and potentially impactful treatment option to patients.</data>
    </edge>
    <edge id="e70" source="31" target="66">
      <data key="d3">17.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Tirzepatide is being studied for the treatment of type 1 diabetes</data>
    </edge>
    <edge id="e71" source="31" target="67">
      <data key="d3">52.0</data>
      <data key="d4">Tirzepatide medication that...</data>
      <data key="d6">Tirzepatide and Obesity

Tirzepatide is a medication that is currently being investigated for its potential in treating obesity and overweight conditions. The studies surrounding this drug are primarily focused on participants who are either obese or overweight.

Tirzepatide is being studied for its effect on morbidity and mortality in adults with obesity. This means that researchers are examining whether the use of tirzepatide can help reduce the risk of health complications and improve overall survival rates in individuals who are obese. Additionally, tirzepatide is being studied as a potential treatment for obesity itself, with the goal of helping individuals achieve and maintain a healthier weight.

The research on tirzepatide is not limited to adult populations. The drug is also being studied for the treatment of obesity in pediatric and adolescent participants. This is an important area of investigation, as childhood and adolescent obesity can have significant long-term health implications and may require specialized treatment approaches.

Furthermore, tirzepatide is being studied in combination with another medication, ixekizumab, for the treatment of obesity or overweight. The use of combination therapies is a common approach in the management of complex conditions like obesity, as it may provide more comprehensive and effective treatment options.

Overall, the data suggests that tirzepatide is a promising drug candidate for the treatment of obesity and overweight conditions. The studies are focused on evaluating the drug's safety, efficacy, and potential impact on morbidity and mortality in both adult and pediatric/adolescent populations. The use of tirzepatide in combination with other medications, such as ixekizumab, further highlights the ongoing efforts to develop comprehensive and tailored treatment approaches for individuals struggling with obesity.

It is important to note that while the available data is promising, the research on tirzepatide is still ongoing. The final outcomes and conclusions regarding the drug's effectiveness and safety will be determined as the studies progress and the results are fully analyzed. Individuals with concerns about obesity or overweight should consult with their healthcare providers to discuss the latest treatment options and determine the most appropriate course of action for their specific needs.</data>
    </edge>
    <edge id="e72" source="31" target="68">
      <data key="d3">17.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Tirzepatide is being studied for the treatment of overweight</data>
    </edge>
    <edge id="e73" source="63" target="14">
      <data key="d3">7.0</data>
      <data key="d4">conducting clinical trial...</data>
      <data key="d6">Eli Lilly is conducting a clinical trial on the product LY3537031</data>
    </edge>
    <edge id="e74" source="64" target="14">
      <data key="d3">24.0</data>
      <data key="d4">prominent pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a prominent pharmaceutical company, is currently conducting clinical research on the drug lebrikizumab. According to the provided descriptions, Eli Lilly is sponsoring a study to evaluate the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis who have previously been treated with dupilumab.

The study is an open-label trial, which means that both the participants and the researchers are aware of the treatment being administered. This type of study design is often used to gather additional safety and efficacy data on a drug that has already undergone previous clinical trials.

Lebrikizumab is the focus of Eli Lilly's research efforts in this case. Lebrikizumab is a monoclonal antibody that targets the interleukin-13 (IL-13) pathway, which is believed to play a key role in the development and progression of atopic dermatitis, a chronic inflammatory skin condition. By targeting IL-13, lebrikizumab aims to reduce the inflammation and symptoms associated with atopic dermatitis.

The study is designed to assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis who have previously been treated with dupilumab, another biologic medication used for the management of atopic dermatitis. This patient population is of particular interest as they may have developed resistance or intolerance to dupilumab, and lebrikizumab could potentially offer an alternative treatment option.

The open-label nature of the study allows Eli Lilly to gather real-world data on the use of lebrikizumab in a clinical setting, which can provide valuable insights into the drug's performance and help inform future clinical development and regulatory decisions.

In summary, Eli Lilly is conducting a clinical trial to evaluate the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis who have previously been treated with dupilumab. This study is part of Eli Lilly's ongoing efforts to develop and bring new treatment options to patients suffering from this chronic and often debilitating skin condition.</data>
    </edge>
    <edge id="e75" source="64" target="69">
      <data key="d3">42.0</data>
      <data key="d4">medication that being...</data>
      <data key="d6">Lebrikizumab is a medication that is being evaluated and studied for the treatment of atopic dermatitis, a chronic inflammatory skin condition. Atopic dermatitis is characterized by dry, itchy, and inflamed skin, and can range in severity from moderate to severe.

The available descriptions indicate that lebrikizumab is being investigated specifically for the treatment of moderate-to-severe atopic dermatitis. The drug is currently undergoing clinical trials to assess its safety and efficacy in this patient population.

Lebrikizumab is a monoclonal antibody that targets and binds to the interleukin-13 (IL-13) cytokine, which plays a key role in the inflammatory process underlying atopic dermatitis. By inhibiting IL-13, lebrikizumab aims to reduce the inflammation and associated symptoms of the condition.

The clinical trials evaluating lebrikizumab for the treatment of atopic dermatitis are exploring the use of the drug in participants with moderate-to-severe forms of the disease. This suggests that lebrikizumab may be a potential treatment option for individuals with more severe or difficult-to-manage atopic dermatitis, who may not have achieved satisfactory results with other available therapies.

Overall, the available information indicates that lebrikizumab is a promising investigational treatment for atopic dermatitis, with a focus on addressing the needs of individuals with moderate-to-severe forms of the condition. The ongoing clinical trials will provide valuable insights into the safety and efficacy of lebrikizumab, and its potential role in the management of this chronic and often challenging skin disorder.</data>
    </edge>
    <edge id="e76" source="65" target="14">
      <data key="d3">20.0</data>
      <data key="d4">product being developed...</data>
      <data key="d6">Bimagrumab is a product being developed by the pharmaceutical company Eli Lilly. According to the provided information, Eli Lilly is conducting a clinical trial on bimagrumab, and is also developing the product for an unspecified purpose.

The descriptions indicate that Eli Lilly is sponsoring a study of bimagrumab, either alone or in combination with semaglutide, for the treatment of overweight or obese men and women. This suggests that bimagrumab may be a potential treatment for obesity or weight-related conditions.

The descriptions do not provide any further details about the specific indications or mechanisms of action for bimagrumab. However, the fact that Eli Lilly is conducting clinical trials and developing the product indicates that it is likely a novel therapeutic candidate with potential clinical applications.

In summary, bimagrumab is a product being developed by Eli Lilly, and the company is currently studying its use, either alone or in combination with semaglutide, for the treatment of overweight and obesity in men and women. The exact purpose and indications for bimagrumab are not clearly specified in the provided information, but the ongoing clinical trial and development efforts suggest that it may have promising therapeutic potential.</data>
    </edge>
    <edge id="e77" source="65" target="67">
      <data key="d3">15.0</data>
      <data key="d4">novel therapeutic agent...</data>
      <data key="d6">Bimagrumab is a novel therapeutic agent that is being investigated for the treatment of obesity. It is a monoclonal antibody that targets the activin type II receptors, which play a crucial role in regulating muscle growth and metabolism.

The current data indicates that bimagrumab is being studied alone or in combination with semaglutide, another medication used for the treatment of overweight or obese individuals. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been shown to promote weight loss and improve metabolic parameters.

The combination of bimagrumab and semaglutide is being explored as a potential treatment for overweight or obese men and women. The rationale behind this approach is that the complementary mechanisms of action of the two drugs may lead to enhanced weight loss and improved metabolic outcomes.

Bimagrumab is also being studied as a standalone therapy for the treatment of obesity. The exact mechanisms by which bimagrumab may exert its effects on weight and metabolism are not yet fully understood, but it is believed to involve the modulation of muscle growth and energy expenditure.

The ongoing clinical trials are aimed at evaluating the safety, tolerability, and efficacy of bimagrumab, both as a monotherapy and in combination with semaglutide, in individuals with overweight or obesity. These studies will provide valuable insights into the potential of bimagrumab as a new therapeutic option for the management of this prevalent and challenging condition.

In summary, bimagrumab is a promising investigational drug that is being explored for the treatment of obesity, either as a standalone therapy or in combination with semaglutide. The available data suggests that this approach may offer a novel and potentially effective way to address the growing global burden of overweight and obesity. However, further research is needed to fully understand the mechanisms of action and to establish the long-term safety and efficacy of this therapeutic approach.</data>
    </edge>
    <edge id="e78" source="65" target="68">
      <data key="d3">1.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Bimagrumab is being studied for the treatment of overweight</data>
    </edge>
    <edge id="e79" source="61" target="14">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring clinical study...</data>
      <data key="d6">Eli Lilly is sponsoring the clinical study that Almena Free is participating in</data>
    </edge>
    <edge id="e80" source="70" target="14">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring clinical study...</data>
      <data key="d6">Eli Lilly is sponsoring the clinical study that Marshall Schreeder is participating in</data>
    </edge>
    <edge id="e81" source="71" target="14">
      <data key="d3">1.0</data>
      <data key="d4">sponsoring two clinical...</data>
      <data key="d6">Eli Lilly is sponsoring the two clinical studies that Oliver Klein is participating in</data>
    </edge>
    <edge id="e82" source="72" target="73">
      <data key="d3">8.0</data>
      <data key="d4">investigated combination with...</data>
      <data key="d6">LY3537982 is being investigated in combination with pembrolizumab in a clinical study</data>
    </edge>
    <edge id="e83" source="72" target="74">
      <data key="d3">8.0</data>
      <data key="d4">investigated combination with...</data>
      <data key="d6">LY3537982 is being investigated in combination with pemetrexed and platinum in a clinical study</data>
    </edge>
    <edge id="e84" source="72" target="75">
      <data key="d3">8.0</data>
      <data key="d4">investigated combination with...</data>
      <data key="d6">LY3537982 is being investigated in combination with pemetrexed and platinum in a clinical study</data>
    </edge>
    <edge id="e85" source="16" target="77">
      <data key="d3">17.0</data>
      <data key="d4">medication that currently...</data>
      <data key="d6">Retatrutide is a medication that is currently being investigated for its potential effects on renal function and major adverse kidney events in individuals with chronic kidney disease (CKD).

Chronic kidney disease is a condition characterized by the gradual loss of kidney function over time. It can be caused by a variety of factors, including diabetes, high blood pressure, and glomerulonephritis, and can lead to serious complications if left untreated.

The available data suggests that Retatrutide is being studied for its potential to address some of the challenges associated with CKD. Specifically, the descriptions indicate that Retatrutide is being investigated for its effect on renal function and major adverse kidney events in participants with CKD.

While the exact mechanisms of action are not fully understood, Retatrutide may have the potential to help preserve or even improve kidney function in individuals with CKD. This could potentially lead to a reduction in the risk of major adverse kidney events, such as kidney failure, dialysis, or kidney transplantation.

It is important to note that the available descriptions do not provide any information about the specific outcomes or results of the ongoing studies. As such, it is not possible to determine the efficacy or safety of Retatrutide in the treatment of CKD at this time. Further research and clinical trials will be necessary to fully understand the potential benefits and risks of this medication.

In summary, Retatrutide is a medication that is currently being investigated for its potential effects on renal function and major adverse kidney events in individuals with chronic kidney disease. While the available data is limited, the descriptions suggest that Retatrutide may have the potential to help address some of the challenges associated with CKD. However, more research is needed to fully understand the efficacy and safety of this medication in the treatment of this condition.</data>
    </edge>
    <edge id="e86" source="16" target="44">
      <data key="d3">17.0</data>
      <data key="d4">medication that currently...</data>
      <data key="d6">Retatrutide is a medication that is currently being investigated for the treatment of type 2 diabetes. Type 2 diabetes is a chronic condition characterized by the body's inability to effectively use insulin, a hormone that regulates blood sugar levels.

The available descriptions indicate that retatrutide is being studied in participants both with and without type 2 diabetes. This suggests that the medication may have potential applications beyond just the treatment of type 2 diabetes, and could potentially be used for other conditions or as a preventative measure.

Retatrutide is likely a novel therapeutic agent that is undergoing clinical trials to evaluate its safety and efficacy in managing type 2 diabetes. The exact mechanism of action and the specific indications for which retatrutide is being investigated are not clearly specified in the provided information.

It is important to note that the descriptions do not contain any contradictory information. The statements that retatrutide is being investigated for the treatment of type 2 diabetes, and that it is being studied in participants with or without the condition, are not mutually exclusive and can be reconciled into a coherent summary.

In conclusion, retatrutide is a medication that is currently being investigated for its potential in the management of type 2 diabetes. The available information suggests that the medication may have broader applications beyond just the treatment of type 2 diabetes, and that further research is needed to fully understand its therapeutic potential and the specific indications for which it may be used.</data>
    </edge>
    <edge id="e87" source="76" target="66">
      <data key="d3">8.0</data>
      <data key="d4">investigated participants with...</data>
      <data key="d6">LY4057996 is being investigated in participants with type 1 diabetes</data>
    </edge>
    <edge id="e88" source="76" target="44">
      <data key="d3">8.0</data>
      <data key="d4">investigated participants with...</data>
      <data key="d6">LY4057996 is being investigated in participants with type 2 diabetes</data>
    </edge>
    <edge id="e89" source="15" target="78">
      <data key="d3">8.0</data>
      <data key="d4">investigated treatment...</data>
      <data key="d6">Orforglipron is being investigated for the treatment of hypertension</data>
    </edge>
    <edge id="e90" source="15" target="67">
      <data key="d3">8.0</data>
      <data key="d4">investigated participants with...</data>
      <data key="d6">Orforglipron is being investigated in participants with obesity</data>
    </edge>
    <edge id="e91" source="15" target="68">
      <data key="d3">1.0</data>
      <data key="d4">investigated participants who...</data>
      <data key="d6">Orforglipron is being investigated in participants who are overweight</data>
    </edge>
    <edge id="e92" source="15" target="92">
      <data key="d3">9.0</data>
      <data key="d4">drug being investigated...</data>
      <data key="d6">Orforglipron is the drug being investigated in the ATTAIN-HYPERTENSION study</data>
    </edge>
    <edge id="e93" source="79" target="92">
      <data key="d3">8.0</data>
      <data key="d4">independent study conducted...</data>
      <data key="d6">GZL2 is an independent study conducted under the GZPL master protocol to evaluate orforglipron</data>
    </edge>
    <edge id="e94" source="79" target="93">
      <data key="d3">9.0</data>
      <data key="d4">independent study conducted...</data>
      <data key="d6">GZL2 is an independent study conducted under the GZPL master protocol</data>
    </edge>
    <edge id="e95" source="31" target="80">
      <data key="d3">17.0</data>
      <data key="d4">evaluated GPI1 participants...</data>
      <data key="d6">Tirzepatide is being evaluated in GPI1 for participants with obstructive sleep apnea and obesity who are unwilling or unable to use PAP therapy</data>
    </edge>
    <edge id="e96" source="31" target="81">
      <data key="d3">17.0</data>
      <data key="d4">evaluated GPI2 participants...</data>
      <data key="d6">Tirzepatide is being evaluated in GPI2 for participants with obstructive sleep apnea and obesity who are and plan to stay on PAP therapy</data>
    </edge>
    <edge id="e97" source="14" target="84">
      <data key="d3">8.0</data>
      <data key="d4">protocol being conducted...</data>
      <data key="d6">The CWMM master protocol is being conducted by Eli Lilly</data>
    </edge>
    <edge id="e98" source="14" target="85">
      <data key="d3">8.0</data>
      <data key="d4">evaluated study conducted...</data>
      <data key="d6">LY4086940 is being evaluated in a study conducted by Eli Lilly</data>
    </edge>
    <edge id="e99" source="14" target="91">
      <data key="d3">36.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is conducting clinical trials to investigate the efficacy and safety of their investigational drug, LY3502970, in various therapeutic areas.

According to the provided information, Eli Lilly is sponsoring the Phase 3 studies of LY3502970, which is being evaluated for the treatment of type 2 diabetes in adults. The company is conducting clinical trials to assess the drug's potential in this indication.

In addition to the type 2 diabetes studies, the data also indicates that Eli Lilly is investigating the use of LY3502970 for the treatment of obesity. The descriptions state that LY3502970 is an investigational drug being studied by Eli Lilly for obesity, suggesting that the company is exploring the drug's potential in this therapeutic area as well.

It is important to note that the descriptions provided do not appear to be contradictory. The information indicates that Eli Lilly is conducting clinical trials to evaluate the efficacy and safety of LY3502970 in both type 2 diabetes and obesity, which are two distinct therapeutic areas.

In summary, Eli Lilly, a prominent pharmaceutical company, is conducting comprehensive clinical trials to investigate the potential of their investigational drug, LY3502970, in the treatment of type 2 diabetes and obesity. The company is sponsoring the Phase 3 studies of LY3502970 for type 2 diabetes, and is also evaluating the drug's potential in the treatment of obesity. This comprehensive research effort by Eli Lilly aims to explore the therapeutic applications of LY3502970 and potentially bring new treatment options to patients in these important disease areas.</data>
    </edge>
    <edge id="e100" source="82" target="83">
      <data key="d3">9.0</data>
      <data key="d4">same drug being...</data>
      <data key="d6">LY3372993 and remternetug are the same drug being evaluated for Alzheimer's disease</data>
    </edge>
    <edge id="e101" source="86" target="87">
      <data key="d3">9.0</data>
      <data key="d4">study drug being...</data>
      <data key="d6">Selpercatinib is the study drug being evaluated in the LIBRETTO-432 study</data>
    </edge>
    <edge id="e102" source="89" target="16">
      <data key="d3">9.0</data>
      <data key="d4">drug being evaluated...</data>
      <data key="d6">Retatrutide is the drug being evaluated in the J1I-MC-GZQE study</data>
    </edge>
    <edge id="e103" source="89" target="90">
      <data key="d3">9.0</data>
      <data key="d4">retatrutide metoprolol pharmacokinetics...</data>
      <data key="d6">The effect of retatrutide on metoprolol pharmacokinetics is being evaluated in the J1I-MC-GZQE study</data>
    </edge>
    <edge id="e104" source="91" target="44">
      <data key="d3">10.0</data>
      <data key="d4">compound that currently...</data>
      <data key="d6">LY3502970 is a compound that is currently being evaluated for the treatment of type 2 diabetes. Type 2 diabetes is a chronic metabolic disorder characterized by the body's inability to effectively use insulin, a hormone that regulates blood sugar levels.

The available descriptions indicate that LY3502970 is being investigated as a potential treatment option for individuals with type 2 diabetes. The compound is being evaluated in clinical studies involving participants with this condition. The goal of these studies is to assess the safety and efficacy of LY3502970 in managing the symptoms and complications associated with type 2 diabetes.

Type 2 diabetes is a prevalent health issue, affecting millions of people worldwide. It is often associated with lifestyle factors, such as obesity, physical inactivity, and poor dietary habits. Untreated or poorly managed type 2 diabetes can lead to a range of serious health complications, including cardiovascular disease, kidney damage, nerve damage, and vision loss.

The development of new treatment options, such as LY3502970, is crucial in addressing the growing burden of type 2 diabetes. By providing alternative or complementary therapies, healthcare professionals can work to improve the management of this chronic condition and enhance the overall well-being of individuals living with type 2 diabetes.

It is important to note that the available information does not indicate any contradictions or inconsistencies regarding the use of LY3502970 for the treatment of type 2 diabetes. The descriptions consistently suggest that the compound is being evaluated as a potential treatment option for this condition.

In summary, LY3502970 is a compound that is currently being investigated for the treatment of type 2 diabetes. The ongoing clinical studies aim to assess the safety and efficacy of LY3502970 in managing the symptoms and complications associated with this chronic metabolic disorder. The development of new treatment options, such as LY3502970, is crucial in addressing the growing burden of type 2 diabetes and improving the overall health and well-being of individuals living with this condition.</data>
    </edge>
    <edge id="e105" source="14" target="94">
      <data key="d3">17.0</data>
      <data key="d4">conducting clinical trial...</data>
      <data key="d6">Eli Lilly is conducting a clinical trial to assess the efficacy and safety of olomorasib in combination with immunotherapy for treating KRAS G12C-mutant non-small cell lung cancer
Eli Lilly is conducting a clinical trial to assess the efficacy and safety of olomorasib in combination with immunotherapy in participants with KRAS G12C-mutant non-small cell lung cancer</data>
    </edge>
    <edge id="e106" source="14" target="31">
      <data key="d3">52.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is conducting extensive research and clinical trials on tirzepatide, an investigational drug, for the treatment of various health conditions.

Tirzepatide is being studied by Eli Lilly for its potential in treating type 2 diabetes, obesity, and overweight. The company is conducting multiple clinical trials to evaluate the efficacy and safety of tirzepatide in these areas.

One of the studies is focused on the safety of tirzepatide in participants with type 2 diabetes during the Ramadan fasting period. This study aims to assess the safety and tolerability of tirzepatide in this specific population.

Additionally, Eli Lilly is conducting a Phase 3 study to evaluate the efficacy and safety of tirzepatide in adults with type 1 diabetes and obesity or overweight. This study is designed to explore the potential of tirzepatide as a treatment option for individuals with this combination of conditions.

Furthermore, Eli Lilly is investigating the safety and efficacy of tirzepatide in adolescents with obesity or overweight and weight-related comorbidities. This study aims to assess the potential of tirzepatide as a treatment option for young individuals struggling with these health challenges.

Eli Lilly is also conducting the SURPASS-CVOT study, which is evaluating tirzepatide versus dulaglutide in patients with type 2 diabetes and increased cardiovascular risk. This study is designed to assess the impact of tirzepatide on cardiovascular outcomes in this high-risk population.

Lastly, Eli Lilly is investigating the effect of tirzepatide on morbidity and mortality in adults with obesity. This study aims to provide insights into the potential of tirzepatide to improve overall health outcomes for individuals with obesity.

Overall, Eli Lilly's extensive research on tirzepatide demonstrates the company's commitment to developing innovative treatments for a wide range of health conditions, including type 2 diabetes, obesity, and overweight. The company is conducting multiple clinical trials to evaluate the safety and efficacy of tirzepatide, with the goal of providing new treatment options for individuals struggling with these health challenges.</data>
    </edge>
    <edge id="e107" source="14" target="95">
      <data key="d3">17.0</data>
      <data key="d4">conducting proof-of-concept study...</data>
      <data key="d6">Eli Lilly is conducting a proof-of-concept study to evaluate mazdutide for treating alcohol use disorder
Eli Lilly is conducting a proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder</data>
    </edge>
    <edge id="e108" source="14" target="96">
      <data key="d3">17.0</data>
      <data key="d4">conducting Phase study...</data>
      <data key="d6">Eli Lilly is conducting a Phase 1/2 study of the oral RET inhibitor LOXO-292 in pediatric patients with advanced RET-altered solid or primary central nervous system tumors
Eli Lilly is conducting a Phase 1/2 study of the oral RET inhibitor LOXO-292 for treating advanced RET-altered solid or primary central nervous system tumors in pediatric patients</data>
    </edge>
    <edge id="e109" source="14" target="97">
      <data key="d3">9.0</data>
      <data key="d4">conducting Phase study...</data>
      <data key="d6">Eli Lilly is conducting a Phase 1 study of LOXO-435 in locally advanced or metastatic solid tumors including urothelial cancer with FGFR3 alterations
Eli Lilly is conducting a Phase 1 study of LOXO-435 for treating locally advanced or metastatic solid tumors including urothelial cancer with FGFR3 alterations</data>
    </edge>
    <edge id="e110" source="98" target="31">
      <data key="d3">8.0</data>
      <data key="d4">involved clinical trial...</data>
      <data key="d6">Kristin Castorino is involved in the clinical trial of tirzepatide</data>
    </edge>
    <edge id="e111" source="99" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor clinical...</data>
      <data key="d6">Eli Lilly is the sponsor of the clinical trial for LY4066434</data>
    </edge>
    <edge id="e112" source="99" target="104">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">LY4066434 is being studied for the treatment of KRAS mutant solid tumors</data>
    </edge>
    <edge id="e113" source="14" target="100">
      <data key="d3">9.0</data>
      <data key="d4">sponsor clinical...</data>
      <data key="d6">Eli Lilly is the sponsor of the clinical trial for LY3962673</data>
    </edge>
    <edge id="e114" source="14" target="87">
      <data key="d3">9.0</data>
      <data key="d4">sponsor clinical...</data>
      <data key="d6">Eli Lilly is the sponsor of the clinical trial for selpercatinib</data>
    </edge>
    <edge id="e115" source="14" target="101">
      <data key="d3">25.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is conducting a clinical study on the pharmacokinetics of their investigational compound LY3437943 in participants with hepatic (liver) impairment. The study is designed to evaluate the effects of varying degrees of liver dysfunction on the absorption, distribution, metabolism, and elimination of LY3437943.

LY3437943 is an investigational drug that is currently being developed by Eli Lilly. As the sponsor of the clinical trial, Eli Lilly is responsible for the design, implementation, and oversight of the study. The study aims to gather important data on the behavior of LY3437943 in individuals with compromised liver function, which is crucial for understanding the appropriate dosing and safety considerations for this investigational compound.

Hepatic impairment can significantly impact the way a drug is processed and eliminated from the body, potentially leading to altered pharmacokinetic profiles and the need for dose adjustments. By conducting this study, Eli Lilly seeks to gather the necessary information to ensure the safe and effective use of LY3437943 in patients with liver disease, should the compound be approved for clinical use in the future.

The study is likely to involve the enrollment of participants with varying degrees of liver dysfunction, ranging from mild to severe impairment. Participants will undergo various assessments, including blood sampling and pharmacokinetic analyses, to determine the impact of liver function on the disposition of LY3437943. The data collected from this study will be crucial in guiding the further development and potential regulatory approval of LY3437943.

In summary, Eli Lilly, a prominent pharmaceutical company, is conducting a clinical study to investigate the pharmacokinetics of their investigational compound LY3437943 in participants with hepatic impairment. The study aims to provide valuable insights into the behavior of LY3437943 in individuals with compromised liver function, which is essential for ensuring the safe and effective use of the drug, if approved for clinical use in the future.</data>
    </edge>
    <edge id="e116" source="14" target="102">
      <data key="d3">10.0</data>
      <data key="d4">prominent pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a prominent pharmaceutical company, is currently investigating the use of the drug abemaciclib in the treatment of Ewing's sarcoma. Abemaciclib is an investigational drug, meaning it is still undergoing clinical trials and has not yet been approved for widespread use.

The clinical trial for abemaciclib is being sponsored by Eli Lilly, indicating the company's involvement in the development and testing of this potential new treatment. Ewing's sarcoma is a rare type of bone and soft tissue cancer that primarily affects children and young adults, and the combination of abemaciclib with other drugs is being explored as a possible therapeutic approach.

Eli Lilly's decision to investigate abemaciclib for Ewing's sarcoma suggests the company's commitment to expanding its portfolio of cancer treatments and exploring new avenues for addressing this challenging disease. As the sponsor of the clinical trial, Eli Lilly is responsible for overseeing the study, ensuring the safety and efficacy of the investigational drug, and ultimately seeking regulatory approval for its use.

The combination of abemaciclib with other drugs is a common approach in cancer research, as combining different therapies can often lead to more effective treatment outcomes. By exploring this combination, Eli Lilly aims to provide a more comprehensive and potentially more effective treatment option for patients with Ewing's sarcoma.

Overall, the information provided indicates that Eli Lilly is actively engaged in the development and testing of abemaciclib as a potential new treatment for Ewing's sarcoma, a rare and challenging form of cancer. The company's sponsorship of the clinical trial demonstrates its commitment to advancing the field of cancer research and providing innovative treatment solutions for patients in need.</data>
    </edge>
    <edge id="e117" source="14" target="103">
      <data key="d3">1.0</data>
      <data key="d4">sponsor clinical...</data>
      <data key="d6">Eli Lilly is the sponsor of the clinical trial for LOXO-260</data>
    </edge>
    <edge id="e118" source="100" target="112">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">LY3962673 is being studied for the treatment of KRAS G12D-mutant solid tumors</data>
    </edge>
    <edge id="e119" source="87" target="105">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Selpercatinib is being studied for the treatment of advanced solid tumors</data>
    </edge>
    <edge id="e120" source="87" target="106">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Selpercatinib is being studied for the treatment of medullary thyroid cancer</data>
    </edge>
    <edge id="e121" source="87" target="107">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Selpercatinib is being studied for the treatment of RET fusion-positive solid tumors</data>
    </edge>
    <edge id="e122" source="17" target="108">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Pirtobrutinib is being studied for the treatment of chronic lymphocytic leukemia</data>
    </edge>
    <edge id="e123" source="17" target="109">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Pirtobrutinib is being studied for the treatment of small lymphocytic lymphoma</data>
    </edge>
    <edge id="e124" source="17" target="110">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Pirtobrutinib is being studied for the treatment of non-Hodgkin lymphoma</data>
    </edge>
    <edge id="e125" source="101" target="67">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">LY3437943 is being studied for the treatment of obesity</data>
    </edge>
    <edge id="e126" source="101" target="68">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">LY3437943 is being studied for the treatment of overweight</data>
    </edge>
    <edge id="e127" source="101" target="111">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">LY3437943 is being studied for the treatment of osteoarthritis of the knee</data>
    </edge>
    <edge id="e128" source="102" target="88">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Abemaciclib is being studied for the treatment of stage IV non-small cell lung cancer</data>
    </edge>
    <edge id="e129" source="103" target="105">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">LOXO-260 is being studied for the treatment of solid tumors</data>
    </edge>
    <edge id="e130" source="103" target="106">
      <data key="d3">17.0</data>
      <data key="d4">drug that being...</data>
      <data key="d6">LOXO-260 is a drug that is being evaluated and studied for the treatment of medullary thyroid cancer. Medullary thyroid cancer is a rare type of thyroid cancer that originates from the C cells of the thyroid gland, which are responsible for producing the hormone calcitonin.

LOXO-260 is a targeted therapy that is designed to inhibit the activity of certain proteins that are involved in the growth and spread of cancer cells. Specifically, LOXO-260 targets the RET (rearranged during transfection) protein, which is known to play a key role in the development of medullary thyroid cancer.

The clinical development of LOXO-260 for the treatment of medullary thyroid cancer is currently in the research and evaluation stage. Researchers are conducting studies to assess the safety, tolerability, and efficacy of LOXO-260 in patients with this type of cancer.

The available data suggests that LOXO-260 may be a promising treatment option for patients with medullary thyroid cancer. The drug has shown activity in preclinical studies and early-stage clinical trials, and it has the potential to provide a new therapeutic approach for this rare and challenging form of thyroid cancer.

However, it is important to note that the development of LOXO-260 for the treatment of medullary thyroid cancer is still in the early stages, and more research is needed to fully understand its potential benefits and risks. Patients with medullary thyroid cancer should discuss all available treatment options with their healthcare providers to determine the best course of action for their individual situation.

In summary, LOXO-260 is a targeted therapy that is being evaluated and studied for the treatment of medullary thyroid cancer, a rare and challenging form of thyroid cancer. While the available data is promising, further research is needed to fully understand the potential of this drug as a treatment option for patients with this disease.</data>
    </edge>
    <edge id="e131" source="103" target="107">
      <data key="d3">9.0</data>
      <data key="d4">drug that being...</data>
      <data key="d6">LOXO-260 is a drug that is being evaluated and studied for the treatment of RET fusion-positive solid tumors. RET fusion-positive solid tumors are a type of cancer characterized by the presence of a genetic mutation that involves the RET (rearranged during transfection) gene.

LOXO-260 is a selective and potent inhibitor of the RET kinase, which is the target of the RET fusion mutations. By inhibiting the RET kinase, LOXO-260 aims to disrupt the signaling pathways that drive the growth and proliferation of RET fusion-positive cancer cells.

The clinical development of LOXO-260 for the treatment of RET fusion-positive solid tumors is ongoing. The drug is being evaluated in clinical trials to assess its safety, tolerability, and efficacy in patients with this type of cancer. The available data from these studies suggest that LOXO-260 may have the potential to provide a new treatment option for patients with RET fusion-positive solid tumors.

The comprehensive summary of the data provided indicates that LOXO-260 is being actively investigated as a potential treatment for RET fusion-positive solid tumors. The descriptions do not contain any contradictory information, and the overall focus is on the evaluation and study of LOXO-260 for this specific type of cancer.

In conclusion, LOXO-260 is a promising drug candidate that is being evaluated and studied for the treatment of RET fusion-positive solid tumors. The ongoing clinical trials aim to further assess the safety, tolerability, and efficacy of LOXO-260 in patients with this type of cancer, with the goal of potentially providing a new and effective treatment option for this patient population.</data>
    </edge>
    <edge id="e132" source="102" target="14">
      <data key="d3">25.0</data>
      <data key="d4">Lilly, leading pharmaceutical...</data>
      <data key="d6">Comprehensive Summary:

Eli Lilly, a leading pharmaceutical company, is conducting multiple studies to evaluate the safety and effectiveness of the drug abemaciclib for the treatment of various types of cancer.

Abemaciclib is a targeted therapy that works by inhibiting the activity of certain enzymes, known as cyclin-dependent kinases (CDKs), which play a crucial role in the growth and division of cancer cells. Eli Lilly is investigating the potential of abemaciclib as a treatment for both lung cancer and hormone receptor-positive, HER2-negative metastatic breast cancer.

In one study, Eli Lilly is evaluating the safety and effectiveness of abemaciclib for the treatment of lung cancer. This study aims to determine the optimal dosage and administration of the drug, as well as its ability to control the progression of the disease and improve patient outcomes.

Additionally, Eli Lilly is sponsoring a study to assess the efficacy of abemaciclib, either alone or in combination with the hormone therapy tamoxifen, for the treatment of previously treated hormone receptor-positive, HER2-negative metastatic breast cancer. This study is designed to explore the potential of abemaciclib to improve outcomes for patients with this type of advanced breast cancer.

Across these studies, Eli Lilly is taking a comprehensive approach to understanding the clinical potential of abemaciclib as a treatment for various types of cancer. The company is committed to advancing the development of this targeted therapy and bringing new treatment options to patients in need.

Overall, Eli Lilly's research efforts with abemaciclib demonstrate the company's dedication to innovation and its commitment to improving the lives of individuals affected by cancer. As the studies progress, the findings will contribute to a better understanding of the role of abemaciclib in the management of lung cancer and hormone receptor-positive, HER2-negative metastatic breast cancer.</data>
    </edge>
    <edge id="e133" source="102" target="121">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">Abemaciclib is being evaluated for the treatment of lung cancer</data>
    </edge>
    <edge id="e134" source="103" target="14">
      <data key="d3">8.0</data>
      <data key="d4">conducting study evaluate...</data>
      <data key="d6">Eli Lilly is conducting a study to evaluate the safety, side effects, and effectiveness of LOXO-260 for the treatment of RET fusion-positive solid tumors, medullary thyroid cancer, and other tumors with RET activation</data>
    </edge>
    <edge id="e135" source="113" target="14">
      <data key="d3">8.0</data>
      <data key="d4">conducting study assess...</data>
      <data key="d6">Eli Lilly is conducting a study to assess the safety, tolerability and effect of LY3372689 in participants with early symptomatic Alzheimer's Disease</data>
    </edge>
    <edge id="e136" source="113" target="6">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">LY3372689 is being evaluated for the treatment of early symptomatic Alzheimer's Disease</data>
    </edge>
    <edge id="e137" source="114" target="14">
      <data key="d3">8.0</data>
      <data key="d4">conducting study evaluate...</data>
      <data key="d6">Eli Lilly is conducting a study to evaluate the effects of LY3549492 in adults with obesity or overweight</data>
    </edge>
    <edge id="e138" source="114" target="67">
      <data key="d3">8.0</data>
      <data key="d4">evaluated weight management...</data>
      <data key="d6">LY3549492 is being evaluated for weight management in adults with obesity</data>
    </edge>
    <edge id="e139" source="114" target="68">
      <data key="d3">8.0</data>
      <data key="d4">evaluated weight management...</data>
      <data key="d6">LY3549492 is being evaluated for weight management in adults with overweight</data>
    </edge>
    <edge id="e140" source="17" target="14">
      <data key="d3">26.0</data>
      <data key="d4">drug being developed...</data>
      <data key="d6">Pirtobrutinib is a drug being developed and studied by the pharmaceutical company Eli Lilly. Eli Lilly is conducting a master protocol study to evaluate the long-term safety and efficacy of pirtobrutinib. This study is designed to assess the drug's performance over an extended period of time, providing valuable insights into its potential benefits and any potential side effects.

In addition to the long-term safety and efficacy study, Eli Lilly is also conducting clinical trials to evaluate the effect of pirtobrutinib on the QTc interval and its drug interactions. The QTc interval is a measure of the time it takes for the heart's electrical activity to complete one cycle, and it is an important factor in assessing the safety of a drug. By studying the impact of pirtobrutinib on the QTc interval and its interactions with other drugs, Eli Lilly can better understand the drug's safety profile and ensure that it can be used safely in combination with other medications.

Overall, Eli Lilly's research efforts on pirtobrutinib are focused on establishing its long-term safety and efficacy, as well as understanding its potential interactions with other drugs. This comprehensive approach to drug development is crucial in ensuring that pirtobrutinib, if approved, can be used safely and effectively by patients who may benefit from its therapeutic properties.</data>
    </edge>
    <edge id="e141" source="115" target="14">
      <data key="d3">8.0</data>
      <data key="d4">conducting study measure...</data>
      <data key="d6">Eli Lilly is conducting a study to measure the change in hemoglobin A1c with LY3457263 compared to placebo in participants with type 2 diabetes</data>
    </edge>
    <edge id="e142" source="115" target="120">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">LY3457263 is being evaluated for the treatment of type 2 diabetes mellitus</data>
    </edge>
    <edge id="e143" source="116" target="14">
      <data key="d3">8.0</data>
      <data key="d4">conducting study find...</data>
      <data key="d6">Eli Lilly is conducting a study to find out whether LY4101174, an antibody-drug conjugate targeting Nectin-4, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors</data>
    </edge>
    <edge id="e144" source="116" target="117">
      <data key="d3">7.0</data>
      <data key="d4">expert involved...</data>
      <data key="d6">Craig Gedye is an expert involved in the study of LY4101174</data>
    </edge>
    <edge id="e145" source="116" target="105">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">LY4101174 is being evaluated for the treatment of recurrent, advanced or metastatic solid tumors</data>
    </edge>
    <edge id="e146" source="15" target="14">
      <data key="d3">17.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is conducting a clinical study to investigate the effects of the investigational drug orforglipron on body fat levels in individuals with obesity or overweight. The study is a Phase 3b trial, which means it is a late-stage clinical evaluation of the drug's safety and efficacy.

Orforglipron is the focus of this study, and Eli Lilly is the sponsor of the research. The study aims to compare the impact of orforglipron on body fat levels to that of a placebo (an inactive substance) in the participants. This type of study is designed to provide valuable insights into the potential of orforglipron as a treatment option for individuals struggling with excess body weight.

The study is currently ongoing, and Eli Lilly is actively recruiting participants to take part in the research. The findings from this study will contribute to the overall understanding of orforglipron's effects and its potential as a therapeutic option for individuals with obesity or overweight.

Eli Lilly, a well-established pharmaceutical company, has a long history of developing innovative treatments and conducting rigorous clinical trials to ensure the safety and efficacy of its products. The company's involvement in the orforglipron study demonstrates its commitment to exploring new avenues for addressing the growing public health challenge of obesity and overweight.

In summary, Eli Lilly is conducting a Phase 3b clinical study to investigate the effects of the investigational drug orforglipron on body fat levels in individuals with obesity or overweight. The study is designed to provide valuable insights into the potential of orforglipron as a treatment option for this population.</data>
    </edge>
    <edge id="e147" source="118" target="119">
      <data key="d3">1.0</data>
      <data key="d4">expert involved...</data>
      <data key="d6">John Tesser is an expert involved in the study of LY3541860</data>
    </edge>
    <edge id="e148" source="14" target="122">
      <data key="d3">8.0</data>
      <data key="d4">conducting phase study...</data>
      <data key="d6">Eli Lilly is conducting the phase 1 study of DC-853 in healthy participants</data>
    </edge>
    <edge id="e149" source="14" target="124">
      <data key="d3">9.0</data>
      <data key="d4">conducting phase ACCLAIM-Lp(a)...</data>
      <data key="d6">Eli Lilly is conducting the phase 3 ACCLAIM-Lp(a) study to investigate the effect of lepodisiran on reducing major adverse cardiovascular events in adults with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease or at risk of a first cardiovascular event</data>
    </edge>
    <edge id="e150" source="17" target="118">
      <data key="d3">8.0</data>
      <data key="d4">involved phase...</data>
      <data key="d6">John Tesser is involved in the phase 1/2 dose-finding study of pirtobrutinib for immune thrombocytopenia</data>
    </edge>
    <edge id="e151" source="31" target="123">
      <data key="d3">8.0</data>
      <data key="d4">comparator drug...</data>
      <data key="d6">Dulaglutide is used as a comparator drug in the SURPASS-CVOT study evaluating tirzepatide in patients with type 2 diabetes and increased cardiovascular risk</data>
    </edge>
    <edge id="e152" source="31" target="44">
      <data key="d3">26.0</data>
      <data key="d4">medication that being...</data>
      <data key="d6">Tirzepatide is a medication that is being extensively studied for its potential applications in the management of type 2 diabetes. This dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist is currently undergoing clinical trials to assess its efficacy in various aspects of type 2 diabetes treatment.

One of the key areas of investigation is the effect of tirzepatide on major adverse cardiovascular events (MACE) in patients with type 2 diabetes. Cardiovascular disease is a significant complication associated with type 2 diabetes, and the ability of tirzepatide to potentially reduce the risk of MACE could have important implications for the management of this patient population.

In addition to its cardiovascular effects, tirzepatide is also being studied for its potential in weight management for individuals with type 2 diabetes. Obesity is a major risk factor for the development of type 2 diabetes, and the ability of tirzepatide to facilitate weight loss could be a valuable tool in the comprehensive management of this chronic condition.

Furthermore, tirzepatide is being evaluated for its direct effects on the treatment of type 2 diabetes itself. As a dual GIP and GLP-1 receptor agonist, tirzepatide may offer unique advantages in improving glycemic control and potentially delaying the progression of the disease.

The comprehensive evaluation of tirzepatide in the context of type 2 diabetes highlights the ongoing efforts to develop more effective and targeted therapies for this prevalent and complex condition. By addressing various aspects of type 2 diabetes management, including cardiovascular risk, weight management, and direct glycemic control, tirzepatide has the potential to become a valuable addition to the arsenal of treatments available for individuals living with this chronic metabolic disorder.

As the clinical trials continue, the research community and healthcare providers will closely monitor the outcomes to better understand the full scope of tirzepatide's capabilities in the management of type 2 diabetes. The ultimate goal is to provide patients with a more comprehensive and personalized approach to managing this condition, ultimately improving their overall health and quality of life.</data>
    </edge>
    <edge id="e153" source="124" target="126">
      <data key="d3">2.0</data>
      <data key="d4">involved phase...</data>
      <data key="d6">Nova Law is involved in the phase 3 ACCLAIM-Lp(a) study of lepodisiran</data>
    </edge>
    <edge id="e154" source="124" target="129">
      <data key="d3">9.0</data>
      <data key="d4">evaluated effect...</data>
      <data key="d6">Lepodisiran is being evaluated for its effect on reducing major adverse cardiovascular events in adults with established atherosclerotic cardiovascular disease or at risk of a first cardiovascular event</data>
    </edge>
    <edge id="e155" source="124" target="132">
      <data key="d3">9.0</data>
      <data key="d4">studied adults with...</data>
      <data key="d6">Lepodisiran is being studied in adults with elevated lipoprotein(a)</data>
    </edge>
    <edge id="e156" source="16" target="127">
      <data key="d3">2.0</data>
      <data key="d4">involved phase...</data>
      <data key="d6">Phillip Madonia is involved in the phase 3 study investigating the effect of retatrutide on major adverse cardiovascular events and major adverse kidney events in participants with obesity and cardiovascular or kidney disease</data>
    </edge>
    <edge id="e157" source="16" target="129">
      <data key="d3">9.0</data>
      <data key="d4">investigated effect...</data>
      <data key="d6">Retatrutide is being investigated for its effect on major adverse cardiovascular events in participants with atherosclerotic cardiovascular disease</data>
    </edge>
    <edge id="e158" source="16" target="67">
      <data key="d3">9.0</data>
      <data key="d4">evaluated participants with...</data>
      <data key="d6">Retatrutide is being evaluated in participants with a body mass index of 27 kg/m^2 or higher</data>
    </edge>
    <edge id="e159" source="125" target="128">
      <data key="d3">1.0</data>
      <data key="d4">involved EMBER-4 study,...</data>
      <data key="d6">Michael Meshad is involved in the EMBER-4 study, a phase 3 trial comparing imlunestrant to standard adjuvant endocrine therapy in patients with ER+, HER2- early breast cancer</data>
    </edge>
    <edge id="e160" source="125" target="130">
      <data key="d3">9.0</data>
      <data key="d4">studied adjuvant therapy...</data>
      <data key="d6">Imlunestrant is being studied as an adjuvant therapy in patients with early breast cancer</data>
    </edge>
    <edge id="e161" source="125" target="131">
      <data key="d3">1.0</data>
      <data key="d4">evaluated patients with...</data>
      <data key="d6">Imlunestrant is being evaluated in patients with ER+, HER2- early breast cancer</data>
    </edge>
    <edge id="e162" source="133" target="128">
      <data key="d3">8.0</data>
      <data key="d4">researcher involved...</data>
      <data key="d6">Michael Meshad is a researcher involved in the TRIUMPH-1 study</data>
    </edge>
    <edge id="e163" source="133" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor TRIUMPH-1...</data>
      <data key="d6">Eli Lilly is the sponsor of the TRIUMPH-1 study</data>
    </edge>
    <edge id="e164" source="133" target="140">
      <data key="d3">8.0</data>
      <data key="d4">investigating participants with...</data>
      <data key="d6">The TRIUMPH-1 study is investigating participants with estrogen receptor positive cancer</data>
    </edge>
    <edge id="e165" source="133" target="138">
      <data key="d3">8.0</data>
      <data key="d4">investigating participants with...</data>
      <data key="d6">The TRIUMPH-1 study is investigating participants with human epidermal receptor 2 negative cancer</data>
    </edge>
    <edge id="e166" source="133" target="44">
      <data key="d3">8.0</data>
      <data key="d4">investigating participants without...</data>
      <data key="d6">The TRIUMPH-1 study is investigating participants without type 2 diabetes</data>
    </edge>
    <edge id="e167" source="133" target="67">
      <data key="d3">8.0</data>
      <data key="d4">investigating participants with...</data>
      <data key="d6">The TRIUMPH-1 study is investigating participants with obesity</data>
    </edge>
    <edge id="e168" source="133" target="68">
      <data key="d3">8.0</data>
      <data key="d4">investigating participants who...</data>
      <data key="d6">The TRIUMPH-1 study is investigating participants who are overweight</data>
    </edge>
    <edge id="e169" source="134" target="135">
      <data key="d3">8.0</data>
      <data key="d4">researcher involved...</data>
      <data key="d6">Victoria Horstman is a researcher involved in the study of donanemab versus placebo in participants at risk for cognitive and functional decline of Alzheimer's disease</data>
    </edge>
    <edge id="e170" source="135" target="6">
      <data key="d3">25.0</data>
      <data key="d4">investigational drug being...</data>
      <data key="d6">Donanemab is an investigational drug being assessed for the treatment of early Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder that affects cognitive function, memory, and daily living activities.

The donanemab study is investigating the drug's effects on adults with early symptomatic Alzheimer's disease. Specifically, the study is evaluating donanemab's impact on ARIA-E (Amyloid-Related Imaging Abnormalities-Edema) and amyloid lowering. Amyloid is a protein that can accumulate in the brain, leading to the development of Alzheimer's disease.

In addition, the donanemab study is examining the drug's potential to affect the cognitive and functional decline associated with Alzheimer's disease. Participants in the study are considered to be at risk for these declines, which can significantly impact an individual's quality of life and ability to perform daily tasks.

Donanemab is a monoclonal antibody that targets a specific form of amyloid, known as N3pG, which is believed to play a key role in the development and progression of Alzheimer's disease. By targeting this form of amyloid, donanemab aims to reduce the accumulation of the protein in the brain and potentially slow or halt the cognitive and functional decline associated with the disease.

The ongoing clinical trials for donanemab are designed to evaluate the safety and efficacy of the drug in individuals with early Alzheimer's disease. The results of these studies will provide valuable insights into the potential of donanemab as a treatment option for this debilitating condition.

Overall, the donanemab study represents an important step in the ongoing efforts to develop new and effective therapies for Alzheimer's disease. By targeting the underlying pathological processes of the disease, donanemab has the potential to offer hope to individuals and their families affected by this devastating condition.</data>
    </edge>
    <edge id="e171" source="136" target="137">
      <data key="d3">1.0</data>
      <data key="d4">researcher involved...</data>
      <data key="d6">William Sandborn is a researcher involved in the LUCENT 3 study evaluating the long-term efficacy and safety of mirikizumab in patients with moderately to severely active ulcerative colitis</data>
    </edge>
    <edge id="e172" source="44" target="141">
      <data key="d3">8.0</data>
      <data key="d4">investigating participants with...</data>
      <data key="d6">The GZBK study is investigating participants with type 2 diabetes</data>
    </edge>
    <edge id="e173" source="67" target="142">
      <data key="d3">8.0</data>
      <data key="d4">investigating participants with...</data>
      <data key="d6">The GZBJ study is investigating participants with obesity</data>
    </edge>
    <edge id="e174" source="68" target="142">
      <data key="d3">8.0</data>
      <data key="d4">investigating participants who...</data>
      <data key="d6">The GZBJ study is investigating participants who are overweight</data>
    </edge>
    <edge id="e175" source="139" target="143">
      <data key="d3">8.0</data>
      <data key="d4">study investigating long-term...</data>
      <data key="d6">The LUCENT 3 study is investigating the long-term efficacy and safety of mirikizumab in patients with ulcerative colitis</data>
    </edge>
    <edge id="e176" source="67" target="15">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">Orforglipron will be evaluated for the treatment of obesity</data>
    </edge>
    <edge id="e177" source="67" target="16">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">Retatrutide will be evaluated for the treatment of obesity, compared to tirzepatide</data>
    </edge>
    <edge id="e178" source="67" target="31">
      <data key="d3">9.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">Tirzepatide will be evaluated for the treatment of obesity, compared to retatrutide
Tirzepatide will be evaluated for the treatment of obesity and weight-related comorbidities in adolescents</data>
    </edge>
    <edge id="e179" source="68" target="15">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">Orforglipron will be evaluated for the treatment of overweight</data>
    </edge>
    <edge id="e180" source="137" target="144">
      <data key="d3">8.0</data>
      <data key="d4">evaluated long-term treatment...</data>
      <data key="d6">Mirikizumab will be evaluated for the long-term treatment of Crohn's disease</data>
    </edge>
    <edge id="e181" source="16" target="14">
      <data key="d3">24.0</data>
      <data key="d4">drug candidate being...</data>
      <data key="d6">Retatrutide is a drug candidate being developed by the pharmaceutical company Eli Lilly for the treatment of type 2 diabetes. Eli Lilly is the sponsor of the clinical studies investigating retatrutide.

Retatrutide is a novel therapeutic agent that is currently in the research and development stage. It is being evaluated as a potential treatment option for individuals with type 2 diabetes, a chronic metabolic disorder characterized by the body's inability to effectively use insulin, leading to high blood sugar levels.

Eli Lilly, a renowned global pharmaceutical company, is responsible for the development and clinical investigation of retatrutide. As the sponsor of the retatrutide studies, Eli Lilly is overseeing the research and clinical trials to assess the safety, efficacy, and potential therapeutic benefits of the drug candidate.

The development of retatrutide by Eli Lilly is a significant step in the ongoing efforts to address the growing burden of type 2 diabetes. This condition affects millions of people worldwide and is associated with an increased risk of various health complications, including cardiovascular disease, kidney disease, and nerve damage.

By investing in the research and development of retatrutide, Eli Lilly aims to contribute to the advancement of diabetes treatment options and potentially provide a new therapeutic approach for individuals living with this chronic condition. The company's involvement in the retatrutide studies underscores its commitment to developing innovative solutions to improve the health and well-being of patients.

As the research and clinical trials progress, further details about the specific mechanisms of action, dosage, and potential benefits of retatrutide may become available. Eli Lilly's continued efforts in this area will be closely monitored by the medical and scientific community, as well as individuals affected by type 2 diabetes, who are hopeful for the emergence of new and effective treatment options.</data>
    </edge>
    <edge id="e182" source="16" target="152">
      <data key="d3">7.0</data>
      <data key="d4">author related...</data>
      <data key="d6">Wayne Ho is an author related to the retatrutide study</data>
    </edge>
    <edge id="e183" source="145" target="146">
      <data key="d3">17.0</data>
      <data key="d4">medication that being...</data>
      <data key="d6">Baricitinib is a medication that is being studied for the treatment of alopecia areata, a condition characterized by hair loss. Alopecia areata is an autoimmune disorder that can lead to patchy or complete loss of hair on the scalp, face, and other parts of the body.

The available data indicates that baricitinib is being evaluated for the treatment of severe or very severe alopecia areata in both adults and children. Baricitinib is a Janus kinase (JAK) inhibitor, a class of drugs that work by blocking the activity of certain enzymes involved in the inflammatory response, which is believed to play a role in the development of alopecia areata.

The studies on the use of baricitinib for alopecia areata are still ongoing, and the results have not yet been fully reported. However, the available information suggests that baricitinib may be a promising treatment option for individuals with this condition.

It is important to note that the use of baricitinib for the treatment of alopecia areata is still under investigation, and the safety and efficacy of the medication for this purpose have not yet been fully established. Patients with alopecia areata should consult with their healthcare providers to discuss the available treatment options and the potential risks and benefits of using baricitinib or other therapies.

In summary, baricitinib is a medication that is being studied for the treatment of severe or very severe alopecia areata in both adults and children. The available data suggests that baricitinib may be a promising treatment option for this condition, but further research is needed to fully understand its safety and efficacy.</data>
    </edge>
    <edge id="e184" source="145" target="151">
      <data key="d3">7.0</data>
      <data key="d4">author related...</data>
      <data key="d6">James Krell is an author related to the baricitinib study</data>
    </edge>
    <edge id="e185" source="64" target="147">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">Lebrikizumab will be evaluated for the treatment of chronic rhinosinusitis with nasal polyps</data>
    </edge>
    <edge id="e186" source="64" target="148">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">Lebrikizumab will be evaluated for the treatment of chronic rhinosinusitis with nasal polyps</data>
    </edge>
    <edge id="e187" source="64" target="60">
      <data key="d3">1.0</data>
      <data key="d4">author related...</data>
      <data key="d6">Weily Soong is an author related to the lebrikizumab study</data>
    </edge>
    <edge id="e188" source="102" target="149">
      <data key="d3">8.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Abemaciclib will be evaluated in combination with pembrolizumab for the treatment of non-small cell lung cancer</data>
    </edge>
    <edge id="e189" source="102" target="150">
      <data key="d3">16.0</data>
      <data key="d4">medication that being...</data>
      <data key="d6">Abemaciclib is a medication that is being studied for the treatment of breast cancer. It is being investigated as a potential treatment option for patients with previously treated hormone receptor-positive, HER2-negative metastatic breast cancer. In this context, abemaciclib is being studied both as a standalone therapy and in combination with the hormone therapy tamoxifen.

Additionally, abemaciclib is also being evaluated in combination with the immunotherapy drug pembrolizumab for the treatment of breast cancer. This combination approach aims to explore the potential synergistic effects of targeting different pathways involved in cancer progression and immune response.

Breast cancer is a type of cancer that originates in the breast tissue. It is one of the most common types of cancer, affecting millions of people worldwide. Breast cancer can be classified based on various factors, including the presence or absence of certain receptors, such as hormone receptors (estrogen and progesterone) and the HER2 protein. The specific subtypes of breast cancer, such as hormone receptor-positive, HER2-negative metastatic breast cancer, have different treatment approaches and prognoses.

The use of abemaciclib, either alone or in combination with other therapies, is being explored as a potential treatment option for patients with breast cancer. The goal of these studies is to evaluate the safety, tolerability, and efficacy of abemaciclib in improving outcomes for individuals with this disease.

It is important to note that the information provided in the descriptions does not appear to be contradictory. The descriptions indicate that abemaciclib is being investigated for the treatment of breast cancer, with specific focus on its use in hormone receptor-positive, HER2-negative metastatic breast cancer, as well as in combination with pembrolizumab. This comprehensive summary aims to provide a clear and concise overview of the available information regarding the potential role of abemaciclib in the management of breast cancer.</data>
    </edge>
    <edge id="e190" source="149" target="73">
      <data key="d3">8.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Pembrolizumab will be evaluated in combination with abemaciclib for the treatment of non-small cell lung cancer</data>
    </edge>
    <edge id="e191" source="150" target="73">
      <data key="d3">8.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Pembrolizumab will be evaluated in combination with abemaciclib for the treatment of breast cancer</data>
    </edge>
    <edge id="e192" source="31" target="156">
      <data key="d3">18.0</data>
      <data key="d4">evaluating use...</data>
      <data key="d6">The SURMOUNT-ADOLESCENTS-2 trial is evaluating the use of tirzepatide for the treatment of obesity and weight-related comorbidities in adolescents</data>
    </edge>
    <edge id="e193" source="31" target="157">
      <data key="d3">10.0</data>
      <data key="d4">evaluating use...</data>
      <data key="d6">The SURMOUNT-MAINTAIN trial is evaluating the use of tirzepatide for the maintenance of body weight reduction</data>
    </edge>
    <edge id="e194" source="31" target="159">
      <data key="d3">8.0</data>
      <data key="d4">involved tirzepatide...</data>
      <data key="d6">Andrew Sharobeem is involved in the tirzepatide and ixekizumab study for psoriatic arthritis</data>
    </edge>
    <edge id="e195" source="153" target="14">
      <data key="d3">16.0</data>
      <data key="d4">developing LOXO-783 treatment...</data>
      <data key="d6">Eli Lilly is developing LOXO-783 for the treatment of advanced breast cancer and other solid tumors with a PIK3CA H1047R mutation</data>
    </edge>
    <edge id="e196" source="154" target="14">
      <data key="d3">16.0</data>
      <data key="d4">developing eltrekibart treatment...</data>
      <data key="d6">Eli Lilly is developing eltrekibart for the treatment of moderate to severe hidradenitis suppurativa</data>
    </edge>
    <edge id="e197" source="154" target="160">
      <data key="d3">8.0</data>
      <data key="d4">involved eltrekibart study...</data>
      <data key="d6">Lindsay Ackerman is involved in the eltrekibart study for hidradenitis suppurativa</data>
    </edge>
    <edge id="e198" source="155" target="14">
      <data key="d3">16.0</data>
      <data key="d4">developing galcanezumab preventive...</data>
      <data key="d6">Eli Lilly is developing galcanezumab for the preventive treatment of chronic migraine in adolescents</data>
    </edge>
    <edge id="e199" source="156" target="158">
      <data key="d3">8.0</data>
      <data key="d4">involved SURMOUNT-ADOLESCENTS-2 trial...</data>
      <data key="d6">Alaina Vidmar is involved in the SURMOUNT-ADOLESCENTS-2 trial</data>
    </edge>
    <edge id="e200" source="157" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor SURMOUNT-MAINTAIN...</data>
      <data key="d6">Eli Lilly is the sponsor of the SURMOUNT-MAINTAIN clinical trial</data>
    </edge>
    <edge id="e201" source="157" target="31">
      <data key="d3">9.0</data>
      <data key="d4">evaluated SURMOUNT-MAINTAIN trial...</data>
      <data key="d6">Tirzepatide is being evaluated in the SURMOUNT-MAINTAIN trial for weight management</data>
    </edge>
    <edge id="e202" source="161" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor ADVANCE-ATTAIN-ADOLESCENTS...</data>
      <data key="d6">Eli Lilly is the sponsor of the ADVANCE-ATTAIN-ADOLESCENTS clinical trial</data>
    </edge>
    <edge id="e203" source="161" target="15">
      <data key="d3">9.0</data>
      <data key="d4">evaluated ADVANCE-ATTAIN-ADOLESCENTS trial...</data>
      <data key="d6">Orforglipron is being evaluated in the ADVANCE-ATTAIN-ADOLESCENTS trial for weight management in adolescents</data>
    </edge>
    <edge id="e204" source="162" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor TOGETHER-PsA...</data>
      <data key="d6">Eli Lilly is the sponsor of the TOGETHER-PsA clinical trial</data>
    </edge>
    <edge id="e205" source="162" target="168">
      <data key="d3">9.0</data>
      <data key="d4">evaluated TOGETHER-PsA trial...</data>
      <data key="d6">Ixekizumab is being evaluated in the TOGETHER-PsA trial for psoriatic arthritis and obesity</data>
    </edge>
    <edge id="e206" source="163" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor POSTMONARCH...</data>
      <data key="d6">Eli Lilly is the sponsor of the POSTMONARCH clinical trial</data>
    </edge>
    <edge id="e207" source="163" target="170">
      <data key="d3">9.0</data>
      <data key="d4">POSTMONARCH trial previously...</data>
      <data key="d6">Participants in the POSTMONARCH trial had previously received a CDK4 &amp; 6 inhibitor</data>
    </edge>
    <edge id="e208" source="163" target="171">
      <data key="d3">9.0</data>
      <data key="d4">POSTMONARCH trial previously...</data>
      <data key="d6">Participants in the POSTMONARCH trial had previously received endocrine therapy</data>
    </edge>
    <edge id="e209" source="164" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor LY3454738...</data>
      <data key="d6">Eli Lilly is the sponsor of the LY3454738 clinical trial</data>
    </edge>
    <edge id="e210" source="164" target="69">
      <data key="d3">9.0</data>
      <data key="d4">evaluated phase...</data>
      <data key="d6">LY3454738 is being evaluated in a phase 2 trial for the treatment of moderate-to-severe atopic dermatitis</data>
    </edge>
    <edge id="e211" source="165" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor LY3841136...</data>
      <data key="d6">Eli Lilly is the sponsor of the LY3841136 clinical trial</data>
    </edge>
    <edge id="e212" source="165" target="31">
      <data key="d3">18.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Tirzepatide is being evaluated in combination with LY3841136 in a clinical trial for obesity or overweight
LY3841136 is being evaluated in combination with tirzepatide in a multiple-ascending dose study for obesity or overweight</data>
    </edge>
    <edge id="e213" source="166" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsor LY3200882...</data>
      <data key="d6">Eli Lilly is the sponsor of the LY3200882 clinical trial</data>
    </edge>
    <edge id="e214" source="166" target="105">
      <data key="d3">9.0</data>
      <data key="d4">evaluated phase...</data>
      <data key="d6">LY3200882 is being evaluated in a phase 1 study for solid tumors</data>
    </edge>
    <edge id="e215" source="167" target="14">
      <data key="d3">10.0</data>
      <data key="d4">prominent pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a prominent pharmaceutical company, is conducting clinical trials for a drug called MIBAVADEMAB. The provided descriptions indicate that Eli Lilly is the sponsor of the MIBAVADEMAB clinical trial.

MIBAVADEMAB is a drug that is currently undergoing clinical trials, which are studies conducted to evaluate the safety and efficacy of a new medication. Eli Lilly, as the sponsor of the MIBAVADEMAB clinical trial, is responsible for overseeing the development and testing of this drug.

The descriptions do not provide any additional details about the specific purpose, mechanism of action, or target indication of MIBAVADEMAB. However, the fact that Eli Lilly is conducting clinical trials for this drug suggests that it is a potential new treatment being developed by the company.

In summary, Eli Lilly, a leading pharmaceutical company, is currently conducting clinical trials for a drug called MIBAVADEMAB. The company is the sponsor of the MIBAVADEMAB clinical trial, which means they are responsible for the development and testing of this new medication. The available information does not reveal the specific details about the purpose or intended use of MIBAVADEMAB, but the fact that it is undergoing clinical trials indicates that Eli Lilly is exploring its potential as a new treatment option.</data>
    </edge>
    <edge id="e216" source="167" target="31">
      <data key="d3">1.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Mibavademab is being evaluated in combination with tirzepatide in a phase 2 trial for obesity</data>
    </edge>
    <edge id="e217" source="102" target="169">
      <data key="d3">9.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Abemaciclib is being evaluated in combination with fulvestrant in the POSTMONARCH trial for breast cancer</data>
    </edge>
    <edge id="e218" source="31" target="167">
      <data key="d3">8.0</data>
      <data key="d4">being studied combination...</data>
      <data key="d6">Tirzepatide and mibavademab are being studied in combination for weight loss</data>
    </edge>
    <edge id="e219" source="31" target="174">
      <data key="d3">9.0</data>
      <data key="d4">studied weight loss...</data>
      <data key="d6">Tirzepatide is being studied for weight loss</data>
    </edge>
    <edge id="e220" source="167" target="174">
      <data key="d3">9.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Mibavademab is being studied in combination with tirzepatide for weight loss</data>
    </edge>
    <edge id="e221" source="167" target="67">
      <data key="d3">8.0</data>
      <data key="d4">focused participants with...</data>
      <data key="d6">The studies are focused on participants with obesity or overweight</data>
    </edge>
    <edge id="e222" source="44" target="16">
      <data key="d3">9.0</data>
      <data key="d4">studied type diabetes...</data>
      <data key="d6">Retatrutide is being studied for type 2 diabetes with renal impairment</data>
    </edge>
    <edge id="e223" source="172" target="16">
      <data key="d3">9.0</data>
      <data key="d4">studied type diabetes...</data>
      <data key="d6">Retatrutide is being studied for type 2 diabetes with renal impairment</data>
    </edge>
    <edge id="e224" source="139" target="154">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Eltrekibart is being studied for the treatment of ulcerative colitis</data>
    </edge>
    <edge id="e225" source="139" target="137">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Mirikizumab is being studied for the treatment of ulcerative colitis</data>
    </edge>
    <edge id="e226" source="144" target="137">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Mirikizumab is being studied for the treatment of Crohn's disease</data>
    </edge>
    <edge id="e227" source="6" target="175">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Mevidalen is being studied for the treatment of Alzheimer's disease</data>
    </edge>
    <edge id="e228" source="173" target="155">
      <data key="d3">1.0</data>
      <data key="d4">studied preventive treatment...</data>
      <data key="d6">Galcanezumab is being studied for the preventive treatment of episodic migraine in children and adolescents</data>
    </edge>
    <edge id="e229" source="31" target="168">
      <data key="d3">9.0</data>
      <data key="d4">being studied combination...</data>
      <data key="d6">Ixekizumab and tirzepatide are being studied in combination for the treatment of moderate-to-severe plaque psoriasis and obesity or overweight</data>
    </edge>
    <edge id="e230" source="31" target="176">
      <data key="d3">8.0</data>
      <data key="d4">involved study related...</data>
      <data key="d6">Yessica Sachdeva is involved in a study related to tirzepatide for weight management in type 2 diabetes</data>
    </edge>
    <edge id="e231" source="31" target="151">
      <data key="d3">8.0</data>
      <data key="d4">involved study related...</data>
      <data key="d6">James Krell is involved in a study related to tirzepatide</data>
    </edge>
    <edge id="e232" source="31" target="177">
      <data key="d3">1.0</data>
      <data key="d4">investigating use tirzepatide...</data>
      <data key="d6">A study is investigating the use of tirzepatide in participants with type 2 diabetes during Ramadan</data>
    </edge>
    <edge id="e233" source="31" target="178">
      <data key="d3">9.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Tirzepatide is being studied in combination with ixekizumab for the treatment of moderate-to-severe plaque psoriasis</data>
    </edge>
    <edge id="e234" source="160" target="168">
      <data key="d3">8.0</data>
      <data key="d4">involved studies related...</data>
      <data key="d6">Lindsay Ackerman is involved in studies related to ixekizumab</data>
    </edge>
    <edge id="e235" source="160" target="64">
      <data key="d3">8.0</data>
      <data key="d4">involved studies related...</data>
      <data key="d6">Lindsay Ackerman is involved in studies related to lebrikizumab</data>
    </edge>
    <edge id="e236" source="176" target="165">
      <data key="d3">8.0</data>
      <data key="d4">involved study related...</data>
      <data key="d6">Yessica Sachdeva is involved in a study related to LY3841136 and tirzepatide for weight management in type 2 diabetes</data>
    </edge>
    <edge id="e237" source="14" target="168">
      <data key="d3">8.0</data>
      <data key="d4">sponsor studies related...</data>
      <data key="d6">Eli Lilly is the sponsor of studies related to ixekizumab</data>
    </edge>
    <edge id="e238" source="151" target="168">
      <data key="d3">8.0</data>
      <data key="d4">involved study related...</data>
      <data key="d6">James Krell is involved in a study related to ixekizumab</data>
    </edge>
    <edge id="e239" source="168" target="178">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Ixekizumab is being studied for the treatment of moderate-to-severe plaque psoriasis</data>
    </edge>
    <edge id="e240" source="168" target="67">
      <data key="d3">9.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Ixekizumab is being studied in combination with tirzepatide for the treatment of obesity or overweight</data>
    </edge>
    <edge id="e241" source="179" target="137">
      <data key="d3">16.0</data>
      <data key="d4">involved mirikizumab studies...</data>
      <data key="d6">Jeannie Huang is involved in the mirikizumab studies for pediatric Crohn's disease and ulcerative colitis</data>
    </edge>
    <edge id="e242" source="180" target="145">
      <data key="d3">16.0</data>
      <data key="d4">involved baricitinib study...</data>
      <data key="d6">Diego Viola is involved in the baricitinib study for systemic juvenile idiopathic arthritis</data>
    </edge>
    <edge id="e243" source="181" target="114">
      <data key="d3">2.0</data>
      <data key="d4">involved LY3549492 study...</data>
      <data key="d6">Yasuko Owada is involved in the LY3549492 study for type 2 diabetes in Japanese participants</data>
    </edge>
    <edge id="e244" source="14" target="137">
      <data key="d3">42.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is conducting extensive research and clinical studies on the drug mirikizumab. Mirikizumab is the focus of these investigations, which aim to evaluate its efficacy, safety, and pharmacokinetic properties in various patient populations.

According to the provided information, Eli Lilly is conducting studies on the use of mirikizumab in pediatric participants with Crohn's disease and ulcerative colitis. These studies are designed to assess the drug's effectiveness, safety, and how it is absorbed, distributed, metabolized, and eliminated in the body (pharmacokinetics) in this specific patient group.

In addition, Eli Lilly is also evaluating the bioequivalence of mirikizumab when administered via prefilled syringe or autoinjector in healthy participants. Bioequivalence studies are crucial to determine if two different formulations or delivery methods of the same drug are comparable in terms of their rate and extent of absorption, ensuring consistent therapeutic effects.

Furthermore, Eli Lilly is the sponsor of the mirikizumab clinical study, indicating the company's significant involvement and investment in the development and evaluation of this drug.

Overall, Eli Lilly's research efforts on mirikizumab cover a range of aspects, including its potential use in pediatric patients with Crohn's disease and ulcerative colitis, as well as the assessment of different delivery methods to ensure consistent and reliable administration of the drug. The company's role as the sponsor of the mirikizumab clinical study underscores its commitment to advancing the understanding and potential therapeutic applications of this medication.</data>
    </edge>
    <edge id="e245" source="14" target="183">
      <data key="d3">16.0</data>
      <data key="d4">conducting study compare...</data>
      <data key="d6">Eli Lilly is conducting a study to compare the pharmacokinetics of a single capsule and multiple capsules of Orforglipron in healthy participants</data>
    </edge>
    <edge id="e246" source="14" target="145">
      <data key="d3">25.0</data>
      <data key="d4">leading pharmaceutical company,...</data>
      <data key="d6">Eli Lilly, a leading pharmaceutical company, is currently investigating the use of the drug baricitinib for various medical conditions. According to the provided information, Eli Lilly is conducting studies on the use of baricitinib in two distinct areas:

1. COVID-19 in Pediatric Patients:
Baricitinib is being studied by Eli Lilly as an investigational drug for the treatment of COVID-19 in pediatric patients. This study aims to evaluate the safety, efficacy, and pharmacokinetics (the movement of the drug within the body) of baricitinib in this specific patient population.

2. Systemic Juvenile Idiopathic Arthritis:
Eli Lilly is also conducting a study to evaluate the safety, efficacy, and pharmacokinetics of baricitinib in children with systemic juvenile idiopathic arthritis (sJIA). sJIA is a type of arthritis that can cause inflammation in various parts of the body, including the joints, and typically affects children.

The information provided does not indicate any contradictions between the two areas of investigation. Eli Lilly's research efforts appear to be focused on exploring the potential therapeutic applications of baricitinib in both COVID-19 and sJIA, with a specific emphasis on pediatric populations.

Baricitinib is an investigational drug, meaning it is still undergoing clinical trials and has not yet been approved for widespread use. The studies being conducted by Eli Lilly aim to gather data on the safety, efficacy, and pharmacokinetics of baricitinib in these specific medical conditions and patient populations.

In summary, Eli Lilly, a prominent pharmaceutical company, is currently investigating the use of the drug baricitinib in two distinct areas: the treatment of COVID-19 in pediatric patients and the management of systemic juvenile idiopathic arthritis in children. These studies are focused on evaluating the safety, efficacy, and pharmacokinetics of baricitinib in these specific medical conditions and patient populations.</data>
    </edge>
    <edge id="e247" source="14" target="114">
      <data key="d3">16.0</data>
      <data key="d4">conducting study evaluate...</data>
      <data key="d6">Eli Lilly is conducting a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY3549492 in Japanese participants with type 2 diabetes and healthy Japanese participants</data>
    </edge>
    <edge id="e248" source="14" target="184">
      <data key="d3">16.0</data>
      <data key="d4">conducting phase study...</data>
      <data key="d6">Eli Lilly is conducting a phase 1 study of the Aurora Kinase A inhibitor LY3295668 as a single agent and in combination in patients with relapsed/refractory neuroblastoma</data>
    </edge>
    <edge id="e249" source="14" target="179">
      <data key="d3">8.0</data>
      <data key="d4">conducting study sponsored...</data>
      <data key="d6">Jeannie Huang is conducting a study sponsored by Eli Lilly on LY3295668 Erbumine in patients with relapsed/refractory neuroblastoma</data>
    </edge>
    <edge id="e250" source="14" target="185">
      <data key="d3">8.0</data>
      <data key="d4">conducting study sponsored...</data>
      <data key="d6">Michael Mangum is conducting a study sponsored by Eli Lilly on LY3954068 in patients with early symptomatic Alzheimer's Disease</data>
    </edge>
    <edge id="e251" source="14" target="186">
      <data key="d3">8.0</data>
      <data key="d4">conducting study sponsored...</data>
      <data key="d6">Alexander Prezioso is conducting a study sponsored by Eli Lilly on LY3484356 in Chinese patients with estrogen receptor positive, HER2 negative locally advanced or metastatic breast cancer</data>
    </edge>
    <edge id="e252" source="14" target="187">
      <data key="d3">1.0</data>
      <data key="d4">conducting study sponsored...</data>
      <data key="d6">Joel Neutel is conducting a study sponsored by Eli Lilly to assess the pharmacokinetics, safety, and tolerability of LY3537982 in participants with hepatic impairment</data>
    </edge>
    <edge id="e253" source="14" target="139">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring study...</data>
      <data key="d6">Eli Lilly is sponsoring a study of a drug in pediatric participants with ulcerative colitis</data>
    </edge>
    <edge id="e254" source="14" target="182">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring study...</data>
      <data key="d6">Eli Lilly is sponsoring a study of a drug in participants with relapsed/refractory neuroblastoma</data>
    </edge>
    <edge id="e255" source="14" target="188">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring study...</data>
      <data key="d6">Eli Lilly is sponsoring a study of a drug in participants with newly diagnosed high-grade glioma</data>
    </edge>
    <edge id="e256" source="14" target="6">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring study...</data>
      <data key="d6">Eli Lilly is sponsoring a study of a drug in participants with early symptomatic Alzheimer's Disease</data>
    </edge>
    <edge id="e257" source="14" target="150">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring study...</data>
      <data key="d6">Eli Lilly is sponsoring a study of a drug in Chinese participants with estrogen receptor positive, HER2 negative breast cancer</data>
    </edge>
    <edge id="e258" source="14" target="67">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring study...</data>
      <data key="d6">Eli Lilly is sponsoring a study of a drug in participants with obesity under calorie restriction</data>
    </edge>
    <edge id="e259" source="14" target="189">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring study...</data>
      <data key="d6">Eli Lilly is sponsoring a study of a drug in participants with hepatic impairment</data>
    </edge>
    <edge id="e260" source="14" target="190">
      <data key="d3">1.0</data>
      <data key="d4">sponsoring study...</data>
      <data key="d6">Eli Lilly is sponsoring a study of a drug in Chinese participants with KRAS G12C-mutant advanced solid tumors</data>
    </edge>
    <edge id="e261" source="185" target="6">
      <data key="d3">8.0</data>
      <data key="d4">studying drug early...</data>
      <data key="d6">Michael Mangum is studying a drug for early symptomatic Alzheimer's Disease</data>
    </edge>
    <edge id="e262" source="186" target="150">
      <data key="d3">8.0</data>
      <data key="d4">studying drug estrogen...</data>
      <data key="d6">Alexander Prezioso is studying a drug for estrogen receptor positive, HER2 negative breast cancer</data>
    </edge>
    <edge id="e263" source="187" target="189">
      <data key="d3">8.0</data>
      <data key="d4">studying pharmacokinetics...</data>
      <data key="d6">Joel Neutel is studying the pharmacokinetics of a drug in participants with hepatic impairment</data>
    </edge>
    <edge id="e264" source="179" target="182">
      <data key="d3">8.0</data>
      <data key="d4">studying drug relapsed/refractory...</data>
      <data key="d6">Jeannie Huang is studying a drug for relapsed/refractory neuroblastoma</data>
    </edge>
    <edge id="e265" source="187" target="72">
      <data key="d3">16.0</data>
      <data key="d4">involved Phase...</data>
      <data key="d6">Joel Neutel is involved in the Phase 1 study of LY3537982</data>
    </edge>
    <edge id="e266" source="72" target="190">
      <data key="d3">9.0</data>
      <data key="d4">investigated study...</data>
      <data key="d6">LY3537982 is being investigated in a study for KRAS G12C-mutant advanced solid tumors</data>
    </edge>
    <edge id="e267" source="72" target="192">
      <data key="d3">9.0</data>
      <data key="d4">being conducted Chinese...</data>
      <data key="d6">The LY3537982 study is being conducted in Chinese patients</data>
    </edge>
    <edge id="e268" source="91" target="67">
      <data key="d3">9.0</data>
      <data key="d4">investigated treatment...</data>
      <data key="d6">LY3502970 is being investigated for the treatment of obesity</data>
    </edge>
    <edge id="e269" source="91" target="68">
      <data key="d3">9.0</data>
      <data key="d4">investigated treatment...</data>
      <data key="d6">LY3502970 is being investigated for the treatment of overweight</data>
    </edge>
    <edge id="e270" source="15" target="191">
      <data key="d3">16.0</data>
      <data key="d4">compared orforglipron...</data>
      <data key="d6">Semaglutide is being compared to orforglipron in a Phase 3 study</data>
    </edge>
    <edge id="e271" source="191" target="44">
      <data key="d3">8.0</data>
      <data key="d4">used comparator...</data>
      <data key="d6">Semaglutide is being used as a comparator for type 2 diabetes treatments</data>
    </edge>
    <edge id="e272" source="83" target="6">
      <data key="d3">10.0</data>
      <data key="d4">investigated study...</data>
      <data key="d6">Remternetug is being investigated in a study for early Alzheimer's disease</data>
    </edge>
    <edge id="e273" source="44" target="45">
      <data key="d3">8.0</data>
      <data key="d4">background medication used...</data>
      <data key="d6">Metformin is a background medication used in some of the type 2 diabetes studies</data>
    </edge>
    <edge id="e274" source="44" target="193">
      <data key="d3">1.0</data>
      <data key="d4">background medication used...</data>
      <data key="d6">SGLT2 inhibitor is a background medication used in one of the type 2 diabetes studies</data>
    </edge>
    <edge id="e275" source="194" target="6">
      <data key="d3">16.0</data>
      <data key="d4">participant Alzheimer's...</data>
      <data key="d6">James Sullivan is a participant in the Alzheimer's disease study</data>
    </edge>
    <edge id="e276" source="15" target="195">
      <data key="d3">16.0</data>
      <data key="d4">compared dapagliflozin...</data>
      <data key="d6">Orforglipron is being compared to dapagliflozin in a Phase 3 study for type 2 diabetes</data>
    </edge>
    <edge id="e277" source="15" target="196">
      <data key="d3">14.0</data>
      <data key="d4">orforglipron studies...</data>
      <data key="d6">Participants in one of the orforglipron studies are taking insulin glargine</data>
    </edge>
    <edge id="e278" source="15" target="197">
      <data key="d3">14.0</data>
      <data key="d4">orforglipron studies...</data>
      <data key="d6">Participants in one of the orforglipron studies are taking SGLT-2 inhibitors</data>
    </edge>
    <edge id="e279" source="198" target="31">
      <data key="d3">18.0</data>
      <data key="d4">investigated combination with...</data>
      <data key="d6">Eloralintide is being investigated in combination with tirzepatide in a Phase 1 study</data>
    </edge>
    <edge id="e280" source="31" target="199">
      <data key="d3">1.0</data>
      <data key="d4">participant study...</data>
      <data key="d6">Christopher Chow is a participant in the study of tirzepatide for chronic kidney disease</data>
    </edge>
    <edge id="e281" source="77" target="44">
      <data key="d3">16.0</data>
      <data key="d4">tirzepatide focused chronic...</data>
      <data key="d6">The study on tirzepatide is focused on chronic kidney disease in people with or without type 2 diabetes</data>
    </edge>
    <edge id="e282" source="44" target="91">
      <data key="d3">10.0</data>
      <data key="d4">investigated long-term safety...</data>
      <data key="d6">LY3502970 is being investigated in a long-term safety study for type 2 diabetes</data>
    </edge>
    <edge id="e283" source="200" target="14">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring clinical trial...</data>
      <data key="d6">Eli Lilly is sponsoring the clinical trial that Sonia Kalirao is involved in for multiple sclerosis</data>
    </edge>
    <edge id="e284" source="201" target="14">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring clinical trial...</data>
      <data key="d6">Eli Lilly is sponsoring the clinical trial that Gilbert Jenouri is involved in for type 2 diabetes and obesity</data>
    </edge>
    <edge id="e285" source="202" target="14">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring clinical trial...</data>
      <data key="d6">Eli Lilly is sponsoring the clinical trial that Rakesh Sahay is involved in for type 2 diabetes in India</data>
    </edge>
    <edge id="e286" source="176" target="14">
      <data key="d3">8.0</data>
      <data key="d4">sponsoring clinical trial...</data>
      <data key="d6">Eli Lilly is sponsoring the clinical trial that Yessica Sachdeva is involved in for diabetic peripheral neuropathic pain</data>
    </edge>
    <edge id="e287" source="203" target="14">
      <data key="d3">1.0</data>
      <data key="d4">sponsoring clinical trial...</data>
      <data key="d6">Eli Lilly is sponsoring the clinical trial that Federico Laham is involved in for COVID-19 in pediatric patients</data>
    </edge>
    <edge id="e288" source="14" target="119">
      <data key="d3">9.0</data>
      <data key="d4">investigational drug being...</data>
      <data key="d6">LY3541860 is an investigational drug being studied by Eli Lilly for multiple sclerosis</data>
    </edge>
    <edge id="e289" source="14" target="204">
      <data key="d3">9.0</data>
      <data key="d4">insulin lispro-aabc product...</data>
      <data key="d6">Lyumjev is an insulin lispro-aabc product being studied by Eli Lilly for type 2 diabetes in India</data>
    </edge>
    <edge id="e290" source="14" target="205">
      <data key="d3">9.0</data>
      <data key="d4">investigational drug being...</data>
      <data key="d6">LY4006896 is an investigational drug being studied by Eli Lilly for Parkinson's disease</data>
    </edge>
    <edge id="e291" source="14" target="206">
      <data key="d3">9.0</data>
      <data key="d4">investigational drug being...</data>
      <data key="d6">LY3556050 is an investigational drug being studied by Eli Lilly for diabetic peripheral neuropathic pain</data>
    </edge>
    <edge id="e292" source="14" target="198">
      <data key="d3">9.0</data>
      <data key="d4">investigational drug being...</data>
      <data key="d6">Eloralintide (LY3841136) is an investigational drug being studied by Eli Lilly for obesity and overweight in Chinese participants</data>
    </edge>
    <edge id="e293" source="102" target="207">
      <data key="d3">8.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Abemaciclib is being studied in combination with irinotecan for Ewing's sarcoma</data>
    </edge>
    <edge id="e294" source="102" target="208">
      <data key="d3">8.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Abemaciclib is being studied in combination with temozolomide for Ewing's sarcoma</data>
    </edge>
    <edge id="e295" source="102" target="209">
      <data key="d3">9.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Abemaciclib is being studied for the treatment of Ewing's sarcoma</data>
    </edge>
    <edge id="e296" source="102" target="125">
      <data key="d3">9.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Imlunestrant is being studied in combination with abemaciclib for estrogen receptor positive, HER2 negative locally advanced or metastatic breast cancer</data>
    </edge>
    <edge id="e297" source="209" target="210">
      <data key="d3">8.0</data>
      <data key="d4">master protocol speed...</data>
      <data key="d6">CAMPFIRE is a master protocol to speed development of new treatments for Ewing's sarcoma</data>
    </edge>
    <edge id="e298" source="124" target="212">
      <data key="d3">9.0</data>
      <data key="d4">studied evaluate how...</data>
      <data key="d6">Lepodisiran is being studied to evaluate how it is absorbed and eliminated in participants with different levels of liver function</data>
    </edge>
    <edge id="e299" source="123" target="44">
      <data key="d3">9.0</data>
      <data key="d4">studied additional dosing...</data>
      <data key="d6">Dulaglutide is being studied for additional dosing options in pediatric participants with Type 2 Diabetes</data>
    </edge>
    <edge id="e300" source="44" target="31">
      <data key="d3">9.0</data>
      <data key="d4">studied efficacy safety...</data>
      <data key="d6">Tirzepatide is being studied for efficacy and safety in Chinese participants with Type 2 Diabetes</data>
    </edge>
    <edge id="e301" source="31" target="213">
      <data key="d3">1.0</data>
      <data key="d4">involved study...</data>
      <data key="d6">Yiming Mu is involved in the study on Tirzepatide</data>
    </edge>
    <edge id="e302" source="211" target="67">
      <data key="d3">9.0</data>
      <data key="d4">studied weight management...</data>
      <data key="d6">LY3305677 is being studied for weight management in adult participants with obesity</data>
    </edge>
    <edge id="e303" source="211" target="68">
      <data key="d3">9.0</data>
      <data key="d4">studied weight management...</data>
      <data key="d6">LY3305677 is being studied for weight management in adult participants who are overweight</data>
    </edge>
    <edge id="e304" source="125" target="150">
      <data key="d3">9.0</data>
      <data key="d4">novel investigational drug...</data>
      <data key="d6">Imlunestrant is a novel investigational drug being studied for the treatment of breast cancer. Specifically, it is being evaluated for the treatment of estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer.

Breast cancer is a type of cancer that originates in the breast tissue. It is one of the most common types of cancer, affecting millions of people worldwide. Breast cancer can be classified into different subtypes based on the presence or absence of certain receptors, such as ER and HER2. ER-positive, HER2-negative breast cancer is a common subtype that is often treated with endocrine therapies.

Imlunestrant is a selective estrogen receptor degrader (SERD) that is being investigated as a potential treatment for ER-positive, HER2-negative locally advanced or metastatic breast cancer. SERDs are a class of drugs that work by binding to and degrading the estrogen receptor, thereby reducing the growth and proliferation of ER-positive breast cancer cells.

The clinical trial evaluating imlunestrant for the treatment of breast cancer is currently ongoing. The trial is designed to assess the safety, tolerability, and efficacy of imlunestrant in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. The trial is expected to provide valuable insights into the potential role of imlunestrant in the management of this subtype of breast cancer.

In summary, imlunestrant is an investigational drug that is being studied for the treatment of ER-positive, HER2-negative locally advanced or metastatic breast cancer. The clinical trial evaluating imlunestrant is currently ongoing, and the results of this trial are eagerly awaited by the medical community and patients with this type of breast cancer.</data>
    </edge>
    <edge id="e305" source="125" target="102">
      <data key="d3">8.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Abemaciclib is being studied in combination with imlunestrant in a clinical trial</data>
    </edge>
    <edge id="e306" source="125" target="140">
      <data key="d3">9.0</data>
      <data key="d4">studied participants with...</data>
      <data key="d6">Imlunestrant is being studied in participants with estrogen receptor positive breast cancer</data>
    </edge>
    <edge id="e307" source="125" target="138">
      <data key="d3">9.0</data>
      <data key="d4">studied participants with...</data>
      <data key="d6">Imlunestrant is being studied in participants with human epidermal receptor 2 negative breast cancer</data>
    </edge>
    <edge id="e308" source="125" target="215">
      <data key="d3">9.0</data>
      <data key="d4">studied participants with...</data>
      <data key="d6">Imlunestrant is being studied in participants with advanced or metastatic breast cancer</data>
    </edge>
    <edge id="e309" source="82" target="6">
      <data key="d3">8.0</data>
      <data key="d4">studied clinical trial...</data>
      <data key="d6">LY3372993 is being studied in a clinical trial in participants with Alzheimer's disease</data>
    </edge>
    <edge id="e310" source="82" target="214">
      <data key="d3">9.0</data>
      <data key="d4">studied participants with...</data>
      <data key="d6">LY3372993 is being studied in participants with Alzheimer's disease</data>
    </edge>
    <edge id="e311" source="137" target="14">
      <data key="d3">9.0</data>
      <data key="d4">conducting bioequivalence study...</data>
      <data key="d6">Eli Lilly is conducting a bioequivalence study of mirikizumab reference and test solutions</data>
    </edge>
    <edge id="e312" source="62" target="220">
      <data key="d3">8.0</data>
      <data key="d4">involved study...</data>
      <data key="d6">James Swain is involved in the study of LY3209590 in pediatric participants with type 2 diabetes</data>
    </edge>
    <edge id="e313" source="62" target="120">
      <data key="d3">9.0</data>
      <data key="d4">studied pediatric participants...</data>
      <data key="d6">LY3209590 is being studied in pediatric participants with type 2 diabetes mellitus</data>
    </edge>
    <edge id="e314" source="216" target="14">
      <data key="d3">9.0</data>
      <data key="d4">conducting phase study...</data>
      <data key="d6">Eli Lilly is conducting a phase 2 study to investigate the efficacy and safety of LY3473329 in adults with elevated lipoprotein(a) at high risk for cardiovascular events</data>
    </edge>
    <edge id="e315" source="31" target="221">
      <data key="d3">1.0</data>
      <data key="d4">involved study...</data>
      <data key="d6">Jordan Vaughn is involved in the study of tirzepatide compared to semaglutide in adults with obesity or overweight with weight related comorbidities</data>
    </edge>
    <edge id="e316" source="31" target="191">
      <data key="d3">9.0</data>
      <data key="d4">compared semaglutide...</data>
      <data key="d6">Tirzepatide is being compared to semaglutide in a study for adults with obesity or overweight with weight related comorbidities</data>
    </edge>
    <edge id="e317" source="217" target="14">
      <data key="d3">9.0</data>
      <data key="d4">conducting single-ascending dose...</data>
      <data key="d6">Eli Lilly is conducting a single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY3875383 in healthy participants and participants with hypertriglyceridemia</data>
    </edge>
    <edge id="e318" source="217" target="223">
      <data key="d3">9.0</data>
      <data key="d4">studied participants with...</data>
      <data key="d6">LY3875383 is being studied in participants with hypertriglyceridemia</data>
    </edge>
    <edge id="e319" source="218" target="14">
      <data key="d3">9.0</data>
      <data key="d4">conducting single-ascending repeated...</data>
      <data key="d6">Eli Lilly is conducting a single-ascending and repeated subcutaneous dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease who have the PNPLA3 I148M genotype</data>
    </edge>
    <edge id="e320" source="218" target="225">
      <data key="d3">9.0</data>
      <data key="d4">studied participants with...</data>
      <data key="d6">LY3849891 is being studied in participants with the PNPLA3 I148M genotype</data>
    </edge>
    <edge id="e321" source="218" target="222">
      <data key="d3">9.0</data>
      <data key="d4">studied participants with...</data>
      <data key="d6">LY3849891 is being studied in participants with metabolic dysfunction-associated steatotic liver disease</data>
    </edge>
    <edge id="e322" source="219" target="14">
      <data key="d3">9.0</data>
      <data key="d4">conducting single- multiple-ascending...</data>
      <data key="d6">Eli Lilly is conducting a single- and multiple-ascending dose study to evaluate the safety and pharmacokinetics of LY3839840 following oral dosing in healthy participants</data>
    </edge>
    <edge id="e323" source="64" target="224">
      <data key="d3">9.0</data>
      <data key="d4">two different medications...</data>
      <data key="d6">Lebrikizumab and Dupilumab are two different medications that are being studied for the treatment of moderate-to-severe atopic dermatitis.

Lebrikizumab is a medication that is currently being investigated in clinical trials. The data provided indicates that participants in the lebrikizumab study have previously been treated with dupilumab, another medication used for the treatment of moderate-to-severe atopic dermatitis.

Dupilumab is an existing medication that is approved for the treatment of moderate-to-severe atopic dermatitis. The data suggests that the participants in the lebrikizumab study have been previously treated with dupilumab, indicating that they have already received and potentially responded to dupilumab treatment.

The comprehensive summary of the data is as follows:

Lebrikizumab and Dupilumab are two different medications that are being used to treat moderate-to-severe atopic dermatitis. Lebrikizumab is a medication that is currently being studied in clinical trials, and the participants in the lebrikizumab study have previously been treated with dupilumab, another medication used for the treatment of moderate-to-severe atopic dermatitis. This suggests that the participants in the lebrikizumab study have already received and potentially responded to dupilumab treatment before being enrolled in the lebrikizumab study.

The data provided does not indicate any contradictions between the descriptions of the two medications. The information suggests that lebrikizumab is being studied as a potential treatment option for individuals who have previously been treated with dupilumab, which is an approved medication for the treatment of moderate-to-severe atopic dermatitis.

In summary, Lebrikizumab is a medication that is currently being investigated in clinical trials, and the participants in the lebrikizumab study have previously been treated with dupilumab, another medication used for the treatment of moderate-to-severe atopic dermatitis.</data>
    </edge>
    <edge id="e324" source="17" target="226">
      <data key="d3">8.0</data>
      <data key="d4">evaluating effect pirtobrutinib...</data>
      <data key="d6">The study is evaluating the effect of pirtobrutinib on the pharmacokinetics of repaglinide, a CYP2C8 substrate</data>
    </edge>
    <edge id="e325" source="227" target="228">
      <data key="d3">8.0</data>
      <data key="d4">evaluating effect LOXO-305...</data>
      <data key="d6">The study is evaluating the effect of LOXO-305 on the pharmacokinetics of caffeine, a CYP1A2 substrate</data>
    </edge>
    <edge id="e326" source="227" target="229">
      <data key="d3">8.0</data>
      <data key="d4">evaluating effect LOXO-305...</data>
      <data key="d6">The study is evaluating the effect of LOXO-305 on the pharmacokinetics of S-warfarin, a CYP2C9 substrate</data>
    </edge>
    <edge id="e327" source="227" target="230">
      <data key="d3">8.0</data>
      <data key="d4">evaluating effect LOXO-305...</data>
      <data key="d6">The study is evaluating the effect of LOXO-305 on the pharmacokinetics of omeprazole, a CYP2C19 substrate</data>
    </edge>
    <edge id="e328" source="72" target="234">
      <data key="d3">9.0</data>
      <data key="d4">studied patients with...</data>
      <data key="d6">LY3537982 is being studied in patients with KRAS G12C-mutant advanced solid tumors</data>
    </edge>
    <edge id="e329" source="31" target="165">
      <data key="d3">8.0</data>
      <data key="d4">evaluating safety tolerability...</data>
      <data key="d6">The study is evaluating the safety and tolerability of tirzepatide in combination with LY3841136 in overweight and obese participants</data>
    </edge>
    <edge id="e330" source="31" target="232">
      <data key="d3">9.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Tirzepatide is being studied in combination with LY3841136 in overweight and obese participants</data>
    </edge>
    <edge id="e331" source="231" target="102">
      <data key="d3">9.0</data>
      <data key="d4">Abemaciclib Metastatic Prostate...</data>
      <data key="d6">Abiraterone Acetate and Abemaciclib for Metastatic Prostate Cancer

Abiraterone acetate and abemaciclib are two pharmaceutical agents that are being investigated for the treatment of metastatic prostate cancer. Abiraterone acetate is a medication that works by inhibiting the production of testosterone, a hormone that can fuel the growth of prostate cancer cells. Abemaciclib, on the other hand, is a targeted therapy that blocks the activity of certain enzymes (CDK4 and CDK6) that are involved in the proliferation of cancer cells.

The available data indicates that a clinical study is currently evaluating the combination of abiraterone acetate and abemaciclib for the treatment of metastatic castration-resistant prostate cancer. Castration-resistant prostate cancer refers to a form of the disease that continues to progress despite the use of androgen-deprivation therapy, which is a standard treatment approach for metastatic prostate cancer.

The study is designed to assess the safety and efficacy of administering abiraterone acetate in combination with abemaciclib for patients with metastatic castration-resistant prostate cancer. The rationale behind this combination approach is that the dual targeting of the androgen signaling pathway (by abiraterone acetate) and the cell cycle regulation (by abemaciclib) may provide a more comprehensive and effective treatment strategy for this challenging form of prostate cancer.

It is important to note that the available descriptions do not appear to be contradictory. Both descriptions indicate that the combination of abiraterone acetate and abemaciclib is being evaluated for the treatment of metastatic prostate cancer, with a specific focus on the castration-resistant subtype of the disease.

In summary, the comprehensive description of the data provided is as follows:

Abiraterone acetate and abemaciclib are two pharmaceutical agents that are being investigated in combination for the treatment of metastatic castration-resistant prostate cancer. The study is designed to evaluate the safety and efficacy of this combination approach, which aims to target both the androgen signaling pathway and the cell cycle regulation in an effort to provide a more effective treatment strategy for this challenging form of prostate cancer.</data>
    </edge>
    <edge id="e332" source="231" target="233">
      <data key="d3">9.0</data>
      <data key="d4">being studied combination...</data>
      <data key="d6">Abiraterone acetate is being studied in combination with abemaciclib for the treatment of metastatic prostate cancer</data>
    </edge>
    <edge id="e333" source="102" target="233">
      <data key="d3">1.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Abemaciclib is being studied in combination with abiraterone acetate for the treatment of metastatic prostate cancer</data>
    </edge>
    <edge id="e334" source="14" target="236">
      <data key="d3">8.0</data>
      <data key="d4">investigating efficacy safety...</data>
      <data key="d6">Eli Lilly is investigating the efficacy and safety of LY3972406 in adults with moderate-to-severe plaque psoriasis</data>
    </edge>
    <edge id="e335" source="231" target="235">
      <data key="d3">8.0</data>
      <data key="d4">prednisone being evaluated...</data>
      <data key="d6">Abiraterone acetate and prednisone are being evaluated in combination with abemaciclib for metastatic castration-resistant prostate cancer</data>
    </edge>
    <edge id="e336" source="231" target="241">
      <data key="d3">9.0</data>
      <data key="d4">being evaluated treatment...</data>
      <data key="d6">Abiraterone acetate is being evaluated for the treatment of metastatic castration-resistant prostate cancer</data>
    </edge>
    <edge id="e337" source="235" target="241">
      <data key="d3">9.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Prednisone is being evaluated in combination with abiraterone acetate and abemaciclib for the treatment of metastatic castration-resistant prostate cancer</data>
    </edge>
    <edge id="e338" source="102" target="241">
      <data key="d3">9.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Abemaciclib is being evaluated in combination with abiraterone acetate and prednisone for the treatment of metastatic castration-resistant prostate cancer</data>
    </edge>
    <edge id="e339" source="236" target="178">
      <data key="d3">9.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">LY3972406 is being evaluated for the treatment of moderate-to-severe plaque psoriasis</data>
    </edge>
    <edge id="e340" source="237" target="238">
      <data key="d3">1.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Erlotinib is being evaluated in combination with ramucirumab or placebo in previously untreated participants with EGFR mutation-positive metastatic non-small cell lung cancer</data>
    </edge>
    <edge id="e341" source="237" target="239">
      <data key="d3">9.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Erlotinib is being evaluated in combination with ramucirumab or placebo for the treatment of metastatic non-small cell lung cancer</data>
    </edge>
    <edge id="e342" source="237" target="240">
      <data key="d3">1.0</data>
      <data key="d4">evaluated participants with...</data>
      <data key="d6">Erlotinib is being evaluated in participants with EGFR mutation-positive metastatic non-small cell lung cancer</data>
    </edge>
    <edge id="e343" source="238" target="239">
      <data key="d3">9.0</data>
      <data key="d4">evaluated combination with...</data>
      <data key="d6">Ramucirumab is being evaluated in combination with erlotinib for the treatment of metastatic non-small cell lung cancer</data>
    </edge>
    <edge id="e344" source="238" target="88">
      <data key="d3">8.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Ramucirumab is being studied for the treatment of EGFR mutation-positive metastatic NSCLC</data>
    </edge>
    <edge id="e345" source="238" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring study ramucirumab...</data>
      <data key="d6">Eli Lilly is sponsoring the study of ramucirumab for EGFR mutation-positive metastatic NSCLC</data>
    </edge>
    <edge id="e346" source="242" target="88">
      <data key="d3">8.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Gefitinib is being studied in combination with ramucirumab for the treatment of EGFR mutation-positive metastatic NSCLC</data>
    </edge>
    <edge id="e347" source="242" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring study gefitinib...</data>
      <data key="d6">Eli Lilly is sponsoring the study of gefitinib in combination with ramucirumab for EGFR mutation-positive metastatic NSCLC</data>
    </edge>
    <edge id="e348" source="243" target="88">
      <data key="d3">8.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Osimertinib is being studied in combination with ramucirumab for the treatment of T790M-positive metastatic NSCLC</data>
    </edge>
    <edge id="e349" source="243" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring study osimertinib...</data>
      <data key="d6">Eli Lilly is sponsoring the study of osimertinib in combination with ramucirumab for T790M-positive metastatic NSCLC</data>
    </edge>
    <edge id="e350" source="145" target="69">
      <data key="d3">8.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Baricitinib is being studied for the treatment of moderate to severe atopic dermatitis in pediatric patients</data>
    </edge>
    <edge id="e351" source="145" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring study baricitinib...</data>
      <data key="d6">Eli Lilly is sponsoring the study of baricitinib for moderate to severe atopic dermatitis in pediatric patients</data>
    </edge>
    <edge id="e352" source="145" target="246">
      <data key="d3">1.0</data>
      <data key="d4">listed expert...</data>
      <data key="d6">Amer Al Khoudari is listed as an expert related to the baricitinib study in rheumatoid arthritis</data>
    </edge>
    <edge id="e353" source="244" target="245">
      <data key="d3">8.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Merestinib is being studied in combination with cisplatin and gemcitabine for the treatment of advanced or metastatic biliary tract cancer</data>
    </edge>
    <edge id="e354" source="244" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring study merestinib...</data>
      <data key="d6">Eli Lilly is sponsoring the study of merestinib in combination with cisplatin and gemcitabine for advanced or metastatic biliary tract cancer</data>
    </edge>
    <edge id="e355" source="169" target="150">
      <data key="d3">1.0</data>
      <data key="d4">studied combination with...</data>
      <data key="d6">Fulvestrant is being studied in combination with abemaciclib for the treatment of hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer</data>
    </edge>
    <edge id="e356" source="169" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring study fulvestrant...</data>
      <data key="d6">Eli Lilly is sponsoring the study of fulvestrant in combination with abemaciclib for hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer</data>
    </edge>
    <edge id="e357" source="237" target="88">
      <data key="d3">8.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Erlotinib is being studied for the treatment of stage IV non-small cell lung cancer (NSCLC) with EGFR mutations</data>
    </edge>
    <edge id="e358" source="237" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring study erlotinib...</data>
      <data key="d6">Eli Lilly is sponsoring the study of erlotinib for stage IV non-small cell lung cancer</data>
    </edge>
    <edge id="e359" source="247" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring MONARCH clinical...</data>
      <data key="d6">Eli Lilly is sponsoring the MONARCH 2 clinical trial</data>
    </edge>
    <edge id="e360" source="247" target="251">
      <data key="d3">9.0</data>
      <data key="d4">trial studying hormone...</data>
      <data key="d6">The MONARCH 2 trial is studying hormone receptor positive breast cancer</data>
    </edge>
    <edge id="e361" source="247" target="252">
      <data key="d3">9.0</data>
      <data key="d4">trial studying HER2...</data>
      <data key="d6">The MONARCH 2 trial is studying HER2 negative breast cancer</data>
    </edge>
    <edge id="e362" source="247" target="253">
      <data key="d3">9.0</data>
      <data key="d4">trial studying locally...</data>
      <data key="d6">The MONARCH 2 trial is studying locally advanced breast cancer</data>
    </edge>
    <edge id="e363" source="247" target="254">
      <data key="d3">9.0</data>
      <data key="d4">trial studying metastatic...</data>
      <data key="d6">The MONARCH 2 trial is studying metastatic breast cancer</data>
    </edge>
    <edge id="e364" source="248" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring Phase study...</data>
      <data key="d6">Eli Lilly is sponsoring the Phase 1 study of LY4060874</data>
    </edge>
    <edge id="e365" source="249" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring Phase study...</data>
      <data key="d6">Eli Lilly is sponsoring the Phase 2 study of LY2875358 in combination with erlotinib</data>
    </edge>
    <edge id="e366" source="250" target="14">
      <data key="d3">9.0</data>
      <data key="d4">sponsoring Phase study...</data>
      <data key="d6">Eli Lilly is sponsoring the Phase 1 study of LY3985297</data>
    </edge>
    <edge id="e367" source="65" target="191">
      <data key="d3">8.0</data>
      <data key="d4">studied alone addition...</data>
      <data key="d6">Bimagrumab is being studied alone or in addition to semaglutide</data>
    </edge>
    <edge id="e368" source="67" target="255">
      <data key="d3">8.0</data>
      <data key="d4">trial studying participants...</data>
      <data key="d6">The Phase 3b trial is studying participants with obesity</data>
    </edge>
    <edge id="e369" source="68" target="255">
      <data key="d3">1.0</data>
      <data key="d4">trial studying participants...</data>
      <data key="d6">The Phase 3b trial is studying participants who are overweight</data>
    </edge>
    <edge id="e370" source="256" target="14">
      <data key="d3">18.0</data>
      <data key="d4">sponsor LY2784544...</data>
      <data key="d6">Eli Lilly is the sponsor of the LY2784544 clinical study</data>
    </edge>
    <edge id="e371" source="14" target="257">
      <data key="d3">18.0</data>
      <data key="d4">sponsor LY2835219...</data>
      <data key="d6">Eli Lilly is the sponsor of the LY2835219 clinical study</data>
    </edge>
    <edge id="e372" source="14" target="64">
      <data key="d3">18.0</data>
      <data key="d4">sponsor lebrikizumab...</data>
      <data key="d6">Eli Lilly is the sponsor of the lebrikizumab clinical study</data>
    </edge>
    <edge id="e373" source="64" target="258">
      <data key="d3">16.0</data>
      <data key="d4">involved lebrikizumab clinical...</data>
      <data key="d6">Steven Weinstein is involved in the lebrikizumab clinical study</data>
    </edge>
    <edge id="e374" source="15" target="259">
      <data key="d3">2.0</data>
      <data key="d4">evaluating drug-drug interaction...</data>
      <data key="d6">The study is evaluating the drug-drug interaction between orforglipron and quinidine</data>
    </edge>
    <edge id="e375" source="259" target="15">
      <data key="d3">8.0</data>
      <data key="d4">studied effect...</data>
      <data key="d6">Quinidine is being studied for its effect on the pharmacokinetics of orforglipron</data>
    </edge>
    <edge id="e376" source="238" target="260">
      <data key="d3">8.0</data>
      <data key="d4">evaluated treatment...</data>
      <data key="d6">Ramucirumab is being evaluated for the treatment of desmoplastic small round cell tumor</data>
    </edge>
    <edge id="e377" source="238" target="210">
      <data key="d3">8.0</data>
      <data key="d4">evaluated part...</data>
      <data key="d6">Ramucirumab is being evaluated as part of the CAMPFIRE master protocol</data>
    </edge>
    <edge id="e378" source="87" target="261">
      <data key="d3">8.0</data>
      <data key="d4">compared standard treatment...</data>
      <data key="d6">Selpercatinib is being compared to standard treatment for RET fusion-positive non-small cell lung cancer</data>
    </edge>
    <edge id="e379" source="87" target="50">
      <data key="d3">8.0</data>
      <data key="d4">selpercatinib being conducted...</data>
      <data key="d6">The study of selpercatinib is being conducted in China</data>
    </edge>
    <edge id="e380" source="227" target="262">
      <data key="d3">8.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">LOXO-305 is being studied for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma</data>
    </edge>
    <edge id="e381" source="227" target="110">
      <data key="d3">8.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">LOXO-305 is being studied for the treatment of non-Hodgkin lymphoma</data>
    </edge>
    <edge id="e382" source="31" target="120">
      <data key="d3">10.0</data>
      <data key="d4">medication that being...</data>
      <data key="d6">Tirzepatide is a medication that is being evaluated for the treatment of type 2 diabetes mellitus in pediatric and adolescent participants. Type 2 diabetes mellitus is a chronic condition characterized by the body's inability to effectively use insulin, a hormone that regulates blood sugar levels.

The descriptions provided indicate that tirzepatide is being studied as a potential treatment option for type 2 diabetes mellitus in children and adolescents. Tirzepatide is a dual agonist that targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which play important roles in glucose homeostasis and insulin secretion.

The studies on the use of tirzepatide for the treatment of type 2 diabetes mellitus in pediatric and adolescent participants are ongoing, and the results of these studies will provide valuable insights into the efficacy and safety of this medication in this patient population. The comprehensive evaluation of tirzepatide for the treatment of type 2 diabetes mellitus in children and adolescents is crucial, as the prevalence of this condition has been increasing in recent years, particularly among younger individuals.

The descriptions provided do not contain any contradictory information, and the summary presented above aims to provide a coherent and comprehensive overview of the available data. The summary is written in the third person and includes the entity names (tirzepatide and type 2 diabetes mellitus) to maintain the full context.</data>
    </edge>
    <edge id="e383" source="31" target="45">
      <data key="d3">1.0</data>
      <data key="d4">studied participants with...</data>
      <data key="d6">Tirzepatide is being studied in participants with type 2 diabetes mellitus who are taking metformin</data>
    </edge>
    <edge id="e384" source="31" target="266">
      <data key="d3">9.0</data>
      <data key="d4">studied clinical trials...</data>
      <data key="d6">Tirzepatide is being studied in clinical trials involving pediatric and adolescent participants</data>
    </edge>
    <edge id="e385" source="17" target="263">
      <data key="d3">16.0</data>
      <data key="d4">studied effect...</data>
      <data key="d6">Pirtobrutinib is being studied for its effect on the pharmacokinetics of midazolam, a CYP3A4 substrate</data>
    </edge>
    <edge id="e386" source="17" target="264">
      <data key="d3">16.0</data>
      <data key="d4">studied effect...</data>
      <data key="d6">Pirtobrutinib is being studied for its effect on the pharmacokinetics of digoxin, a P-glycoprotein substrate</data>
    </edge>
    <edge id="e387" source="123" target="14">
      <data key="d3">16.0</data>
      <data key="d4">conducting clinical trial...</data>
      <data key="d6">Eli Lilly is conducting a clinical trial to evaluate the safety of dulaglutide in patients with type 2 diabetes mellitus in India</data>
    </edge>
    <edge id="e388" source="123" target="120">
      <data key="d3">8.0</data>
      <data key="d4">studied treatment...</data>
      <data key="d6">Dulaglutide is being studied for the treatment of type 2 diabetes mellitus in patients in India</data>
    </edge>
    <edge id="e389" source="123" target="267">
      <data key="d3">1.0</data>
      <data key="d4">dulaglutide being conducted...</data>
      <data key="d6">A clinical trial for dulaglutide is being conducted in India</data>
    </edge>
    <edge id="e390" source="265" target="14">
      <data key="d3">28.0</data>
      <data key="d4">antipsychotic medication manufactured...</data>
      <data key="d6">Zyprexa Relprevv is an antipsychotic medication manufactured by the pharmaceutical company Eli Lilly. Zyprexa Relprevv is a long-acting injectable formulation of the active ingredient olanzapine, which is used to treat schizophrenia and bipolar disorder.

Eli Lilly has implemented a patient care program for Zyprexa Relprevv to help mitigate the risk of negative outcomes associated with post-injection delirium/sedation syndrome (PDSS). PDSS is a serious adverse event that can occur after the administration of Zyprexa Relprevv, and it is characterized by symptoms such as sedation, confusion, and disorientation.

The patient care program for Zyprexa Relprevv is designed to ensure that patients receive appropriate monitoring and support before, during, and after the administration of the medication. This includes requirements for healthcare providers to observe patients for at least 3 hours after each injection and to have access to necessary medical resources in case of an emergency.

Eli Lilly's manufacturing of Zyprexa Relprevv is an important aspect of the medication's availability and distribution. The company is responsible for the production, quality control, and supply of the drug to healthcare providers and patients. Ensuring a reliable and consistent supply of Zyprexa Relprevv is crucial for the continuity of care for individuals with schizophrenia or bipolar disorder who rely on this medication.

In summary, Zyprexa Relprevv is an antipsychotic medication manufactured by Eli Lilly, and the company has implemented a patient care program to mitigate the risk of post-injection delirium/sedation syndrome associated with the use of this medication. Eli Lilly's manufacturing and distribution of Zyprexa Relprevv are essential for providing access to this treatment option for individuals with schizophrenia or bipolar disorder.</data>
    </edge>
    <edge id="e391" source="265" target="269">
      <data key="d3">18.0</data>
      <data key="d4">Program aimed mitigating...</data>
      <data key="d6">The Patient Care Program is aimed at mitigating the risks associated with Zyprexa Relprevv</data>
    </edge>
    <edge id="e392" source="265" target="268">
      <data key="d3">2.0</data>
      <data key="d4">potentially cause post-injection...</data>
      <data key="d6">Zyprexa Relprevv can potentially cause post-injection delirium/sedation syndrome (PDSS)</data>
    </edge>
    <edge id="e393" source="14" target="26">
      <data key="d3">18.0</data>
      <data key="d4">markets obesity drug...</data>
      <data key="d6">Eli Lilly manufactures and markets the obesity drug Mounjaro</data>
    </edge>
    <edge id="e394" source="14" target="28">
      <data key="d3">18.0</data>
      <data key="d4">markets obesity drug...</data>
      <data key="d6">Eli Lilly manufactures and markets the obesity drug Zepbound, which is the same as Mounjaro</data>
    </edge>
    <edge id="e395" source="14" target="272">
      <data key="d3">1.0</data>
      <data key="d4">LillyDirect patient access...</data>
      <data key="d6">Eli Lilly operates the LillyDirect patient access program to improve access to its obesity drugs</data>
    </edge>
    <edge id="e396" source="26" target="270">
      <data key="d3">16.0</data>
      <data key="d4">competing GLP-1 agonist...</data>
      <data key="d6">Mounjaro and Trulicity are competing GLP-1 agonist drugs for obesity and type 2 diabetes, respectively</data>
    </edge>
    <edge id="e397" source="26" target="271">
      <data key="d3">18.0</data>
      <data key="d4">compared cardiovascular outcomes...</data>
      <data key="d6">The SURPASS-CVOT trial compared the cardiovascular outcomes of Mounjaro versus Trulicity</data>
    </edge>
    <edge id="e398" source="15" target="275">
      <data key="d3">18.0</data>
      <data key="d4">orforglipron, oral GLP-1...</data>
      <data key="d6">Eli Lilly developed orforglipron, an oral GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity</data>
    </edge>
    <edge id="e399" source="15" target="31">
      <data key="d3">8.0</data>
      <data key="d4">oral GLP-1 receptor...</data>
      <data key="d6">Orforglipron is an oral GLP-1 receptor agonist, while tirzepatide is a once-weekly subcutaneous injection, both developed by Eli Lilly for the treatment of type 2 diabetes and obesity</data>
    </edge>
    <edge id="e400" source="31" target="275">
      <data key="d3">16.0</data>
      <data key="d4">tirzepatide, once-weekly subcutaneous...</data>
      <data key="d6">Eli Lilly developed tirzepatide, a once-weekly subcutaneous injection for the treatment of type 2 diabetes and obesity</data>
    </edge>
    <edge id="e401" source="273" target="275">
      <data key="d3">18.0</data>
      <data key="d4">agreement with...</data>
      <data key="d6">Eli Lilly has an agreement with the US Government to expand access to its obesity medicines and reduce drug costs</data>
    </edge>
    <edge id="e402" source="274" target="275">
      <data key="d3">16.0</data>
      <data key="d4">negotiated with Medicaid...</data>
      <data key="d6">Eli Lilly has negotiated with Medicaid to increase coverage for its obesity treatments</data>
    </edge>
    <edge id="e403" source="275" target="276">
      <data key="d3">7.0</data>
      <data key="d4">considered inclusion...</data>
      <data key="d6">Peripheral arterial disease was considered in the inclusion criteria for Eli Lilly's obesity treatments</data>
    </edge>
    <edge id="e404" source="275" target="277">
      <data key="d3">7.0</data>
      <data key="d4">considered inclusion criteria...</data>
      <data key="d6">Myocardial infarction was considered in the inclusion criteria for Eli Lilly's obesity treatments</data>
    </edge>
    <edge id="e405" source="275" target="278">
      <data key="d3">7.0</data>
      <data key="d4">inclusion criteria...</data>
      <data key="d6">Stroke was considered in the inclusion criteria for Eli Lilly's obesity treatments</data>
    </edge>
    <edge id="e406" source="275" target="279">
      <data key="d3">7.0</data>
      <data key="d4">considered inclusion criteria...</data>
      <data key="d6">Prediabetic symptoms were considered in the inclusion criteria for Eli Lilly's obesity treatments</data>
    </edge>
    <edge id="e407" source="275" target="280">
      <data key="d3">6.0</data>
      <data key="d4">market where Eli...</data>
      <data key="d6">The UK is a market where Eli Lilly sees high self-pay demand for its GLP-1 therapies</data>
    </edge>
    <edge id="e408" source="275" target="50">
      <data key="d3">6.0</data>
      <data key="d4">market that Eli...</data>
      <data key="d6">China is a market that Eli Lilly is targeting for its GLP-1 therapies</data>
    </edge>
    <edge id="e409" source="275" target="267">
      <data key="d3">6.0</data>
      <data key="d4">market that Eli...</data>
      <data key="d6">India is a market that Eli Lilly is targeting for its GLP-1 therapies</data>
    </edge>
    <edge id="e410" source="275" target="281">
      <data key="d3">1.0</data>
      <data key="d4">market that Eli...</data>
      <data key="d6">Brazil is a market that Eli Lilly is targeting for its GLP-1 therapies</data>
    </edge>
    <edge id="e411" source="282" target="0">
      <data key="d3">1.0</data>
      <data key="d4">financial performance...</data>
      <data key="d6">Investors are interested in the financial performance and developments of Eli Lilly and Company</data>
    </edge>
  </graph>
</graphml>